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Abstract 
 
Background: Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) is 
an accessory protein that interacts with a number of host cellular and other viral 
proteins. Vpr exerts several functions such as induction of apoptosis, induction of cell 
cycle G2 arrest, modulation of gene expression, and suppression of immune 
activation. The functionality of subtype C Vpr, especially South African strains, has 
not been studied. The aim of this study was to describe the diversity of South African 
HIV-1 subtype C vpr genes and to investigate selected functions of these Vpr 
proteins. 
Methodology: The HIV-1 vpr region of 58 strains was amplified, sequenced, and 
subtyped using phylogenetic analysis. Fragments containing natural mutations were 
cloned in mammalian expression vectors. A consensus subtype C vpr gene was 
constructed and site-directed mutagenesis was used to induce mutations in postions in 
which no natural mutations have been described. The functionality of all constructs 
was compared with the wild-type subtype B Vpr, by transfecting human 293T cell 
line to investigate subcellular localization, induction of apoptosis and cell cycle G2 
arrest. The modulation of genes expressed in the induction of apoptosis using TaqMan 
Low density arrays (TLDA) was also investigated.  
Results: Phylogenetic analysis characterized 54 strains as HIV-1 subtype C and 4 
strains as HIV-1 subtype B. The overall amino acid sequence of Vpr was conserved 
including motifs FPRPWL and TYGDTW, but the C-terminal was more variable. The 
following mutations were constructed using site-directed mutagenesis: P14I, W18C, 
Y47N, Q65H and Q88S. Subtype B and all natural mutants of subtype C Vpr 
localized to the nucleus but the W18C mutation disturbed the nuclear localization of 
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Vpr. The cell cycle G2 arrest activity of all the mutants, as well as consensus-C, was 
lower than that of subtype B Vpr. All the natural mutants of subtype C Vpr induced 
cell cycle G2 arrest in 54.0-66.3% of the cells, while subtype B Vpr induced cell cycle 
G2 arrest in 71.5% of the cells. Subtype B and the natural mutant Vpr proteins 
induced apoptosis in a similar manner, ranging from 95.3-98.6% of transfected cells. 
However, an artificially designed Vpr protein containing the consensus sequences of 
subtype C Vpr indicated a reduced ability to induce apoptosis. While consensus-C 
Vpr induced apoptosis in only 82.0% of the transfected cells, the artificial mutants of 
Vpr induced apoptosis in 88.4 to 96.2% of the cells. The induction of apoptosis-
associated gene expression was similar for all constructs, indicated that apoptosis was 
efficiently induced through the intrinsic pathway by the mutants.  
Conclusion: This study indicated that both HIV-1 subtype B and C Vpr display a 
similar ability for nuclear localization and apoptosis induction. The induction of cell 
cycle G2 arrest by HIV-1 subtype B Vpr may be more robust than many subtype C 
Vpr proteins. The natural mutations studied in the isolates did not disturb the 
functions of subtype C Vpr and in some cases even potentiated the protein to induce 
apoptosis. Naturally occurring mutations in HIV-1 Vpr cannot be regarded as 
defective, since enhanced functionality would be more indicative of an adaptive role. 
The increased potency of the mutated Vpr proteins suggests that Vpr may increase the 
pathogenicity of HIV-1 by adapting apoptotic enhancing mutations.   
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Abstrak 
Agtergrond: Die virus protein R (Vpr) van Menslike Immuungebrek Virus tipe 1 
(MIV-1) is ‘n bykomstige protein wat met ‘n aantal sellulêre proteine van die gasheer 
en ander virus proteine in wisselwerking tree. Vpr het 'n invloed op verskeie funksies 
onder andere die induksie van apoptose, die induksie van selsiklus G2 staking, 
modulering van geen uitdrukking en onderdrukking van immuun aktivering. Die 
funksionaliteit van subtipe C Vpr, en veral die van Suid-Afrikaanse stamme, is nie 
beskryf nie. Die doelwit van die studie was om die diversiteit van Suid Afrikaanse 
MIV-1 subtipe C vpr gene te beskryf en ook om selektiewe funksies van die Vpr 
proteine te ondersoek  
Metodiek: Die MIV-1 vpr streek van 58 stamme is vermeerder, die DNA volgordes is 
bepaal en die stamme is gesubtipeer deur filogenetiese analise. Fragmente met 
natuurlike mutasies is in ekspressie vektore gekloon. ‘n Konsensus subtipe C Vpr 
geen is ontwerp en mutasies in posisies waar geen natuurlike mutasies beskryf is nie, 
is ontwerp deur mutagenese. Die funksionaliteit van die konstrukte is met die wilde 
tipe subtype B vergelyk deur 293T sellyn te transfekteer en te ondersoek vir 
subsellulêre lokalisering, induksie van apoptose, en G2 selsiklus stilstand. Die 
modulering van geen uitdrukking in die induksie van apoptose is deur TLDA 
ondersoek. 
Resultate: Filogenetiese analise het 54 stamme as HIV-1 subtipe C geklassifiseer en 
4 stamme as subtype B. Die Vpr aminosuur volgordes was konstant insluitend die 
FPRPWL en TYGDTW motiewe, maar die C-terminaal was meer variëerbaar. Deur 
mutagenese is die volgende mutasies ontwerp: P14I, W18C, Y47N, Q65H and Q88S.  
Subtipe B en al die natuurlike mutante van subtipe C het in die selkern gelokaliseer, 
maar die W18C mutasie het die lokalisasie versteur. Die G2 selsiklus stilstand van 
 6
alle mutante en konsensus C was laer as die van subtype B. Al die natuurlike subtipe 
C mutante het G2 selsiklus tot stilstand gebring in 54.0-66.3% van die selle, terwyl 
subtype B selsiklus tot stilstand gebring het in 71.5% van die selle.  Subtipe B en die 
natuurlike Vpr mutante het apoptose op ‘n soortgelyke wyse geinduseer, wat wissel 
tussen 95.3-98.6% van getransfekteerde selle. Die protein met die kunsmatig 
ontwerpte konsensus C volgorde het egter ‘n verlaagde vermoë gehad om apoptose te 
induseer. Die konsensus subtipe C het apoptose in 82.0% van getransfekteerde selle 
geinduseer en die kunsmatige mutante in 88.4 – 96.2% van die selle. Die induksie van 
die apoptose verwante geen ekspressie deur die mutante  was soortgelyk as die van 
konsensus C en subtipe B Vpr wat ’n aangeduiding is dat apoptose effektief 
veroorsaak is deur die intrinsieke roete. 
Gevolgtrekking: Hierdie studie het aangetoon dat kern lokalisering en apoptose op ‘n 
soortgelyke wyse by beide MIV-1 subtipe B en C Vpr plaasvind. Die induksie van 
selsiklus G2 stilstand deur MIV-1 subtipe B Vpr is egter meer robuust as baie van die 
subtipe C Vpr proteïene. Natuurlike mutasies in MIV-1 Vpr kan nie as gebrekkig 
beskou word nie, aangesien beter funksionaliteit 'n aanduiding is vandie  aanpasbare 
rol. Die verhoogde krag van die gemuteerde Vpr proteïen dui daarop dat Vpr die 
patogenisiteit van MIV-1 kan verbeter deur die aanpassing van mutasies. 
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Chapter 1 
 
1. Introduction and literature review 
 
1.1 Introduction 
 
Viral virulence is dependent on the interplay between virus and host. Route of virus 
entry, dose of the virus and the host’s age, sex, immune status and species all play a 
role in determining virulence. The host may suppress every stage of the virus 
replication cycle by posing different obstacles to the progression of virus replication. 
A successful virus must adapt to overcome these obstacles. Viruses have evolved 
proteins to aid in overcoming the defensive mechanisms of the host (Tungaturthi et 
al., 2004a). In this regard, Lentivirus genomes, such as HIV-1 genome, contain a 
number of accessory and regulatory genes in addition to the gag, pol and env genes 
that are commonly found in all retroviruses. Human immunodeficiency virus type 1 
(HIV-1) encodes two regulatory proteins, Tat and Rev, and four accessory proteins 
[viral infectivity factor (Vif), viral protein R (Vpr), viral protein U (Vpu) and negative 
factor (Nef)]. The regulatory proteins are essential for virus replication by controlling 
HIV gene expression in host cells. In contrast, accessory proteins are often 
dispensable for virus replication in vitro (Anderson & Hope, 2004). All of these 
proteins are however implicated in viral manipulation of host defences.  
 
The HIV-1 genome encodes a 14 kDa accessory protein, Vpr, which is a versatile, 
virion-associated protein composed of 96 AA (Felzien et al., 1998; Muller et al., 
2000; Muthumani et al., 2000). Vpr is incorporated into HIV-1 virions through direct 
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interaction with the p6 domain of the Gag protein (Bachand et al., 1999; Lavallee et 
al., 1994). Vpr has a variety of roles in determining HIV- 1 infectivity, and the 
number of its newly identified roles is still increasing. Some of the functions proposed 
for this protein include modulation of transcription of the virus genome (Sawaya et 
al., 2000), induction of apoptosis, disruption of cell-cycle control, induction of defects 
in mitosis (Chang et al., 2004), nuclear transport of the HIV-1 pre-integration 
complex (PIC) (Vodicka et al., 1998), facilitation of reverse transcription (Rogel et 
al., 1995), suppression of immune activation (Ramanathan et al., 2002) and reduction 
of the HIV mutation rate (Jowett et al., 1999). In addition, the interactions of Vpr with 
a number of human proteins have been identified, but the functions of some of those 
interactions are not clear (Felzien et al., 1998; Ramanathan et al., 2002; Sawaya et al., 
2000). The NMR structure of Vpr indicates that Vpr contains a flexible N-terminal 
region, three α-helical domains with amphipathic properties and a flexible C-terminal 
region (Figure 1.1) (Morellet et al., 2003). Each function or interaction of Vpr is 
attributed to one or more of its domains. Identification of the functions of Vpr 
domains is usually carried out by mutagenesis studies (Tungaturthi et al., 2004a).  
 
HIV-2, SIVsm and SIVmac encode two proteins that are homologous to HIV-1 Vpr, 
called Vpr and Vpx. HIV-2 Vpr shares the ability to induce cell cycle G2 arrest with 
HIV-1 Vpr, but HIV-2 Vpx has no effect on the cell cycle and, instead, is required for 
efficient infection of non-dividing cells such as macrophages and dendritic cells. It is 
believd that Vpx has originated from duplication of vpr within the HIV-2, SIVsm and 
SIVmac. The high degree of homology, and the divergent functions of Vpx with 
respect to HIV-1 Vpr, suggest that Vpx is a paralog of HIV-1 Vpr (Planelles & 
Barker, 2010).  
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The 3-dimentional structure of Vpr has been analyzed in the presence in pure water at 
low pH. The structure of Vpr is characterized by three well-defined α-helices 
surrounded by flexible N and C-terminal domains. The three α-helices are folded 
around a hydrophobic core constituted of Leu, Ile, Val and aromatic residues. This 
structure accounts for the interaction of Vpr with different targets (Morellet et al., 
2003). 
 
The cytopathic effects induced by Vpr are mostly attributed to the N terminus, which 
forms ion channels in cell membranes. These effects are unrelated to the reported 
activities of Vpr, including virion association, G2 arrest and induction of apoptosis 
(Piller et al., 1999; Somasundaran et al., 2002). Incorporation of Vpr into HIV-1 
virions is blocked by a range of mutations distributed in different regions of the 
protein, indicating that different domains of Vpr are involved in its incorporation into 
virions. Alterations in the cell cycle, including apoptosis, cell-cycle arrest and defects 
in mitosis, are mostly carried out by the C-terminal domain of Vpr, although 
alterations in the cell cycle by the other regions of Vpr have also been reported (Piller 
et al., 1999; Roumier et al., 2002; Srinivasan et al., 2008).  
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Figure 1.1: The HIV-1 Vpr protein. (A) Three-dimensional structure of HIV-1 Vpr, representing the 
N- and C-terminal regions in white, α-helix I in yellow, α -helix II in green and α -helix III in red. (B) 
Amino acid sequence of the HIV-1 Vpr according to the reference sequence HXB2 (GenBank 
accession no. K03455), showing the positions of the domains (Romani & Engelbrecht, 2009). 
 
Using mutagenesis approaches, HIV-1 Vpr has been extensively studied to obtain 
information on the functions of different domains of this protein. Software analysis of 
solution structure of full length Vpr reveals that Vpr contains a flexible N-terminal 
region, followed by three helices connected by loops and ends with flexible C-
terminus. The N-terminus of Vpr consistes of the first 16 residues Met1-Asn16 
followed by the first α-helix of 17 amino acids encompassing residues Asp17 to 
His33. The first α-helix is connected to the second α-helix by a short inter-helical loop 
consisting of residues Phe34 to Leu39. The second α-helix is formed between residues 
His40 to Glu48, followed by a second inter-helical loop between Glu48 to Trp54 
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connecting to the third α-helix. The third α-helix, which is extended between Ala55 to 
Val83, is followed by a C-terminal domain (Thr84 to Ser96). All 3 α-helices have 
characteristic amphipathic properties and all are packed with hydrophobic side chains 
forming the core of the protein (Pandey et al., 2009). The important impact of Vpr 
mutagenesis on functional integrity of the viral protein was the rationale for the 
current study. Both variability of vpr and associated mutations have not been 
described for the subtype C epidemic in South Africa, and this study addresses both 
these issues. 
 
1.2 Literature Review 
 
An overview of the current literature on the functions and molecular interactions of 
HIV-1 Vpr protein is presented. Most of the functions proposed for Vpr have been 
well established, however there are several functions proposed for Vpr that have not 
been well documented to date. 
 
1.2.1 Nuclear import of the PIC by Vpr 
 
DNA viruses and some RNA viruses need to access the nucleus for replication. The 
interior of the nucleus is isolated from the cytoplasm by a nuclear envelope that is 
contiguous with the endoplasmic reticulum. The nuclear envelope is composed of two 
lipid bilayers, the inner and outer nuclear membranes. The traffic of macromolecules 
such as proteins and mRNAs takes place through the nuclear pore complexes (NPCs) 
located in the nuclear envelope. The translocation of cargoes larger than ~40 kD 
usually requires signals called nuclear localization signals (NLSs). The nuclear import 
of basic NLS-bearing proteins is mediated by specific shuttling factors, such as 
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importin-α (Impα), importin-β (Impβ), small GTPase Ran/TC4, and NTF2 (Aida & 
Matsuda, 2009). 
 
HIV-1 Vpr enhances the ability of HIV-1 to replicate in terminally differentiated 
macrophages, which is attributed to the activity of Vpr in active nuclear import of the 
virus PIC (Jenkins et al., 1998; Le-Rouzic et al., 2002; Schang, 2003; Suzuki et al., 
2009). The HIV-1 PIC is composed of viral proteins, such as Vpr, reverse 
transcriptase (RT), integrase (IN), nucleocapsid (NC) and matrix (MA), in addition to 
viral nucleic acids. Although the precise role(s) of some of these proteins has not been 
described, their importance for nuclear import of the PIC has been demonstrated. The 
nuclear-localization signals (NLSs) in both MA and IN have been identified, and it is 
believed that both utilize the classical nuclear-import pathway that includes 
interaction with importins. In contrast, a canonical NLS has not been identified in 
Vpr, but it does display karyophilic properties. It is believed that the nuclear 
localization of Vpr is mediated by an unknown pathway that is distinct from the 
classical NLS- and M9-dependent pathways. In addition, it has also been suggested 
that Vpr utilizes the cellular machinery that regulates nucleocytoplasmic shuttling to 
transfer the proviral DNA to the nucleus. For example, in the presence of importin-α, 
the nuclear localization of Vpr increases. It has been suggested that interaction of Vpr 
with importin-α facilitates its nuclear localization (Gallay et al., 1997; Gallay et al., 
1996; Nitahara-Kasahara et al., 2007).  
 
To identify the role of Vpr in the nuclear import of PIC, green fluorescent protein 
(GFP) has been fused to Vpr. It has been demonstrated that the PIC is associated 
closely with cytoplasmic microtubules that direct it toward the nucleus, where it 
localizes in the perinuclear region close to centrosomes. It has also been shown that 
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the PIC utilizes cytoplasmic dynein to travel toward the nucleus. It has not been 
confirmed whether Vpr plays an active role during the transfer of the PIC along 
microtubules, or whether it is only associated with PIC in this step and starts its role 
during the next steps of the nuclear transfer of PIC (Le-Rouzic & Benichou, 2005).  
 
Selective trafficking between the nucleus and cytoplasm is carried out through NPCs, 
which form aqueous channels in the nuclear envelope. NPCs are large protein 
complexes composed of 30 distinct nuclear-pore proteins, called nucleoporins (Nups). 
Some Nups that contain phenylalanine-glycine (FG) repeats are found in the 
filamentous structures emanating from both sides of NPCs; thereby provide docking 
sites for various transport factors. Importin-α is a floating receptor that binds to the 
NLSs of cargo proteins. FG repeats on the cytoplasmic filaments and cytoplasmic ring 
moiety of NPCs recognize the importin receptor. It has been shown that HIV-1 Vpr 
binds to the FG repeats of several Nups, including human p54 and p58. HIV-1 Vpr 
also binds to human CG1 (hCG1), but this interaction is not mediated by the FG 
repeat of this Nup. Interaction of Vpr with the N-terminal region (which does not 
contain FG repeats) of hCG1 is essential for docking of Vpr to the nuclear envelope 
(Le-Rouzic & Benichou, 2005; Vodicka et al., 1998; Zeitler & Weis, 2004). It has 
been demonstrated that the α-helical domains of Vpr are essential for its interaction 
with hCG1. This interaction results in Vpr accumulation in the nuclear envelope, 
which is believed to be involved in active nuclear import of the PIC in nondividing 
cells, such as macrophages. It may also be involved in targeting the PIC to the NPC 
before its translocation into the nucleus. In addition to the conventional routes 
suggested for nuclear import of the PIC, it has also been reported that Vpr mediates 
transient, localized herniations in the nuclear envelope, resulting in the mixing of 
cytoplasmic and nuclear components. These herniations probably contribute to the 
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G2-arrest activity of Vpr and may also provide an unconventional route for nuclear 
import of the PIC. In fact, the interaction between Vpr and hCG1 could cause 
misassembly of the NPC, resulting in alterations of the architecture of the nuclear 
envelope that facilitate nuclear import of the PIC (de-Noronha et al., 2001; Le-Rouzic 
et al., 2002). Vpr-induced herniation and bursting may not be the only mechanism by 
which the HIV PIC enters to the nucleus because HIV vectors that lack Vpr can 
replicate in at least some nondividing cells (Segura-Totten & Wilson, 2001). 
 
When the HIV-1 nucleoprotein complex reaches the nucleus, it must cross the nuclear 
envelope to integrate into the host genome. Theoretically, molecules of up to 9 nm in 
diameter can be transferred through the NPC by passive diffusion. However, the HIV-
1 PIC is too large for passive transport. Although the central molecular mechanisms 
of PIC nuclear import are unknown, there is enough evidence to discuss several 
proposed theories (Figure 1. 2). The first theory proposes a role in the uncoating 
process. It has been shown that a small PIC (~80S) is detected in the nucleus, while a 
larger PIC (~100-350S) is detected in the cytoplasm. Thus, remarkable shedding of 
components and/or major conformational changes may occur to reduce its size, 
indicating that capsid (CA) dissociates from PIC. In fact, HIV-1 apparently is 
uncoated during infection; probably after reverse transcription is completed at the 
nuclear pore. Therefore, the uncoating step is essential for efficient nuclear import. 
The second theory proposes that although viral capsid uncoating is likely necessary 
for nuclear import, specific signals and import factors also likely to direct the 
intracellular trafficking of PIC. Importantly, MA, Vpr, and IN have also been 
implicated in PIC nuclear import via interaction with NLS receptors (i.e., importins or 
karyopherins); however, the role(s) of these interactions to HIV-1 replication in non-
dividing cells is controversial. Vpr can also bind to Impα to be transported into the 
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nucleus by an interaction with Impα alone, but not with the Impα/Impβ heterodimer. 
It has been suggested that Vpr, IN and MA work either sequentially or synergistically 
to regulate PIC nuclear import. The third theory proposes that a new player, tRNA, 
which mediates translation in the cytoplasm, may be involved in PIC nuclear import. 
Some tRNA species lacking the 3 -CCA end are essential for nuclear import. In 
addition, these tRNA species are packaged into budding viral particles, and tRNA has 
been indicated to travel in a retrograde direction from the cytoplasm to the nucleus 
(Aida & Matsuda, 2009). 
 
 
 
Figure 1.2: Different theories on HIV-1 PIC nuclear import. The Impα/Impβ heterodimer, Imp7, 
the Imp7/Impβ heterodimer, TNPO-SR2 or tRNA species contribute to the nuclear import of HIV-1 
PIC (Aida & Matsuda, 2009). 
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1.2.2 Induction of G2 arrest by Vpr 
 
The role of HIV-1 Vpr in inhibition of normal cell growth is well established. It is 
believed that the interruption of cell division by Vpr increases virus replication and 
induces programmed cell death. Vpr mediates cell-cycle arrest at the G2/M transition 
in various mammalian cells. The cell cycle G2 arrest provides a replication advantage 
for the virus, because the transcription level of the provirus is higher in cell cycle G2 
arrested cells than in dividing cells (Belzile et al., 2007; Elder et al., 2001; Goh et al., 
1998). As the pathways regulating the cell cycle are highly conserved in eukaryotic 
cells (Krylov et al., 2003; Warbrick & Fantes, 1988), transfection of yeast cells by 
vectors expressing Vpr also interrupts the cell cycle. Therefore, in studies of cell-
cycle arrest induced by Vpr, the use of yeast cells is common, because they are easy 
to handle (Benko et al., 2007; Elder et al., 2001; Huard et al., 2008).  
 
The eukaryotic cell cycle is controlled by a complex network of proteins and genes. 
Cyclin-dependent protein kinases (CDKs) initiate the crucial events of the cell cycle 
by phosphorylating specific protein targets. The phosphorylation activity of CDKs is 
tightly dependent on binding to cyclins. Binding of cyclins to CDKs results in CDK–
cyclin complexes. As there are always excess amounts of CDKs in eukaryotic cells, it 
is the availability of cyclins that determines the number of CDK–cyclin complexes in 
eukaryotic cells. CDK–cyclin complexes can be downregulated either by inhibitory 
phosphorylation of the CDK subunit or by binding to inhibitory molecules designated 
cyclin-dependent kinase inhibitors (Csikasz-Nagy et al., 2006). G2 arrest is 
characterized by low levels of cyclin B1–p34Cdc2 activity and inhibitory 
phosphorylation of p34Cdc2. It has been shown that Vpr directly inhibits the in vitro 
activity of a phosphatase, Cdc25C, which normally activates cyclin B1-p34Cdc2 
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(Figure 1.3). Although the Vpr binding site on Cdc25C is not its catalytic site, 
Cdc25C is inactivated by binding to Vpr, resulting in inhibition of Cdc25C 
phosphatase activity. In the absence of Cdc25C phosphatase activity, cyclin B1–
p34Cdc2 remains in its phosphorylated form, which is inactive (Goh et al., 2004; He 
et al., 1995). 14-3-3 proteins are also involved in this pathway. These proteins 
normally regulate cell-cycle progression by changing the activities of cyclins, 
including Cdc25C. DNA damage results in Cdc25C phosphorylation, providing the 
active binding site for 14-3-3. It has been shown that the C-terminal region of Vpr 
interacts with the C-terminal region of 14-3-3, leading to the association of 14-3-3 
with Cdc25C. This complex is not able to activate cyclin B1-p34Cdc2; therefore the 
cell cycle is arrested (Figure 1.3) (Kino et al., 2005b).  
 
 
Figure 1.3: Cell-cycle arrest through inactivation of Cdc25C. (a) 14-3-3 protein binds to Cdc25C, 
resulting in a complex that possesses phosphatase activity. The complex removes the phosphate 
molecule from the inactive form of cyclin B1–p34Cdc2, altering it to the active form that drives 
progression of the cell cycle. (b) Vpr binds to the 14-3-3 protein and Cdc25C and inactivates this 
complex. In the absence of the phosphatase activity of Cdc25C, cyclin B1–p34Cdc2 remains inactive, 
resulting in G2 arrest (Romani & Engelbrecht, 2009). 
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Inactivating Cdc25C is not the only pathway utilized by Vpr to arrest the cell cycle. 
Several studies have documented the association of HIV-1 Vpr with a cellular protein 
that now is called DCAF-1 (DDB1- and CUL4-associated factor 1), also known as 
VprBP (Vpr-binding protein). Further research demonstrated the role of this protein in 
DNA replication and embryonic development. It has recently been demonstrated that 
Vpr exploits DCAF-1, damaged DNA-binding protein 1 (DDB1) and the cullin 4A 
(CUL4A) ubiquitin ligase complex to interfere with the DNA replication machinery 
of infected cells, resulting in cell-cycle arrest (Figure 1.4). The pathway exploited by 
Vpr implies that it functions as an adaptor protein in protein networks to interfere with 
the cell cycle and replication machinery (Giaccia & Kastan, 1998; Gieffers et al., 
2000; Hrecka et al., 2007; Wen et al., 2007). Vpr exploits DCAF-1 as an adaptor to 
engage DDB1 as a component of the CUL4A ubiquitin ligase complex. As this 
complex is involved in proteasomal degradation, it was suggested that G2 arrest is 
induced by Vpr through degradation of an unidentified protein that is needed for 
progression of cells from G2 arrest to mitosis (Wen et al., 2007). In fact, the CUL4A 
ubiquitin ligase complex acts as a pivotal step, regulating different cellular pathways 
by targeting proteins for ubiquitin-dependent degradation. It has recently been 
demonstrated that, in this complex, DDB1 interacts with multiple WD40-repeat 
(WDR) proteins, which serve as the substrate-recognition subunits of the CUL4-
DDB1 ubiquitin ligase. More than 150-300 WDR proteins have been identified in the 
human genome. Considering the variety of WDR proteins, the impact of biological 
processes through CUL4 ligase-mediated proteolysis can be understood. It has been 
reported that CDT2 interacts with the CUL4A ubiquitin ligase complex, enabling it to 
target CDT1 for degradation. CDT1 is a replication factor, depletion of which 
prevents DNA replication. Although cell-cycle arrest cannot be attributed to the 
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degradation of a single protein through CUL4 ligase-mediated proteolysis, which 
would result in G2 arrest, CDT1 can be addressed as a key protein that is 
ubiquitinated by the CUL4A ubiquitin ligase complex, activated by Vpr. Indeed, 
many other proteins may play similar roles in parallel with CDT1 (Higa & Zhang, 
2007; Jin et al., 2006; Rialland et al., 2002).  
 
 
Figure 1.4: Cell-cycle arrest by triggering ubiquitination. Vpr functions as an adaptor protein to 
interfere with the cell cycle and replication machinery. Vpr exploits DCAF-1 as an adaptor to engage 
DDB1, a component of the CUL4A ubiquitin ligase complex, which is involved in proteasomal 
degradation. DDB1 interacts with multiple WDR proteins, including CDT2, which serve as the 
substrate-recognition subunits of the CUL4A ubiquitin ligase complex. CDT2 enables the complex to 
target CDT1 for ubiquitin-dependent degradation. CDT1 degradation results in G2 arrest (Romani & 
Engelbrecht, 2009). 
 
It has been demonstrated that the expression of wild-type Vpr protein in HeLa cells 
induces transient herniations in the nuclear envelope. Sporadically and spectacularly, 
these herniations burst, releasing soluble nuclear proteins into the cytoplasm and 
presumably also allowing cytoplasmic proteins to enter the nucleus. The broken 
sections of the nuclear envelope apparently reseal within minutes. These transient 
ruptures of the nuclear envelope may provide an unconventional mechanism for 
nuclear entry that bypasses the size-restricted nuclear pore complexes. Bursting of the 
Vpr-induced nuclear herniations releases key cell cycle regulators, including the 
kinase Wee1, the phosphatase Cdc25C, and cyclin B into the cytoplasm of the host 
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cell. The repeated release of these proteins into the cytoplasm might explain how Vpr 
causes G2 arrest. Consistent with this idea, Vpr mutants that fail to cause herniations 
also fail to cause G2 arrest (Segura-Totten & Wilson, 2001). 
 
1.2.3 Induction of apoptosis by Vpr 
 
Although a variety of stimuli have been described as causes of apoptosis, apoptosis is 
regulated through one of two known cell death-signaling pathways: the extrinsic and 
intrinsic pathways. Both pathways share similar molecules (especially caspases) and 
features. The extrinsic pathway is initiated by external stimuli that are sensed by cell-
death receptors on the cell membrane. Mitochondria play the central role in the 
intrinsic pathway by releasing molecules that trigger apoptosis (Budihardjo et al., 
1999; Green, 2000). Several studies have shown that HIV-1 Vpr induces the intrinsic 
pathway of apoptosis in a number of human cell lines and to promote apoptosis during 
HIV-1 infection. Not only does Vpr induce apoptosis in infected cells, but it has also 
been suggested that induction of apoptosis in uninfected bystander cells is caused by 
Vpr. However, neither HIV-2 nor simian immunodeficiency virus Vpr induces 
apoptosis in mammalian cell lines. Induction of apoptosis by several other HIV-1 
proteins, including Nef, Vpu, Tat and Rev, has also been reported (Andersen et al., 
2008; Arokium et al., 2009; Chang et al., 2000; Conti et al., 2000; Stewart et al., 
1999; Yedavalli et al., 2005). While primary CD4+ T cells show high susceptibility to 
Vpr-inuced apoptosis, macrophages show a surprising resistance to HIV Vpr-induced 
apoptosis during infection and in non-virion associated forms in vitro. Therefor it has 
been suggested that Vpr may play a pivotal role in maintenance of macrophages as the 
reservires of HIV-1 (Thieu et al., 2009). 
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Apoptosis studies indicate that mitochondrial intermembrane proteins, including 
adenine nucleotide translocator (ANT), apoptosis-inducing factor (AIF), cytochrome 
c, procaspases and heat-shock proteins (HSPs), are released during apoptosis and are 
essential for the activation of caspases and DNases. Several studies have 
demonstrated that HIV-1 Vpr permeabilizes the mitochondrial membrane by binding 
to the permeability transition pore complex (PTPC); lack of PTPC results in resistance 
to the apoptotic effect of Vpr. It has also been demonstrated that, in the presence of 
Vpr, cytochrome c is released from mitochondria, resulting in apoptosis. In fact, the 
mechanism responsible for mitochondrial-membrane permeabilization involves a 
number of proteins, including PTPC, proapoptotic members of the Bcl-2 family, ANT 
and the voltage dependent anion channel (VDAC) (Jacotot et al., 2000).  
 
The impact of Vpr on mitochondrial-membrane permeability is also attributed to its 
interaction with ANT in the inner mitochondrial membrane. It is believed that the 
interaction between Vpr and ANT cooperatively forms large conductance channels in 
the inner membrane. This suggests that the interactions of Vpr with PTPC and ANT 
lead to the formation of channels in the outer and inner mitochondrial membranes, 
respectively. These events in turn result in release of a number of molecules, such as 
cytochrome c, from mitochondria (Jacotot et al., 2001; Yedavalli et al., 2005). The 
released cytochrome c molecules bind to Apaf-1 (apoptotic peptidase-activating factor 
1) and form apoptosome complexes that become activated by caspase 9. Activated 
apoptosome complexes trigger the caspase cascade and apoptosis (Figure 1.5) (Kim et 
al., 2005; Muthumani et al., 2002b; Zhu et al., 2003).  
 
It has been documented that a conserved motif in the C-terminal region of Vpr is 
responsible for the induction of apoptosis. Interestingly, the C-terminal peptides 
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containing the conserved sequence at AA 71–82 can even induce apoptosis. 
Extracellular addition of C-terminal peptides to human CD4+ T cells causes 
membrane permeabilization, DNA fragmentation and formation of apoptotic bodies, 
which are all signs of apoptosis. Similar effects can also be observed by adding the 
polypeptides to yeast, indicating that Vpr targets fundamental cellular pathways 
common to many eukaryotic cells (Arunagiri et al., 1997).  
 
The number of molecules that have been found to be involved in Vpr-induced 
apoptosis is still increasing. For example, HS1-associated protein X-1 (HAX-1) has 
also been demonstrated as a target for Vpr in the induction of apoptosis. HAX-1 is a 
proapoptotic factor that is found mainly in mitochondria. Overexpression of HAX-1 
has been found to inhibit Vpr-induced apoptosis. These findings and others suggest 
that additional mechanisms and molecules may be utilized by Vpr for induction of 
apoptosis (Vafiadaki et al., 2009; Vafiadaki et al., 2006; Yedavalli et al., 2005). 
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Figure 1.5: Induction of apoptosis through impact of Vpr on mitochondrial-membrane 
permeability and release of cytochrome c. (a) Vpr interaction with ANT and PTPC in mitochondrial 
membranes cooperatively forms large channels in the inner and outer mitochondrial membranes, 
respectively. Cytochrome c molecules are released from the channels. (b) The released cytochrome c 
molecules bind to Apaf-1 proteins and (c) apoptosome complexes are formed. (d) Caspase 9 activates 
apoptosomes; (e) once the apoptosome is activated; it triggers a caspase cascade, resulting in apoptosis 
(Romani & Engelbrecht, 2009). 
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The proapoptotic property of each form of Vpr (soluble, intracellular or virion-
associated) has been studied. It is now clear that de novo expressed Vpr can induce 
apoptosis in various types of cells in vitro and in vivo. Recombinant Vpr has been 
indicated to induce apoptosis in neuronal cells, thus mimicking the potential in vivo 
effects of the extra-cellular soluble form of Vpr found in the plasma and cerebrospinal 
fluid of HIV infected patients. Recently, it has been shown that virion-associated Vpr 
is also able to trigger apoptosis. This form of Vpr induces apoptosis through caspases 
-3, -7 and -9 in human T cells independently of other HIV de novo expressed proteins. 
Vpr has been shown to activate caspase-8, the initiator caspase of the death receptor 
pathway. However, activation of caspases by virion-associated Vpr is independent of 
the Fas death receptor pathway. It has been suggested that virion-associated Vpr can 
contribute to the depletion of CD4+ lymphocytes either directly or by enhancing Fas 
mediated apoptosis during acute HIV-1 infection and in AIDS (Arokium et al., 2009). 
 
It is believed that Vpr-induced apoptosis contributes to the adverse effects of HIV-1 
on neurons that occurs in HIV-1 infected individuals. Soluble Vpr protein is 
detectable in the CSF and serum of HIV-1-infected patients with neurological 
disorders. A number of studies have suggested that HIV-1 Vpr might be a potential 
toxic molecule mediating neuronal cell death during HIV-1 infection, albeit at high 
concentrations. In vitro studies of cultured rat hippocampal neurons, rat cortical and 
striatal neurons, or human neuronal cell lines have revealed that HIV-1 Vpr might 
cause neuronal apoptosis (Jones et al., 2007). 
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1.2.4 Modulation of gene expression by Vpr 
 
Although the first reported function for Vpr was transactivation of the virus long 
terminal repeat (LTR), the mechanism has not yet been elucidated completely. The 
ability of Vpr to induce G2 arrest has also been linked to transactivation of the LTR. 
Transactivation activity of the LTR during G2 is five to ten times higher than that 
during G1; therefore, the reproduction level of wild-type HIV-1 is five to ten times 
higher than that of Vpr-mutated viruses, indicating the importance of transactivation 
by Vpr (Zhu et al., 2001). Indeed, Vpr transactivation activity is moderate as 
compared to HIV-1 Tat protein transactivation, which is stronger (Kino & Chrousos, 
2004; Poon et al., 2007). Vpr affects not only virus replication, but also cellular gene 
expression, proliferation and differentiation. As Vpr circulates in the blood of HIV-1-
infected individuals, it may also affect the gene expression of non-infected cells 
(Balasubramanyam et al., 2007; Xiao et al., 2008).  
 
Vpr-induced viral transcription in quiescent cells, such as macrophages, becomes 
more striking at low viral input states, which more closely approximates human 
infection. Vpr significantly increases the expression of unintegrated HIV-1 DNA that 
is the prevalent form of viral DNA in patients on highly active antiretroviral therapy. 
This can serve as latent reservoirs for HIV-1. These observations underscore the 
importance of Vpr in viral transcription and replication (Thieu et al., 2009).  
 
Vpr has been shown to function as a necessary factor in the primary infection of 
resting macrophages and to enhance viral reproduction following latency. The Vpr-
induced transactivation of LTR is believed to play a pivotal role in reactivation of 
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latent resorvires. Since Vpr is present in the plasma of HIV-1-positive patients and it 
is necessary for infection of resting macrophages it is believd that Vpr could 
reactivate viral production from latency (Hoshino et al., 2010). 
 
The efficacy of transactivation of LTR apparently correlates with the Vpr-induced G2 
arrest in host cells. It has been demonstrated that LTR activity is increased in the G2 
phase of the cell cycle. Vpr mutants lacking the ability to induce G2 arrest fail to 
increase HIV-1 LTR expression. On the other hand, the HIV-1 and -2 strains lacking 
Vpr can increase LTR transcription through induction of G2 arrest via other means, 
thus suggesting that the ability of Vpr to prolong the G2 phase of infected cells is 
sufficient for LTR transactivation. It has been suggested that G2 arrest creates a 
cellular milieu which supports LTR activation, probably by allowing cell cycle 
transcription factors more time to exert their full effect on the HIV LTR (Thieu et al., 
2009). 
 
Modulation of gene expression by Vpr has been shown to prevent establishment of 
chronic infections in T cells that could have minor effect on total virus burden. But it 
has been shown that Vpr-mediated transactivation of HIV-1 LTR in peripheral blood 
mononuclear cells results in viral gene transcription after infection. The major 
reservoir of infected cells in vivo contains latent rather than active proviruses. 
Therefore, the importance of Vpr in macrophages could ensure its continued selection 
in vivo (Rogel et al., 1995; Vanitharani et al., 2001).  
 
As already mentioned, Vpr enhances the activity of the HIV-1 promoter located in the 
LTR. This region is also a target for the p53 and Sp1 transcription factors. The ability 
of Vpr to stimulate the HIV-1 promoter is affected negatively in the presence of p53. 
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Sp1 is a cellular transcription factor essential for the transcriptional activation of the 
LTR by Vpr (Pauls et al., 2006; Sawaya et al., 1998). Vpr specifically activates HIV-
1 LTR-directed transcription on a minimal promoter containing a TATA box and the 
binding motifs for Sp1. Studies indicate that Vpr contains a leucine zipper-like 
domain, AA 60–81 in α-helix III, which interacts with Sp1 when it is bound to the 
Sp1 motifs on the HIV-1 LTR (Wang et al., 1995; Wang et al., 1996). It has been 
reported that Vpr cooperates with nuclear receptor coactivators p300/CBP and SRC-
1a to activate the glucocorticoid-responsive mouse mammary tumor virus promoter 
(MMTV). Several studies have also reported that Vpr transactivates the HIV-1 LTR 
promoter by direct interaction with the p300 coactivator. It has been suggested that 
Vpr recruits p300/CBP to transactivate the HIV-1 LTR (Kino et al., 2002).  
 
Direct interaction between HIV-1 Vpr and the glucocorticoid receptor (GR) has also 
been reported to affect virus replication and gene expression. Human Vpr-interacting 
protein (hVIP) is also critical for the interaction of HIV-1 Vpr with GR. 
Glucocorticoids exert anti-inflammatory and immunosuppressive effects by 
interacting with their specific intracellular receptors, such as GR. Recent studies 
suggest that Vpr mimics some of the effects of glucocorticoids through interaction 
with GR (Ramanathan et al., 2002). Vpr has also been suggested to bind to the LTR 
through interaction with GR. Vpr shares the LXXLL motif, aa 64-68, with steroid-
receptor coactivators. This motif enables Vpr to bind to ligand-activated GR. These 
results suggest that Vpr functions as an adaptor molecule to connect the different 
molecules required for high promoter activity (Kino et al., 2002; Shrivastav et al., 
2008).  
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HIV-1 Vpr has been demonstrated to bind specifically to the general transcription 
factor TFIIB. The interacting motif of TFIIB overlaps the domain of TFIIB that is 
involved in the intramolecular bridge between its N and C termini. Binding of Vpr 
may induce a conformational change in TFIIB that could possibly affect its activity 
(Agostini et al., 1999; Agostini et al., 1996).  
 
Nuclear factor κB (NF-κB) is one of the main mediators of the HIV-1 LTR. The N-
terminal region of NF-κB mediates DNA binding, dimerization and interaction with 
inhibitory proteins. Activator protein 1 (AP-1) is also a transcription factor that has 
been suggested as a mediator for Vpr. Some studies have shown that the extracellular 
form of synthetic Vpr can stimulate the HIV-1 LTR via both AP-1 and NF-κB 
activation. Extracellular Vpr is commonly found in the blood of HIV-positive 
individuals and may be involved in the stimulation of virus transactivation. Although 
no receptor has yet been identified for extracellular Vpr, studies using confocal 
microscopy indicate that it can enter cells easily, and it is believed that even this form 
of the protein enhances transcription of the promoters that interact with NF-κB and 
AP-1 (Varin et al., 2005).  
 
Upregulation of human survivin at the transcriptional level by HIV-1 Vpr has also 
been reported. Human survivin is involved in inhibition of apoptosis and regulation of 
cell division. The survivin gene is regulated in a cell cycled-pendent manner. Vpr 
specifically upregulates survivin expression through a cell cycle-regulated 
mechanism. It is still not clear what elements on the survivin gene are used in survivin 
upregulation by Vpr (Zhu et al., 2003).  
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The transactivation activity of Vpr is related to the cis-acting elements within the U3 
region of the HIV-1 LTR, and the binding sites for several proteins, including Sp1, 
NF-κB, AP-1 and GRE, also lie in this region. The impact of Vpr on Nef expression 
from unintegrated HIV-1 has recently been demonstrated, suggesting that Vpr 
increases Nef expression before integration (Poon et al., 2007; Varin et al., 2005).  
 
1.2.5  Role of Vpr in suppression of immune activation  
 
Although many studies indicate that HIV-1 Env, Tat and Nef affect immune 
responses (Muthumani et al., 2005), the immune suppression observed in HIV-1-
infected patients is also partly attributed to Vpr. This protein suppresses antigen-
specific CD8-mediated cytotoxic T-lymphocyte (CTL) and T-helper type 1 (Th1) 
immune responses. The molecular mechanisms of the suppression of CTL and 
antibody production by Vpr are still under debate, but it has been suggested that Vpr 
may prevent production of antibodies against the virus by inhibiting T-cell clonal 
expansion through inducing G2 arrest and suppressing T-cell proliferation. Since T 
cells stimulate B cells to produce antibodies, inhibition of T cell expansion may affect 
antibody production. Suppression of the host inflammatory responses by Vpr has also 
been reported. Vpr downregulates proinflammatory cytokines and chemokines, 
resulting in inhibition of the host inflammatory responses (Muthumani et al., 2004a; 
Zhao et al., 2005). A recent study also suggests that Vpr may alter sensitivity to 
insulin and thereby play a role in the development of lipodystrophy and insulin 
resistance (Shrivastav et al., 2008).  
 
In vitro studies have implicated the ability of Vpr to downregulate the expression of 
several immunologically important molecules on macrophages and dendritic cells 
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which are involved in stimulation of T cells, such as CD40, CD80, CD83 and CD86,. 
Vpr reduces the capacity of monocytes to mature to dendritic cells in tissue culture 
(Muthumani et al., 2004b). A recent study indicates that Vpr impairs natural killer 
(NK) cell function in vitro. Production of gamma interferon is reduced in these 
impaired NK cells (Majumder et al., 2008). It has also been shown that Vpr triggers 
natural killer cell-mediated lysis of infected cells through activation of the ATR-
mediated DNA-damage response (Ward et al., 2009).  
 
Many of the experiments indicating that Vpr suppresses immune-cell activation and 
cytokine production have been performed in vitro. Vpr targets and suppresses NF-κB 
activity, which is critical for T-cell activation and cytokine production. Similar results 
have been obtained from several in vivo studies (Ayyavoo et al., 2002; Muthumani et 
al., 2005). In a plasmid vaccine model using Vpr-expressing vectors, Vpr altered the 
induction of the CD8+ T-cell response. The mechanism of immune suppression could 
be complex and may be related to G2 arrest in T cells, suppression of NF-κB, 
induction of apoptosis in T cells and the GR pathway. Even in the absence of the 
effect of Vpr on CD8+ T cells, the immune response is affected by targeting antigen-
presenting cells and T-helper cells, indicating the multi-faceted nature of immune 
suppression by Vpr (Muthumani et al., 2002a).  
 
Another explanation for the possible mechanism of immune suppression by Vpr 
focuses on the GR pathway. As already mentioned, the direct interaction between Vpr 
and GR is well established. Glucocorticoids are known to control inflammation and to 
induce immunosuppressive signals by binding to GR (Andersen & Planelles, 2005). 
Interestingly, the GR–Vpr complex is also able to induce similar effects and is 
suppressed by GR-pathway inhibitors. Apparently, Vpr mimics the interaction of 
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glucocorticoids with GR to suppress immune activation (Moon & Yang, 2006; 
Muthumani et al., 2006).  
 
1.2.6   Induction of DNA double-strand breaks (DSBs) by Vpr 
 
Vpr has been implicated to induce DSBs and increase gene amplification (Shimura et 
al., 1999). Studies using fluorescence in situ hybridization of amplified DNA 
indicated that a bridge-breakage fusion cycle, a proposed mode of gene amplification 
triggered by DSBs, is involved in gene amplification induced by Vpr (Ishizaka et al., 
1995; Nakai-Murakami et al., 2007). Vpr-induced DSBs have also been documented 
by a different approach using pulse-field gel electrophoresis (PFGE).  Tachiwana et 
al. have shown that an altered migration pattern of high-molecular-weight DNA is 
observed in the genomic DNA prepared from HIV-1 infected cells. A similar 
electrophoresis pattern of DNA is also observed in cells treated with X-ray irradiation. 
Mutant virus lacking a functional Vpr induced slight DNA damage, suggesting that 
Vpr is a major viral component responsible for HIV-1-induced DSBs (Tachiwana et 
al., 2006). 
 
Clarifying the role DSB-sensing cellular signals in viral infection is important. It has 
been suggested that ataxia telangiectasia mutated (ATM), a serine/threonine-specific 
protein kinase, is involved in repairing the nucleotide gaps generated between host 
and viral DNAs. Without this repair, apoptosis would be triggered because the DNA 
gaps that could be recognized as DNA damage, causing viral infection to be abortive. 
NBS1 is a protein complex that plays essential roles in the human cellular DNA-
damage response. NBS1 promotes viral transduction by associating with viral DNA 
and employing ATM to the integration site. In addition to ATM, ATR contributes to 
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the HIV-1 provirus integration during post-integration repair processes, but the 
recruitment of ATR proceeds independently of ATM or NBS1 (Smith et al., 2008). 
Activation of ATM-dependent signal pathways by Vpr-induced DSBs results in the 
upregulation of the process which repairs the nucleotide gaps. It has been implicated 
that the role of ATM-dependent signaling is more prominent in resting macrophages 
because ATR is not expressed in resting macrophages. This confirms the proposed 
functions of Vpr, which is essential for HIV-1 infection of macrophages (Nakai-
Murakami et al., 2009). 
 
In vitro studies provide several possible mechanisms by which Vpr may induce DSBs. 
Incubation of isolated nuclei with Vpr has induced DSBs. It has been shown that the 
highly conserved HFRIG motif present in the C-terminal region of Vpr is essential for 
G2 cell cycle arrest. It has also been suggested that the DNA binding activity of Vpr 
is linked with the induction of G2 cell cycle arrest. In contrast, it was reported that the 
nuclear localization of Vpr is not necessary for G2 arrest. Even Vpr mutants that 
localized in the cytoplasm are still able to induce G2 arrest, indicating that DNA-
binding is required for the induction of DSBs but not for G2 arrest (Nakai-Murakami 
et al., 2009). A number of studies have linked the mechanism of Vpr-induced ATR 
activation with impaired nucleotide excision repair. Vpr interferes with the cellular 
ubiquitin proteasome system by inhibiting the complex formation of factors such as 
DCAF1 and Cul4/DDB1 (Dehart et al., 2007; Hrecka et al., 2007; Schröfelbauer et 
al., 2007). 
 
HIV-1-infected patients suffer from a high risk for cancer development with Kaposi’s 
sarcoma and non-Hodgkin’s lymphoma being the major AIDS-related cancers (Biggar 
et al., 1996). Vpr has been found in the serum of HIV infected patients, at a 
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concentration of approximately 0.7 nM (Hoshino et al., 2007). Vpr has also been 
detected in patients who did not suffer from clinical immunodeficiency symptoms. In 
vitro experiments have shown that the physiological concentration of Vpr can induce 
DSBs, it seems logical to imagine that DSBs can be generated within HIV-1-positive 
patients. In addition, it has been observed that the frequency of aneuploidy in 
peripheral blood cells increased after infection with HIV-1. Recently, it has been 
proposed that Vpr induces DNA damage, mimicking the activity of the anticancer 
drug cisplatin. These observations strongly suggest that Vpr is positively involved in 
HIV-1-associated malignancies (Nakai-Murakami et al., 2009). 
 
1.2.7  Role of Vpr in fidelity of reverse transcription 
 
HIV-1 RT is an error-prone enzyme that misincorporates approximately one 
nucleotide in every 2000–5000 polymerized nucleotides (Basavapathruni & 
Anderson, 2007; Li et al., 1997). Reverse transcription of the HIV-1 genomic RNA is 
initiated in the virus core, where NC is associated with the RNA genome. The 
reverse-transcribed genome is directed toward the nucleus by the viral and cellular 
proteins forming the PIC (Gao et al., 2007; Sun et al., 1997). A number of studies 
have confirmed that Vpr colocalizes with IN and virus nucleic acids within the PIC, 
and remains associated with the viral DNA within 4–16 h after infection (Le-Rouzic 
& Benichou, 2005).  
 
HIV-1 Vpr interacts with a cellular protein, uracil–DNA glycosylase 2 (UNG2), 
which is a DNA-repair enzyme involved in nucleotide-excision repair. Uracil can be 
introduced into DNA either by cytosine deamination or by misincorporation of dUTP 
(Chen et al., 2004; Mansky et al., 2000). If the uracil is not repaired by UNG2, after 
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the next round of replication, a CAT transition mutation occurs in that DNA strand 
and a GAA transition mutation occurs in the opposite strand of DNA. In the absence 
of Vpr, a fourfold increase in the rate of GAA mutations has been reported in each 
round of HIV-1 replication (Chen et al., 2002). These GAA mutations are the main 
mutational force in the evolution of drug-resistant HIV-1 strains (Berkhout & de-
Ronde, 2004). On the other hand, accumulation of these mutations can result in 
nonfunctional genomes (Keele et al., 2008; Priet et al., 2003). Vpr may play a role in 
virus evolution by balancing the level of mutations.  
 
Several studies have established that the interaction of Vpr with UNG2 in order to 
incorporate it into HIV-1 virions correlates with the influence of Vpr on the HIV-1 
mutation rate (Chen et al., 2002). The interaction between Vpr and UNG2 has been 
demonstrated both in vitro and ex vivo in Vpr-expressing cells. Vpr has been found to 
incorporate the nuclear form of UNG2 into HIV-1 virions. HIV-1 IN may also 
participate in the virion incorporation of UNG2, but the role of Vpr in the virion 
incorporation of UNG2 seems to be more essential and is correlated with the ability of 
Vpr to alter the mutation rate of HIV-1 (Chen et al., 2004; Mansky, 1996).  
 
dUTPases are another class of enzymes that inhibit uracil incorporation into DNA 
during DNA synthesis, but utilize a mechanism distinct from that utilized by UNG2. 
Both UNG2 and dUTPase are encoded by some DNA viruses, such as poxviruses and 
herpes viruses. Some retroviruses encode only dUTPase. The genomes of non-primate 
lentiviruses, such as equine infectious anemia and feline immunodeficiency viruses, 
contain a dUTPase-encoding sequence as an integral part of the pol gene, lying 
between the RNase H and IN sequences. In contrast, the genomes of primate 
lentiviruses do not contain gene sequences encoding either dUTPase or UNG2. It is 
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believed that the interaction of HIV-1 Vpr with cellular UNG2 compensates for the 
lack of a viral dUTPase to correct uracil misincorporation into virus DNA 
(Bouhamdan et al., 1996).  
 
Vpr has been reported to interact through its N terminus with Lys–tRNA synthetase. 
This interaction has been observed both in vitro and ex vivo. Several cellular and viral 
proteins interact with Vpr and induce conformational changes that expose the N-
terminal region of Vpr and thus regulate its affinity for Lys–tRNA synthetase. During 
the early stages of HIV replication, Vpr binds to NCp7, which may expose the N-
terminal region of Vpr, resulting in a high affinity for Lys–tRNA synthetase. During 
the later stages of infection, the N-terminal region of Vpr interacts with the HIV-
encoded p6, which may also affect Vpr interaction with the Lys–tRNA synthetase. As 
tRNALys acts as a primer for initiation of reverse transcription of the HIV-1 genome, it 
suggests that this mechanism is utilized by Vpr to potentiate HIV-1 reverse 
transcription (Stark & Hay, 1998). 
 
1.2.8  Regulating RNA splicing by Vpr 
 
Primary transcripts of eukaryotic genes usually contain exons that are interrupted by 
introns.  Introns are removed from the pre-mRNA by splicing in the nucleus (Krämer, 
1996). During splicing, recognition of splice sites is carried out through the stepwise 
assembly of spliceosomal complexes E, A, B, and C on the pre-mRNA (Hastings & 
Krainer, 2001). A complex pattern of alternative splicing generates more than 30 
mRNA species from the primary mRNA transcript of the HIV-1 genome (Tang et al., 
1999). This sophisticated pattern of splicing is required to produce mRNAs for the 
viral proteins, and, undoubtedly, plays a critical role in the regulation of HIV-1 gene 
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expression. Viral mRNA species are classified into three groups. The 2kb-class of 
mRNAs, which are fully spliced and exported to the cytoplasm early in the HIV-1 
replication cycle. The singly spliced 4kb-class of mRNAs, which are bicistronic, and 
encode Env, Vpr, Vif, and Vpu. The unspliced 9kb-class of mRNA, which encodes 
Gag and the Gag-Pol polyprotein, and also serves as the source of HIV-1 genomic 
RNA for packaging into HIV-1 virions (Zhang & Aida, 2009).  
 
Regulating the expression of all viral genes is essential for viral replication and 
successful infection. Several suboptimal HIV-1 acceptor sites have been described, 
such as short and interrupted polypyrimidine tracts (O'Reilly et al., 1995; Si et al., 
1997), and irregular branch point sequences (Damier et al., 1997; Dyhr-Mikkelsen & 
Kjems, 2005). Furthermore, there is abundant evidence for the existence of several 
cis-acting elements within the HIV-1 genome such as the exonic splicing silencer 
(ESS), intronic splicing silencer (ISS), and exonic splicing enhancer (ESE) elements 
(Amendt et al., 1995; Caputi et al., 1999; Pongoski et al., 2002; Tange et al., 2001).  
 
SAP145 is an essential component of SF3b, a key factor in spliceosome assembly. It 
has been shown that SAP145 is required for Vpr-induced inhibition of pre-mRNA 
splicing. In a recent report, Vpr was found to play a novel role as a regulator of pre-
mRNA splicing both in vivo and in vitro (Hashizume et al., 2007; Kuramitsu et al., 
2005). SAP145 binds to pre-mRNA and tethers the U2 snRNP to the branch point 
site, which is required for complex A assembly. Thus, in addition to the interaction 
between Vpr and SAP145, it was suggested that Vpr plays a role in splicing. Vpr has 
been shown to bind to RNA through its carboxy-terminal basic domain, which 
suggests the possibility of a functional association with the pre-mRNA. Vpr has been 
shown to inhibit the splicing of certain pre-mRNAs, such as the immunoglobulin 
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M pre-mRNA and the α/β-globin pre-mRNAs, and cause the accumulation of 
incompletely spliced forms. Because the studies showing inhibition of splicing are 
performed at a time in the viral life cycle when Vpr is not efficiently able to induce 
G2 arrest, these novel effects of Vpr must occur via a new pathway rather than arrest 
of the cell cycle at G2. Vpr expressed from an HIV-1 provirus is consistently 
sufficient to inhibit splicing of α-globin 2 pre-mRNA in infected cells (Zhang & Aida, 
2009). 
 
Vpr has also been shown to regulate Env expression by interfering with env pre-
mRNA splicing. Vpr specifically inhibits the removal of the 3´ intron of HIV-1, but 
not the 5  intron. This function of Vpr results in the accumulation of env mRNAs that 
belong to the singly spliced 4-kb class of mRNAs. Consequently, the expression of 
Env is elevated, which provides more Env proteins to be incorporated into the virion 
and maintains the high infectivity of the virus (Zhang & Aida, 2009). 
 
It has been shown that Vpr interacts with SAP145, resulting in the inhibition of 
SAP145 binding to the splicing factor SAP49 which interacts specifically with both 
SAP145 and the pre-mRNA within the essential SF3b splicing factor complex. 
However, interfering with the association between Vpr, SAP145, and SAP49 may 
affect RNA processing, rather than leading to G2 arrest, since the R80A Vpr mutant 
can bind to SAP145 and inhibit pre-mRNA processing but fails to induce G2 arrest 
(Hashizume et al., 2007). Vpr has been suggested to interfere with the assembly of the 
spliceosome, resulting in the inhibition of splicisome. Consistently, it has been 
demonstrated that Vpr binds to U1-70K, U2AF65, U2B, U1 and U2 snRNAs, as well 
as SAP145. These data suggest that Vpr associates with functional spliceosomes to 
regulate splicing (Zhang & Aida, 2009).  
 52
 
1.2.9  Virion incorporation of Vpr 
 
Vpr is the major virion associated accessory protein of HIV-1. Since Vpr is not part of 
the p55 Gag polyprotein precursor (Pr55gag), its incorporation requires an anchor to 
associate with the assembling viral particles. Although the molecular mechanism is 
still unclear, the C-terminal region of the Pr55gag corresponding to the p6 domain 
appears to constitute such an anchor essential for the incorporation of Vpr into the 
newly assembling virions. Pr55gag has been implicated to physically interact with 
Vpr. Mutations affecting the integrity of the conserved LXSLFG motif of p6gag 
completely impair the interaction between Vpr and the Pr55gag and consequently 
prevent Vpr virion incorporation. Vpr and the Pr55gag demonstrate a strong 
interaction in vitro (Bachand et al., 1999). 
 
The karyophilic property of Vpr has raised the paradox why the nuclear localization 
of Vpr does not interfere with its virion incorporation. The answer can be found in the 
ability of Vpr to shuttle between the nucleus and cytoplasm. Vpr has been 
characterized as a nucleocytoplasmic shuttling protein which contains two novel 
nuclear import signals and an exportin-1-dependent nuclear export signal (NES). 
Mutations in this NES impair the incorporation of Vpr into newly formed virions. Vpr 
NES has been shown to be required for efficient HIV replication in tissue 
macrophages present in human spleens and tonsils. It is believed that this property of 
Vpr to shuttle between the nucleus and cytoplasm not only contributes to nuclear 
import of the HIV-1 PIC but also enables Vpr to be present in the cytoplasm for 
incorporation into virions, resulting in enhancement of viral spread within 
nondividing tissue macrophages (Sherman et al., 2003b). Mutations impairing the 
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virion incorporation of Vpr have been reported in HIV long-term non-progressors, 
implying a link between efficient virion incorporation of Vpr and HIV disease 
progression (Caly et al., 2008). 
 
1.2.10  Additional interactions and possible functions of Vpr 
 
HIV-1 Vpr has been observed to form ion channels in planar lipid bilayers, resulting 
in an inward sodium current followed by cell death in cell cultures. Mutagenesis 
studies have shown that the N-terminal region of Vpr is responsible for the above 
functions. A 40 AA peptide in the N-terminal region of Vpr is sufficient to form ion 
channels that are able to cause cell death. It is believed that this region is responsible 
for the ion-channel activity and cytotoxic effects of Vpr. These effects could be 
caused by the extracellular form of Vpr that is found in the serum and cerebrospinal 
fluid of AIDS patients (Piller et al., 1999; Piller et al., 1998). Extracellular Vpr can 
also disturb neuronal communication, resulting in neuronal dysfunction (Rom et al., 
2009). It also inhibits neuronal development through the induction of mitochondrial 
dysfunction (Kitayama et al., 2008). Apparently, extracellular Vpr induces different 
levels of cytopathogenicity depending on the cell type (Huang et al., 2000).  
 
The interaction of HHR23A, a protein involved in nucleotide-excision repair, with 
HIV-1 Vpr has also been reported. It has been demonstrated that a C-terminal, 45 AA 
region of HHR23A binds to Vpr. Overexpression of HHR23A results in partial 
alleviation of the G2 arrest induced by Vpr. It has therefore been suggested that the 
interaction between Vpr and HHR23A could be involved in the G2 arrest induced by 
Vpr (Engler et al., 2001; Withers-Ward et al., 1997). 
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HIV-1 Vif expression has recently been implicated in the inhibition of Vpr-mediated 
G2 arrest, and deletion of Vif from the HIV-1 genome results in an increase in Vpr-
induced G2 arrest. In addition, T cells infected with Vif-deleted HIV-1 express higher 
levels of Vpr than cells infected with the wild-type virus. It has been suggested that 
inhibition of Vpr by Vif is mediated by proteasomal degradation, similar to the other 
proteins that are directed toward proteasomal degradation by Vif (Wang et al., 2008). 
 
1.2.11  The reasons for the abundance of Vpr interactions 
 
Interaction of a single protein with a variety of other different proteins may seem 
surprising. Some proteins, such as proteinases, chaperones and ubiquitin, interact with 
different proteins and direct them toward one pathway, e.g. proteinases only degrade 
proteins. The amazing property of Vpr is that this small polypeptide interacts with 
variety of proteins and directs them toward different pathways. Several hypotheses 
have been suggested to explain the capability of Vpr to exert so many effects through 
direct protein-protein interactions. One hypothesis suggests that Vpr possesses 
structural features similar to those of HSP70, a cellular chaperone, enabling Vpr to 
bind to many proteins with sufficient energy to cause changes in the activity of target 
proteins (Basanez & Zimmerberg, 2001).  
 
In an attempt to find a common characteristic for the proteins that interact with Vpr, 
the WXXF motif (where X is unknown) was identified as an important criterion in 
some Vpr-interacting proteins. The WXXF motif of UNG2 was implicated in its 
interaction with Vpr. The N-terminal region of TFIIB, which binds specifically to 
Vpr, also contains the WXXF motif. Mutant forms of TFIIB that have a point 
mutation in the WXXF motif are not able to interact with Vpr. Interestingly, it was 
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demonstrated that, by attaching the WXXF motif to a non-human protein, 
chloramphenicol acetyltransferase, it was incorporated into HIV-1 virions in the 
presence of Vpr (Agostini et al., 1999; Bouhamdan et al., 1998; Yao et al., 2002). 
Although the main functions of Vpr have been fairly well described and elucidated, 
there are still several interactions between Vpr and proteins of which the functions 
still need to be clarified. 
 
1.2.12. Diversity of mutations in Vpr 
 
Based on the phylogenetic analysis, HIV-1 has been classified into three groups; M, 
N, and O, with viral subtypes in each group (Salminen et al., 1995). The genetic 
diversity of viral isolates has been documented throughout the genome, specifically, 
the env gene exhibits high variation. The variation observed in HIV-1 genes in the 
form of changes at the nucleotide level,  should result in one of the possible scenarios: 
(1) no change in the amino acid, (2) conservative change in the amino acid, (3) 
nonconservative change in the amino acid, and (4) premature stop codon leading to a 
truncated protein (Coffin, 1995; Pang et al., 1991). Therefor, it is likely that the 
variation may impact on the function of the protein, depending on the nature of the 
mutation. Several studies have provided a base for understanding the consequences of 
natural polymorphisms in specific regions of the Vpr molecule. However, it is also 
possible that other mutations (second site or compensatory mutations) may modify the 
effect of a specific mutation and a comprehensive analysis is needed to delineate the 
role of specific residues in Vpr protein. Tungaturthi et al. (2004a) have analyzed the 
sequences of HIV-1 Vpr of different subtypes available in genebanks and described 
the possible natural mutations that could be found in Vpr proteins. These mutations 
are listed in Table 1.1. 
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Table 1.1: Variant amino acid residues reported in HIV-1 Vpr of different subtypes (Tungaturthi 
et al., 2004a). 
Residue Residue in NL4-3 Vpr Variant residues reported in Vpr 
1 M no change 
2 E K 
3 Q R, L 
4 A P, S, T,V 
5 P L 
6 E A, D, G, Q 
7 D E, G, N 
8 Q A, H, R 
9 G R 
10 P S 
11 Q A, P 
12 R K 
13 E Q, V 
14 P no change 
15 H F, M, N, S, Y 
16 N A, H, I, Q, S, T 
17 D A, D, G, Q 
18 W no change 
19 T A, I, M 
20 L I, V 
21 E D, K, T 
22 L I, P, T, V 
23 L S, V 
24 E D, R 
25 E D, G, K 
26 L F, I 
27 K no change 
28 N A, E, H, I, Q, R, S, T 
29 E v 
30 A D, S 
31 V I 
32 R K 
33 H no change 
34 F Y, L 
35 P H 
36 R G, K, Q, W 
37 I D, E, G, H, L, M, P, Q, S, T, V 
38 W C, F, Y 
39 L no change 
40 H L, M, Q, Y 
41 G A, D, N, Q, S 
42 L C, I 
43 G E, R 
44 Q K, N 
45 H L, Y 
46 I V 
47 Y no change 
48 E A, D, H, N, S, T, Y 
49 T N 
50 Y H 
51 G E, K, R 
52 D no change 
 57
53 T A, N, S 
54 W G, R 
55 A E, G, L, P, R, S, T, V 
56 G no change 
57 V A, L 
58 E G, I, K, M, Q, V 
59 A I, M, N, T, V 
60 I L, M, V 
61 I L, T, V 
62 R K 
63 I F, L, M, S, T 
64 L V 
65 Q no change 
66 Q L, R 
67 L I, M, Q 
68 L I, M, R 
69 F L 
70 I A, T, V 
71 H L, Y 
72 F Y 
73 R no change 
74 I no change 
75 G K, R 
76 C S, Y 
77 R H, L, Q 
78 H Y 
79 S N 
80 R no change 
81 I M 
82 G D, S 
83 V I 
84 T F, I, L, M, N, P, V, W 
85 R A, L, P, Q, T, V, Y 
86 Q G, R, S 
87 R G, M, S, T 
88 R E, G 
89 A E, G, I, P, R, S, T, V 
90 R G, N, S 
91 N D, K, S 
92 G A, R 
93 A F, G, M, P, S, T, V 
94 S E, F, G, N, R 
95 R A, K, P 
96 S F, P, V 
 
 
 
Since the vpr gene has a conserved nature in primate lentiviruses, it has been 
suggested that the optimal function of Vpr is achieved by natural selection of 
naturally occurring Vpr mutants in the infected individuals (Macreadie et al., 1995; 
Rouzic & Benichou, 2005; Tristem et al., 1992). There are currently no data 
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pertaining to the functional consequences of naturally occurring mutations in Vpr, 
however it seems logical that naturally occurring mutations may differentially affect 
the functions of Vpr. It has been suggested that the mutations in Vpr represent amino 
acid residues with optimal functions selected in vivo and these mutations might be 
beneficial to Vpr (Tungaturthi et al., 2004b). In addition to mutations, it has been 
shown that the subtype of Vpr also affects its functions such that the functions of Vpr 
are thought to be subtype-dependent. In several studies, the ability of Vpr to induce 
apoptosis has been compared for several subtypes and different levels of apoptosis 
induction have been observed (Bano et al., 2009b; Jian & Zhao, 2003a). However, 
these studies have not sufficiently addressed different functions of subtype C Vpr. It is 
important to study all functions of Vpr, as well as other HIV-1 proteins, that have 
been established for reference sequences of Vpr as the wild-type protein. It has been 
shown that subtype D Vpr, for example, has no detectable apoptotic activity (Jian & 
Zhao, 2003a). Comparative studies of some of the HIV-1 proteins, such as Vif, Vpu, 
Tat, Rev, and envelope proteins, among HIV-1 subtypes have revealed slight to 
significant variations in a number of their functions that are subtype-dependent 
(Campbell et al., 2007; Gupta & Benerjea, 2009; Neogi et al., 2009; Sood et al., 2008; 
Sundaravaradan et al., 2007). Therefore, the established functions of Vpr cannot 
directly be attributed to the Vpr protein of all or other HIV-1 subtypes without 
experimentally confirming and measuring those functions. 
 
1.3  Aim of this study 
 
Most studies addressing the functionality of HIV-1 accessory proteins focus on 
subtype B. The functionality of subtype C Vpr, especially South African strains, has 
 59
not been studied. However, the functions shown in subtype B cannot be attributed to 
other subtypes without evaluating those functions independently.  
 
The overall objective / major aim of this study was to investigate the diversity of 
South African HIV-1 subtype C vpr genes and selected functions of these Vpr 
proteins. 
 
This was achieved by setting the following secondary objectives: 
1. To investigate the sequence diversity of the vpr gene and the Vpr protein in 
South African HIV-1 strains by PCR amplification, sequencing and 
phylogenetic analysis  
2. To identify the natural mutations common in these vpr genes and to design 
vectors expressing these Vpr proteins  
3. To construct a consensus subtype C vpr gene, identify conserved amino acids 
in the coded protein and to induce mutations by site-directed mutagenesis 
4. To transfect human cell lines with either the natural or mutated constructs and 
to investigate the functionality of these Vpr constructs on subcellular 
localization, apoptosis induction and cell cycle G2 arrest. 
5. To further investigate the modulation of genes expressed in the induction of 
apoptosis using TaqMan Low density arrays (TLDA).  
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Chapter 2 
 
2. Materials and methods 
 
2.1 Overview of the methodology 
The diversity of vpr gene of South African HIV-1 strains was studied using the direct 
sequencing of PCR-amplified products. The phylogenetic analysis was performed on 
the sequences. Selected sequences that contained natural mutations in different 
domains were cloned in eucaryotic expression vectors. Alternatively a eukaryotic 
expression vector was designed for the consensus sequence of subtype C Vpr and 
mutations were induced in different domains of Vpr. 293T cells were individually 
transfected with all the vectors. Subcellular localization, Induction of apoptosis, 
induction of cell cycle G2 arrest, and gene expression were studied for the natural and 
artificial mutants in the transfected cells. The diagram of the study is shown in Figure 
2.1. 
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Figure 2.1: Diagram of the study design 
 
 
2.2. Samples 
 
This project was approved by the Human Research Ethics Committee (HREC) of the 
University of Stellenbosch on 07 February 2008. The project number is N08/01/014 
(Appendix A). Plasma samples were collected from 100 HIV-1-positive patients in 
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the Cape Town metropole during 2002–2004. Plasma samples were stored at -80 until 
the viral RNA was extracted.  
 
 
2.3. Molecular characterization of the vpr gene and Phylogenetic 
analysis 
 
2.3.1. RNA extraction 
 
Approximately 3 ml plasma was stored from 20 ml EDTA blood samples by 
separating it from the red blood cells, white blood cells and blood platelets. The 
plasma was collected after centrifugation (Beckman Coulter AllagraTM 6R, Beckman 
Inc., Fullerton, California, USA) at 700 × g for 10 minutes at 4ºC. The samples were 
stored at -80ºC for subsequent analysis. RNA was extracted from 1 ml plasma using 
the QIAamp® Ultrasens Virus protocol (Qiagen GmbH, Hilden, Germany). The kit 
protocol was followed and RNA eluted in 50 μl of low salt buffer AVE containing 
0.04% sodium azide. Briefly, nucleic acids bind specifically to the QIAamp silica-gel 
membrane while contaminants pass through. PCR inhibitors such as divalent cations 
and proteins are removed in two wash steps, leaving pure nucleic acids to be eluted in 
either water or a buffer provided with the kit. QIAamp technology yields viral RNA 
and DNA from cell-free body fluids ready to use in PCR. 
 
2.3.2. The polymerase chain reaction (PCR) for the HIV-1 vpr gene 
 
Reverse transcriptase (RT) polymerase chain reaction (PCR) amplification of a 1361-
bp region (HXB2 positions 4985-6346) was performed using the Access-RT PCR kit 
(Promega, Madison, Wiskinson, USA). The PCR mixtures were prepared in 0.2 ml 
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thin wall PCR® tubes (QSP, Porex BioProducts Inc., California, USA) and reactions 
were carried out on the GeneAMP® 9700 PCR system (Applied Biosystem, Foster 
City, California, USA). 
 
For RT-PCR the primers NACC (5΄-
AGATAATAGTGACATAAAAGTAGTGCCAAGAAG-3΄) and NACD (5΄-
CCATAATAGACTGTGACCCACAA-3΄) were used (Zhang et al., 1997). Access 
RT-PCR kit (Promega, Madison, Wiskinson, USA) was used with 5 μl of RNA, 200 
mM of each nucleotide, 40 μmol of each primer, 1mM MgSO4, 5 units each of AMV 
RT and Tfl DNA polymerase, and AMV/Tfl buffer in a total volume of 50 μl. After 
reverse transcription of 45 min at 48ºC, the reaction was held at 94ºC for 2 min, 
followed by 40 cycles of denaturing the DNA (94ºC; 30 s), annealing of primers 
(50ºC; 30 s), and extension of the annealed primers (68ºC; 2.5 min). This was 
followed by a final extension step of 10 min at 68ºC and the PCR product was kept at 
4ºC.  
 
The RT-PCR was followed by DNA amplification of a 714-bp region (HXB2 
positions 5276–5990) using the primers HIV-vif-1F (50-
GGAATTTGGGTCATGGAGTCTCCATA-30) and HIVvpr-R1 (50-
GTCTCCGCTTCTTCCTGCCATAG-30), with the Promega GoTaq Flexi Kit 
(Promega, Madison, WI, USA). Template DNA for the nested PCR consisted of 3 μl 
of reaction product from the first round with 200 mM of each nucleotide, 20 μmol of 
each primer and 1.5mM MgCl2, and 2.5 units of Taq polymerase and GoTaq buffer 
made up in a total volume of 50 µl. The amplification reaction was held at 94ºC for 2 
min, followed by 40 cycles of denaturing the DNA (94ºC; 30 s), annealing of primers 
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(56ºC; 30 s), and extension of the annealed primers (68ºC; 1 min). This was followed 
by a final extension step of 10 min at 68ºC and the PCR product was kept at 4ºC.  
The products of the nested PCR were visualized using agarose gel electrophoresis on 
a 0.8% agarose (Whitehead Scientific, Cape Town, South Africa) gel in TAE buffer 
(0.04 M Tris acetate, 0.001 M EDTA) and stained with ethidium bromide (final 
concentration of 0.5ug/ml), (Promega, Madison, WI, USA).  
The agarose gel was run at 50 V for 50-60 minutes. The DNA bands were visualized 
under an ultra violet light at a wavelength of 320 nm and photographed with Syngene 
GeneGenius computer system (Synoptics Ltd, Cambridge, United Kingdom). 
 
2.3.3. DNA sequencing 
 
The PCR products were purified for sequencing. The enzymes Exonuclease 1 (Exo1) 
and Shrimp alkaline phosphatase (SAP) (Amersham Pharmacia Biotech, New Jersey, 
USA) were used according to the manufacturer’s instructions. These enzymes are 
used to degrade single-strand DNA (such as excess primers) and diphosphates that 
might interfere with the sequencing reactions (Werle et al., 1994). Ten μl of the PCR 
products was purified with 0.5 μl of Exo1 (1 unit per μl) and 0.5 μl of SAP (1 unit per 
μl). An incubation of 15 minutes at 37ºC followed by an enzyme inactivation step of 
15 minutes at 80ºC was carried out on a Techne Gene E Thermal Cycler (Techne Ltd., 
Cambridge, United Kingdom) The purified aliquot was stored at -20ºC until the 
sequencing reactions were carried out. The DNA concentration of the PCR products 
was measured using the NanodropTM ND-1000 system (Nanodrop Technologies Inc., 
Delaware, USA), which only requires 1-2 μl of sample input. 
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All purified PCR products were sequenced on both strands using the BigDye 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, 
California, USA). To perform the sequencing reactions, 4 μl of Big Dye terminator 
enzyme mix was added to 10 μl of purified products, approximately 50 ng DNA. Five 
pmol of primer, either HIV-vif-1F or HIV-vpr-R1 was added to the reaction mix. The 
reaction volume was brought to 20 μl by adding Nuclease-Free Water (Promega, 
Madison, WI, USA). The following cycle sequencing reaction was applied to the 
samples: denaturation at 96ºC for 10 seconds, primer annealing at 55ºC for 5 seconds, 
and an elongation step at 60ºC for 4 minutes. The cycles were repeated 25 times after 
which the samples were incubated at 4 ºC. After the sequencing reactions were 
accomplished, the reactions were loaded in MicroAmp® 96 well trays (Applied 
Biosystems, Foster City, California, USA) until they were analyzed using an ABI 
Prism 3130xl automated DNA sequencer (Applied Biosystems, Foster City, 
California, USA).  
 
2.3.4. Sequence analysis 
 
The ABI chromatograms of the forward and reverse primers were analyzed and 
overlapping fragments were assembled using Sequencher 4.8 (Gene Codes 
Corporation, Ann Arbor, MI).  
 
2.3.5. Extracting vpr gene sequences from chromatograms 
 
The positive and negative strand of DNA sequences are usually sequenced by a pair 
of forward and reverse primers to ensure that the string of sequences being analyzed is 
correct. The chromatograms of the forward and reverse primers were analyzed and 
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overlapping fragments were assembled using Sequencher 4.8 (Gene Codes 
Corporation, Ann Arbor, MI). Using Clustal X version 1.81 the DNA sequences were 
primarily aligned with HIV-1 HXB2 reference sequence (B.FR.83.HXB2) to detect 
the exact position of the vpr gene in our sequences. The vpr gene was manually 
extracted from all of the sequences. 
 
2.3.6. Multiple alignment and phylogenetic analysis of the sequences 
 
The vpr fragments of all of the DNA sequences were aligned with HIV-1 reference 
sequences obtained from the LANL HIV Database (http://hiv-web.lanl.gov), using 
Clustal X version 1.81 (Thompson et al., 1997). Clustal X creates an optimal 
alignment and performs a global-multiple sequence alignment by the progressive 
method. It performs pair-wise alignment of all the sequences by dynamic 
programming. Multiple alignments were verified manually in BioEdit version 7.090 
(Hall, 1999). The subset of the reference sequences used in the phylogenetic analysis 
is presented in Table 2.1. 
 
A neighbor-joining phylogenetic tree (Saitou & Nei, 1987) was constructed with 
MEGA version 4 (Tamura et al., 2007) using the Kimura two-parameter (Kimura, 
1980). The reliability of the branching and clustering pattern was estimated from 1000 
bootstrap replicates. The tree was rooted with the YBF30 reference sequence of HIV-
1 group N. 
 
To investigate the Vpr protein, the vpr gene sequences were translated into amino 
acids and the amino acid sequences were aligned with the consensus subtype C and 
HXB2 reference sequences using BioEdit version 7.0.9.0 (Hall, 1999). The α-helical 
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domains of Vpr were shaded using GeneDoc version 2.6.003 (Nicholas & Nicholas, 
1997). 
 
Table 2.1: HIV-1 subtype reference sequences used in the phylogenetic analysis 
Name Accession 
number 
Origin of 
sample 
Year of 
sampling 
Subtype Reference 
Q23_17 AF004885 Kenya 1994 A1 (Neilson et al., 1999) 
RW008 AB253421 Rwanda 1992 A1 (Ngandu et al., 2008) 
CDKS10 AF286241 DRC 1997 A2 (Gao et al., 2001) 
CY017 AF286237 Cyprus 1994 A2 (Gao et al., 2001) 
HXB2 K03455 France 1983 B (Ratner et al., 1985) 
BK132 AY173951 Thailand 1990 B (Hierholzer et al., 2002) 
1058 AY331295 USA 1998 B (Bernardin et al., 2005) 
15384 DQ853463 USA 1998 B (Liu et al., 2006) 
BR025 U52953 Brazil 1992 C (Gao et al., 1996) 
ETH2220 U46016 Ethiopia 1986 C (Salminen et al., 1996) 
IN21068 AF067155 India 1995 C (Lole et al., 1999) 
SK164B1 AY772699 Slovakia 2004 C (Rousseau et al., 2006) 
01CM AY371157 Cameron 2001 D (Kijak et al., 2004) 
A280 AY253311 Tanzania 2001 D (Arroyo et al., 2004) 
UG114 U88824 Uganda 1994 D (Gao et al., 1998) 
VI850 AF077336 Belgium 1993 F1 (Laukkanen et al., 2000) 
MP411 AJ249238 France 1996 F1 (Triques et al., 2000) 
MP257 AJ249237 Cameron 1995 F2 (Triques et al., 2000) 
CM53657 AF377956 Cameron 1997 F2 (Carr et al., 2001) 
DRCBL AF084936 Belgium 1996 G (Oelrichs et al., 1999) 
HH8793 AF061641 Kenya 1993 G (Salminen et al., 1993) 
PT2695 AY612637 Portugal 1995 G (Ngandu et al., 2008) 
VI991 AF190127 Belgium 1993 H (Janssens et al., 2000) 
VI997 AF190128 Belgium 1993 H (Janssens et al., 2000) 
056 AF005496 Central African 
Republic 
1990 H (Gao et al., 1998) 
J_97DC EF614151 DRC 1997 J (Abecasis et al., 2007) 
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SE7022 AF082395 Sweden 1994 J (Laukkanen et al., 1999) 
EQTB11C AJ249235 DRC 1997 K (Triques et al., 2000) 
MP535 AJ249239 Cameron 1996 K (Triques et al., 2000) 
YBF30 AJ006022 Cameron 1995 Group N (Simon et al., 1998) 
 
 
 
2.4. Gene cloning and mutagenesis 
 
 
2.4.1. Cloning of vpr gene – selection of samples and control 
 
The most similar protein sequence to the consensus sequence of HIV-1 Vpr (LANL 
HIV Database, 2004) was identified by comparing the protein sequences translated 
from vpr gene sequences. This subtype C sequence, designated as TV1453, and 5 
additional sequences (TV1628, TV1707, TV1642, TV1570, TV1466) containing 
naturally occurring mutations were selected for cloning experiments. The sequences 
were selected that contained natural mutations distributed in different domains of Vpr. 
Although there were other mutants that could have been chosen for the study, only a 
certain number of sequences had to chosen so that they could be regarded as the 
representative sequences of South African strains. The following sections describe the 
methods used to clone the vpr sequences and to produce the consensus sequence of 
Vpr.  
 
The vpr gene from HIV-1 subtype B, strain pNL4-3 (NIH AIDS Research and 
Reagent Program, Maryland, USA), was also included in this study as a control.  
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2.4.2. Primer design for gene cloning 
 
pF4A CMVd1 Flexi® Vector (Promega, Madison,  Wisconsin, USA) was used as the 
eukaryotic expression vector. Protein-coding regions are cloned into Flexi® Vectors 
containing Sgf I and Pme I sites. All Flexi® Vectors carry the lethal barnase gene, 
which is replaced by the DNA fragment of interest that acts as a positive selection for 
successful ligation of the insert. Inserts can be transferred to other Flexi® Vectors 
following digestion with Sgf I and Pme I, which maintains insert orientation and 
reading frame, eliminating the need to resequence the insert after each transfer. To 
insert vpr fragments into the flexi vector, two rare-cutting restriction enzymes, Sgf I 
and Pme I (Promega, Madison, Wisconsin, USA), have to be appended to the protein 
coding regions (vpr fragments). 
 
A pair of primers containing the restriction site at both sides of the vpr gene was 
designed using the online software Flexi Vector Primer Design 
(http://www.promega.com/techserv/tools/flexivectortool/default. aspx). The following 
primers were designed using the software: 
Vpr-Sgf-F: 
5΄-GGGTGCGATCGCCATGGAACAAGCCCCAGAAGAC-3΄ 
 
Vpr-Pme-R: 
5΄-CTTAGTTTAAACTTAGGATCTACTGGCTCCATTTCTTG-3΄ 
 
The melting temperature of the primers was calculated using the online software 
BioMath Calculators (http://www.promega.com/biomath/). 
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2.4.3. Appending restriction sites to vpr fragments using PCR reaction 
 
The 291 bp ORF of vpr gene from the samples TV1453, TV1628, TV1707, TV1642, 
TV1570, TV1466, and the pNL4-3 control was amplified using the primers Vpr-Sgf-F 
and Vpr-Pme-R and the GoTaq Flexi Kit (Promega, Madison, Wisconsin, USA).  The 
PCR reaction consisted of 3 µl of reaction product with 200 mM of each nucleotide, 
20 μmol of each primer, 1.5mM MgCl2, and 2.5 units of Taq polymerase and GoTaq 
buffer made up in a total volume of 50 µl. The amplification reaction was held at 
94ºC for 2 min, followed by 5 cycles of denaturing the DNA (94ºC; 30 s), annealing 
of primers (52ºC; 30 s), and extension of the annealed primers (68ºC; 40 sec). The 
reaction was followed by 35 cycles of denaturing the DNA (94ºC; 30 s), annealing of 
primers (56ºC; 30 s), and extension of the annealed primers (68ºC; 40 sec). This was 
followed by a final extension step of 5 min at 68ºC and the PCR products were kept at 
4ºC. 
 
The products of the PCR were visualized using agarose gel electrophoresis on a 1% 
agarose as described in section 2.3.2. The Wizard® SV Gel and PCR Clean-Up 
System (Promega, Madison, Wisconsin, USA) was used to purify the PCR products 
as recommended by the manufacturer. The eluted DNA were stored at 4°C. 
 
2.4.4. Digestion of the PCR products and the acceptor vector 
 
pF4A CMVd1 Flexi® Vector (Promega, Madison, Wisconsin, USA) was used in this 
study to clone the PCR products. This vector has been designed for constitutive native 
(untagged) protein expression in mammalian cells using the human cytomegalovirus 
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(CMV) intermediate-early enhancer/promoter. The vector can be used for both stable 
and transient gene expression. The vector contains ampicillin resistance for selection 
in E. coli. Digestion reactions for PCR products and the acceptor Flexi® Vector can be 
performed concurrently. The 5X Flexi® Digest Buffer, pF4A CMVd1 Flexi® Vector 
and nuclease-free water were thawed and store on ice. The reaction components for 
digesting both the PCR products and the acceptor flexi vector with Sgf I and Pme I 
were separately assembled according to the protocol. 
 
Both reactions were incubated at 37°C for 30 minutes. The reaction with the Flexi® 
Vector was heated at 65°C for 20 minutes to inactivate the restriction enzymes and 
stored on ice until the PCR product and vector were ligated. Twenty µl of Membrane 
Binding Solution was to the reactions with the PCR products. All reactions were 
stored at 4°C until they were purified as described in section 2.4.3. 
 
 
2.4.5. Ligation of PCR products and acceptor vector 
 
The ligation reactions were performed in 0.2 μl tubes. The DNA concentration of the 
purified PCR products was measured using NanodropTM ND-1000 system (Nanodrop 
Technologies Inc, Delaware, USA). To ligate the PCR products to pF4A CMVd1 
Flexi® Vector as the acceptor vector, 5 μl of the vector (50 ng) was mixed with 100 ng 
DNA of the PCR products. One μl of T4 DNA Ligase (Promega, Madison,  
Wisconsin, USA) and 10 μl of 2X Flexi Ligase Buffer (Promega, Madison, 
Wisconsin, USA) were added to the reaction. The final volume of the reaction was 
brought to 20 μl by adding nuclease-free water (Promega, Madison, Wisconsin, 
USA). The reactions were incubated at room temperature for 1 hour.  
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2.4.6. Transformation of pF4A CMVd1 Flexi® Vectors containing the vpr gene 
 
pF4A CMVd1 Flexi® Vector carries a gene for ampicillin resistance therefore 
selection for recombinants was performed on LB plates supplemented with 100µg/ml 
ampicillin. Two µl of each ligation reaction was added to a sterile 14 ml 
polypropylene round-bottom tube (Becton Dickinson, Franklin Lakes, USA) on ice. 
The tubes of frozen high-efficiency JM109 Competent Cells (Promega, Madison, 
Wisconsin, USA) were removed from 70°C storage and placed on ice until thawed. 
The cells were mixed by gently flicking the tube. Fifty µl of cells was transferred into 
each 14 ml polypropylene containing the ligated DNA. The tubes were placed on ice 
for 20 minutes. The cells were heat-shocked for 45-50 seconds in Haake L water bath 
with Haake D1 heating circulator (LabX, California, USA) at exactly 42°C. The tubes 
were immediately returned to ice for 2 minutes and 950µl of room-temperature SOC 
Medium (Sigma, Saint-Louis, USA) was added to each tube. The tubes were 
incubated for 1.5 hours at 37°C with shaking (150 rpm). After incubation, 20-50µl of 
each transformation was plated onto duplicate plates containing 100µg/ml ampicillin 
and  incubated overnight at 37°C. 
 
2.4.7. Screening the colonies for the vpr gene 
 
In our study, since a sticky end restriction enzyme and a blunt-end enzyme were used, 
a high efficiency of the right colonies was expected. Nine colonies of each plate were 
chosen for screening. After overnight incubation 9 colonies were picked and cultured 
in 5 ml LB broth containing 100µg/ml ampicillin. The LB broth tubes were incubated 
for 16 hours at 37ºC and 150 rpm in shaking incubator Labcon-3081U (Labmark, 
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Johannesburg, South Africa). Longer incubation could damage the plasmids and 
shorter incubation may not yield enough plasmid DNA. 
 
After incubation, 850 μl of the LB broth containing the bacteria was pipetted into 1.5 
microcentrifuge tubes and mixed with 150 μl of glycerol and stored at -20ºC.  The 
plasmids were extracted using QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany) according to the protocol. This kit is designed for purification of up to 20 
μg of high-copy plasmid DNA from 1-5 ml overnight cultures of E. coli in LB 
medium. All the protocol steps were carried out at room temperature. The plasmids 
were extracted from 3 ml of the bacterial cultures and stored at 4ºC until they were 
analyzed for the integration of the vpr gene. The plasmid DNA concentration was 
measured using NanodropTM ND-1000 system (Nanodrop Technologies Inc., 
Delaware, USA).  
 
Restriction enzyme digestion was used to identify recombinant plasmids. Briefly, a 
master mix was prepared by combining 0.5 μl of 10X Flexi Enzyme Blend (Promega, 
Madison, Wisconsin, USA), 4 μl of 5X Flexi Digest Buffer and 10.5 μl Nuclease-Free 
Water. Fifteen µl of master mix was added to 5µl (200-500ng) of each plasmid DNA 
and incubated for 2 hours at 37°C. Five µl of Blue/Orange Loading Dye (Promega, 
Madison, Wisconsin, USA) was mixed with the reactions and incubated at 65°C for 
10 minutes. The whole reaction (20µl) was loaded onto a 0.8% agarose gel to separate 
fragments by electrophoresis as described in section 2.3.2. The fragments were 
visualized by ethidium bromide staining. 
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Recombinant plasmids were sequenced as described before (section 2.3.3). All the 
sequences were compared to the sequence of insert source and the identical sequences 
were chosen for the future experiments. 
 
2.4.8. Constructing a consensus sequence of HIV-1 subtype C Vpr 
 
The clone of TV1453, pF4A-TV1453, contained the most similar sequence to the 
consensus sequence of HIV-1 subtype C Vpr (LANL HIV Database, 2004) except for 
1 mutation at position 45. At this position the original tyrosine in the consensus 
sequence of HIV-1 Vpr was mutated to histamine in TV1453 Vpr. A pair of primers 
was designed to mutate histamine 45 to tyrosine 45 using QuikChange® Lightning 
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, USA). Site-directed mutagenesis 
allows site-specific mutation in virtually any double-stranded plasmid. The 
QuikChange® Lightning Site-Directed Mutagenesis Kit includes a derivative of 
PfuUltra® high-fidelity (HF) DNA polymerase for mutagenic primer-directed 
replication of both plasmid strands with the highest fidelity. The basic procedure 
utilizes a vector with an insert of interest and two synthetic primers, both containing 
the desired mutation (Figure 2.2).  
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Figure 2.2: An overview of site-directed mutagenesis (http://www.promega.com) 
 
 
The mutagenic primers for site-directed mutagenesis were designed individually 
according to the desired mutations. The mutagenic primers must contain the desired 
mutation and anneal to the same sequence on opposite strands of the plasmid. The 
primers should be between 25 and 45 bases in length, with a melting temperature 
(Tm) of ≥78°C. The primer wild-mut-F: 5΄-
CATAGCTTAGGACAATACATCTATGAAAC-3΄ and wild-mut-R: 5΄-
GTTTCATAGATGTATTGTCCTAAGCTATG-3΄ were designed by taking all the 
necessary considerations into account.  
 
The sample reaction was prepared by adding 5 μl of 10× reaction buffer to a 0.2 ml 
thin wall PCR® tubes (QSP, Porex BioProducts Inc., California, USA). One μl of 
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dNTP mix and 100 ng of the pF4A-TV1453 DNA were added to the reaction. One 
hundred twenty five ng of the primer wild-mut-F and wild-mut-R were added to the 
reaction. 1.5 μl of QuikSolution reagent was added and the volume was brought to 
final volume of 50 μl by adding Nuclease-Free Water (Promega, Madison, Wisconsin, 
USA). One μl of QuikChange® Lightning Enzyme (included in the kit) was added to 
the reaction. The PCR reaction was carried out on the GeneAMP® 9700 PCR system 
(Applied Biosystems, Foster City, California, USA) The amplification reaction was 
held at 95ºC for 2 min, followed by 18 cycles of denaturing the DNA (95ºC; 20 
seconds), annealing of primers (55ºC; 30 seconds), and extension of the annealed 
primers (68ºC; 140 seconds, which corresponds to 30 seconds/kb of plasmid length). 
This was followed by a final extension step of 5 min at 68ºC and the PCR product 
was kept at 4ºC. 
 
The PCR reaction contained the parental non-mutated plasmids and the desired 
mutated plasmids. To obtain the desired mutated plasmids, the parental plasmids had 
to be removed from the reaction. Briefly, 2 μl of the Dpn I restriction enzyme was 
directly added to the amplification reaction and then immediately incubated at 37°C 
for 5 minutes. The treated plasmid was transformed into XL10-Gold ultracompetent 
cells (Stratagene, La Jolla, USA) using a method described in section 2.4.6 except for 
the heat-shock (42°C for 30 seconds, instead of 45-50 seconds). The bacteria were 
incubated overnight at 37ºC.  
 
2.4.9. Screening for the consensus sequence of HIV-1 Vpr  
 
The expected colony number using QuikChange® Lightning Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, USA), depends upon the base composition and 
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length of the DNA template employed. Four colonies were cultured in LB broth for 
16 hours at 37ºC and 150 rpm in shaking incubator Labcon-3081U (Labmark, 
Johannesburg, South Africa). The plasmids were extracted using QIAprep Spin 
Miniprep Kit (Qiagen, Hilden, Germany) according to the protocol. The vpr fragment 
of the plasmids was sequenced using Vpr-Sgf-F and Vpr-Pme-R as described in 
section 2.3.3. All the sequences were compared to the sequence of TV1453 vpr to 
verify if the plasmids contain the desired mutation. One of the sequences containing 
the desired mutation that did not contain extra mutations in other positions was 
chosen as the consensus sequence of HIV-1 subtype C Vpr for the future experiments. 
This plasmid was named pF4A-Cons-C. 
 
2.4.10. Mutating Vpr in different domains 
 
To investigate the role of Vpr domains in different functions of the protein, pF4A-
Cons-C was separately mutated in 5 highly conserved domains. In the other word, 5 
different vectors were created to express 5 Vpr proteins, each one carrying 1 
mutation. QuikChange® Lightning Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, USA) was used to induce mutations in the expression vector (pF4A-Cons-C) for 
the consensus sequence of HIV-1 Vpr subtype C. The method was similar to the one 
described in the section 2.4.8 to induce mutations except for the primers. Five pairs of 
primers were manually designed to mutate the vpr gene of pF4A-Cons-C. The 
mutation positions were selected because they have never been described. As already 
shown in tabele 1.1, no natural mutation has been described at position 14, 18, 47, and 
65. The impact of possible mutations at these positions is unknown and in this study 
these positions were addressed. Position 88 was also included in mutagenesis study 
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because it is highly conserved and the impact of mutations at this position has not 
been described.   
 
The mutagenic primers were designed to mutate the original amino acids to one with 
different properties. For example, if the original amino acid was a polar acidic amino 
acid, it was mutated to a nonpolar basic amino acid. The mutagenic primers, the 
newly created vectors, the original mutations and the induced mutations are listed in 
Table 2.2. After site-directed mutagenesis, the plasmids were extracted using 
QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany) according to the protocol. The 
vpr fragment of the plasmids was sequenced according to the protocol describe in 
section 2.3.3. 
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Table 2.2: Mutagenic primers and induced mutations. 
 
 
 
 
 
 
 
 
 
 
Primer (5΄ to 3΄) Original 
AA 
Induced 
mutation 
Vpr 
mutated 
residue 
New 
vector
P14I-F:  
GCAGAGGGAAATATACAATGAATGG 
 
 
Proline 
 
 
Isoleucine 
 
 
14 
 
 
pF4A-
P14I 
P14I-R: 
CCATTCATTGTATATTTCCCTCTGC 
W18C-F: 
CCATACAATGAATGCACACTAGAGC 
 
 
Tryptophan
 
 
Cysteine 
 
 
18 
 
 
pF4A-
W18C
W18C-R: 
GCTCTAGTGTGCATTCATTGTATGG 
Y47N-F: 
GGACAATACATCAATGAAACCTATGG 
 
 
Tyrosine 
 
 
Asparagine 
 
 
47 
 
 
pF4A-
Y47N 
Y47N-R: 
CCATAGGTTTCATTGATGTATTGTCC 
Q65H-F: 
GAATTCTGCACCAACTACTGTTTATTC 
 
 
Glutamine 
 
 
Histidine 
 
 
65 
 
 
pF4A-
Q65H 
Q65H-R: 
GAATAAACAGTAGTTGGTGCAGAATTC 
Q88S-F: 
CTTGCGACAGAGAAGTGCAAGAAATGGAG
 
 
Glutamine 
 
 
Serine 
 
 
88 
 
 
pF4A-
Q88S 
Q88S-R: 
CTCCATTTCTTGCACTTCTCTGTCGCAAG 
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2.4.11. Protein modelling 
 
Protein modelling was used to demonstrate the position of the natural and induced 
mutations in the 3-dimensional structure of Vpr. The sequences of vpr mutants were 
translated into protein sequences using BioEdit version 7.090 (Hall, 1999). The 
proteins sequences were analyzed using the online software SWISS-MODEL 
workspace. The software utilizes homology modelling to build three-dimensional 
protein structure models using experimentally determined structures of related family 
members as templates. SWISS-MODEL workspace is an integrated Web-based 
modelling system. For a given target protein, a library of experimental protein 
structures is searched to identify suitable templates. On the basis of a sequence 
alignment between the target protein and the template structure, a three-dimensional 
model for the target protein is generated. Model quality assessment tools are used to 
estimate the reliability of the resulting models.  
 
The 3-dimensional pictures obtained from SWISS-MODEL workspace were further 
analyzed using Discovery Studio Visualizer v2.0.1.7347  (Goede et al., 2005). The 
Vpr domains were shown in different colours and the position of the mutations and 
the mutated amino acids were shown and annotated using the software. 
 
2.4.12. Transfer of protein-coding regions between the Flexi® Vectors 
 
As described, all the vpr fragments were cloned into the pF4A CMVd1 Flexi® Vector  
for expression of Vpr proteins in mammalian cells. This form of Vpr could be suitable 
for experiments and assays when there is no need to directly track the protein in cells. 
But in some of our experimentsVpr needed to be tracked in apoptotic cells or cell 
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cycle G2 arrested cells. A common method to track proteins in cells is tagging a 
protein reporter to the protein of interest. This reporter can be detected by producing 
fluorescent signals (e.g. green fluorescent protein) or visible light signals (e.g. 
luciferase). In this study, HaloTag® Technology (Promega, Madison, Wisconsin, 
USA) was utilized to track Vpr proteins. The HaloTag® reporter protein is an 
engineered, catalytically inactive derivative of a hydrolase that forms a covalent bond 
with HaloTag® ligands. Under physiological conditions this covalent bond forms 
rapidly and is highly specific and essentially irreversible, yielding a complex that is 
stable even under stringent conditions (Lang et al., 2006; Los, 2005; Los & Wood, 
2007). 
 
To tag a reporter to the expressed Vpr protein, pFN22K CMVd1 Flexi® Vector 
(Promega, Madison, Wisconsin, USA) was used for cloning. The vector contains a 
kanamycin resistance gene that enables us to select it on a kanamycin-selective 
medium after transfer of protein-coding regions between Flexi® Vectors, while the 
donor vector (pF4A CMVd1 Flexi® Vector) cannot survive.  
 
As described, the Vpr-coding region was cloned in pF4A CMVd1 Flexi® Vector. The 
purified clones including, pF4A-TV1453, pF4A-TV1628, pF4A-TV1707, pF4A-
TV1642, pF4A-TV1570, pF4A-TV1466, pF4A-P14I, pF4A-W18C, pF4A-Y47N, 
pF4A-Q65H, pF4A-Q88S, and pF4A-Cons-C were used as donors of the Vpr-coding 
region to pFN22K CMVd1 Flexi® Vector. The reaction was started by digestion of 
the Vpr-coding regions from the donors and barnase gene from the acceptors (Figure 
2.3). Briefly, 4 µl of 5X Flexi® Digest Buffer was separately mixed with 100 ng of 
each donor vector in 0.2 ml thin wall PCR® tubes (QSP, Porex BioProducts Inc., 
California, USA). One µl (100 ng DNA) of the acceptor vector and 2 µl of the Flexi® 
 82
Enzyme Blend (Promega, Madison, Wisconsin, USA) were added to the reactions. 
The Final volume was brought to 20 µl by adding Nuclease-Free Water (Promega, 
Madison, WI, USA). The reactions were incubated at 37ºC for 30 minutes and heated 
at 65°C for 20 minutes to inactivate the restriction enzymes. All the incubations were 
carried out on the GeneAMP® 9700 PCR system (Applied Biosystems, Foster City, 
California, USA). Ten µl of 2X Flexi Ligase Buffer was added to 10 µl of each 
digested DNA in 0.2 ml thin wall PCR® tubes (QSP, Porex BioProducts Inc., 
California, USA). One µl of T4 DNA Ligase (20 U/μl), (Promega, Madison, 
Wisconsin, USA) was added to the reactions and the incubated for 1 hour at room 
temperature. The ligation reactions were transformed into JM109 Competent Cells 
(Promega, Madison, Wisconsin, USA), as described in section 2.4.6. Bacteria were 
cultured on LB plates containing 25µg/ml kanamycin to select clones. The 
recombinant plasmids were extracted using QIAprep Spin Miniprep kit (Qiagen, 
Hilden, Germany) according to the protocol. The integration of Vpr-coding regions 
was verified by PCR using the primer Vpr-Sgf-F and Vpr-Pme-R. 
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Figure 2.3: Transfer of a protein-coding region between N-terminal or native Flexi® Vectors. The 
donor Flexi® Vector containing the protein-coding region is mixed with an acceptor Flexi® Vector that 
has a different antibiotic resistance. The two plasmids are digested with Sgf I and Pme I, and the 
mixture is ligated and transformed into E. coli. The cells are plated on the appropriate selective media 
for the acceptor Flexi® Vector (http://www.promega.com). 
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2.4.13. Construction of control transfection vectors 
 
The intact Flexi® Vectors cannot be used for transfection because of the presence of 
the lethal gene, barnase. To have control vectors for the experiments, barnase had to 
be removed from the original vectors used for cloning. The Flexi® Vectors provide the 
option of expressing the HaloTag® coding region either as an N-terminal or a C-
terminal partner of the fusion protein. In the N-terminal vectors, as the one used in 
this study, the fusion protein is cloned downstream of the HaloTag® coding region, 
replacing the lethal gene, barnase. Hence there is no stop codon in the HaloTag® 
sequence. To express only the HaloTag® protein, or a vector without any coding 
region, it is necessary to both remove the barnase gene and introduce a stop codon for 
the HaloTag® coding region. This can be done by designing and annealing 
oligonucleotides that contain a stop codon (e.g., TAA) and replace barnase in the 
vector. This results in the expression of HaloTag® protein without cell death. A 
schematic of the HaloTag®-only control expression construct created using an oligo-
based cloning strategy is illustrated in Figure 2.4. This construct has all the elements 
to serve as a HaloTag®-only expression control. In this example, the oligos have also 
been designed to recreate the SgfI and PmeI restriction sites. Thus, the construct could 
also be used as a cloning vector for future fusion expression projects requiring N-
terminal HaloTag® fusions. 
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Figure 2.4: Schematic of the HaloTag® control expression construct from N-terminal 
Flexi® Vectors using the oligo-design strategy. N-terminal HaloTag® vectors contain the 
lethal barnase gene downstream of the HaloTag® coding region. The control constructs can be made by 
designing oligos that carry a stop codon and ends compatible for ligation. The vector is digested with 
SgfI and PmeI to remove the barnase gene. In a separate reaction, the oligos are annealed. The digested 
vector and the annealed oligos are ligated using T4 DNA Ligase (http://www.promega.com). 
 
To construct the control vectors, 1 µl of pF4A CMVd1 Flexi® Vector and 1 µl of 
pFN22K CMVd1 Flexi® Vector were separately added to two 0.2 ml thin wall tubes. 
Four µl of Flexi® Digest Buffer and 2 µl of Flexi® Enzyme Blend (Sgf I and Pme I) 
were added to each tube. The final volume was brought to 20 µl by adding Nuclease-
Free Water. The reactions were incubated the reaction at 37°C for 20 minutes and 
then heated at 65°C for 20 minutes to inactivate the restriction enzymes. The reactions 
were stored on ice until the ligation reaction.  
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In a separate reaction, 50 fmol/µl of a pair of oligo nucleotides, Flexi-strand-F: 5´-
CGCGTAAGGGTAGGTTT-3΄ and Flexi-strand-R: 5´- 
AAACCTACCCTTACGCGAT-3΄ that contained the restriction site for the Flexi 
Enzyme Blend® were heated to 95ºC, then slowly cooled to room temperature for 15-
30 minutes. The annealed oligonucleotides then had to be integrated into the control 
vectors to replace the barnase gene. The ligation reaction was assembled according to 
manufacturer’s suggestions. The reaction was incubated at room temperature for 1 
hour. One to two µl of the ligation reaction was transferred into high-efficiency, 
JM109 Competent Cells as described in section 2.4.6.  
 
The potential control vectors were digested using Flexi Enzyme Blend® according to 
the manufactures protocol. The digested reactions and the intact vectors were run on 
0.8% agarose gel to confirm the deletion of barnase in the control vectors. 
 
 
2.5. Cell culture 
 
2.5.1. Cell lines 
 
Two different cell lines, 293T and HeLa cell line were used in this study. Human 
293T cell line is highly tranfectable and supports the expression of high levels of viral 
proteins.  293T cell line has been derived from human embryonic kidney 293 cells, 
also often referred to as HEK 293, 293 cells, or HEK cells. The 293T cell line was 
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kindly provided by Professor Lynn Morris (National Institute for Communicable 
Diseases (NICD), Sandringham, South Africa). 
 
The HeLa cell line [American type culture collection (ATCC) strain CCL-2] was used 
as an alternative cell line for transfection.  
 
 
2.5.2. Cell culture maintenance 
 
293T and HeLa cell lines were removed from the nitrogen freezer and transferred to 
the LabotecTM Biological Safety Cabinet Class II (Labotec, Göttingen, Germany). All 
cell culture experiments were performed in safety cabinets to protect the cell cultures 
from contamination. To remove DMSO, the cells were resuspended in 10 ml of 
DMEM (Lonza, Basel, Switzerland) and centrifuged at 700 × g for 5 minutes. The 
wash was repeated and the cell pellets were resuspended in 10 ml of DMEM 
supplemented with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 100 
units/ml penicillin and 0.1 mg/ml streptomycin (Lonza, Basel, Switzerland). The cells 
were seeded in 25 cm2 Cell Culture Flasks (Corning, New York, USA) and incubated 
at 37ºC supplemented with 5% CO2 in NUAIRETM US Autoflow CO2 Water-Jacketed 
Incubator (Nuaire, Minnesota, USA). The medium was refreshed with complete 
DMEM medium after 48 hours. 
 
 The cell cultures were maintained during the study by regularly subculturing the cells 
in fresh medium. To obtain and maintain easily transfectable cells, regularly when the 
cells had 100% confluency, 5×105 - 1×106 cells were passaged to new 25 cm2 Cell 
Culture Flasks (Corning, New York, USA) containing 7-10 ml of complete DMEM 
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medium. Briefly, all medium was removed from the flask and the cells were washed 
once with 10 ml PBS (Lonza, Basel, Switzerland) to remove excess medium and 
serum. Serum contains inhibitors of trypsin. Five ml of trypsin/versene (EDTA) 
solution (Lonza, Basel, Switzerland) was added to the monolayer and incubated 1 to 5 
minutes at room temperature until cells detached. The cells were observed under a 
microscope to confirm that most of the cells have detached. Five ml of complete 
medium was added to the cells and the cell suspension was transferred to a sterile 15 
ml High-Clarity Polypropylene Conical Tube (Becton-Dickenson, New jersey, USA). 
The cell suspension was centrifuged at 700 × g for 5 minutes. The supernatant was 
removed and the wash was repeated in 5-10 ml DMEM complete medium. The pellet 
was resuspended in 5ml DMEM complete medium.  
 
To transfer 5×105 - 1×106 viable cells to a cell culture flask, the viable and total cell 
counts had to be determined. The cell suspension was mixed to assure an even 
distribution of the cells. Fifty μl of the cell suspension was mixed with the equal 
volume of 0.4% Trypan Blue Stain (Invitrogen, New Jersey, USA). The mix was 
transferred to the Neubauer Improved Bright-Line (Marienfeld Superior, Lauda-
Königshofen, Germany). The viable cells (unstained cells) were counted using Eclipse 
E200 Microscope (Nikon, MelVille, USA). Using the following formula, the number 
of the viable cells per milliliter was calculated: 
                                                    × 104 × dilution factor = Number of cells/ml 
 
 
Between 5×105 - 1×106 viable cells were transferred to a new 25 cm2 Cell Culture 
Flask (Corning, New York, USA) and brought to 7-10 ml by adding fresh complete 
Number of viable cells 
Number of squares 
 89
DMEM to the flask and placed in the incubator. As already described, the cells were 
incubated in NUAIRETM US Autoflow CO2 Water-Jacketed Incubator (Nuaire, 
Minnesota, USA). 
 
2.5.3. Mycoplasma screening 
 
Mycoplasma contamination of continuous cell lines is a major problem in biological 
research using cultured cells. The cells were screened using RIDASCREEN® 
Mycoplasma IFA (R-Biopharm AG, Darmstadt, Germany) for Mycoplasma 
contamination. Briefly, 20,000 cells were placed in a volume of 20 to 30 µl into the 
well area on a coated glass microscope slide and the sample was dried at 50ºC for 45 
minutes. The samples were fixed for 60 seconds by adding cold 70% ethanol. After 
fixation the slides were air-dried at room temperature. One drop of the Anti-
Micoplasma-Conjugate was added to the fixed cells. The slides were carefully rinsed 
with phosphate buffered saline and washed twice for a total of 2 minutes in a bath of 
phosphate buffered saline. The slides were incubated at room temperature to dry. One 
drop of Mounting Fluid was added in the center of each well and a coverslip was 
placed on it. The slides were observed under fluorescent microscope.  
 
 
2.6. Transfection optimization 
 
2.6.1. Transfection control vector 
 
Because the success of the rest of the experiments was highly dependent on 
transfection efficiency, it was decided to optimize the transfection method. The pSV-
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β-Galactosidase Control Vector (Promega, Madison, Wisconsin, USA) was used in 
this study to optimize transfection. 
 
The pSV-β-Galactosidase Control Vector vector was transformed into JM109 cells 
(Promega, Madison, Wisconsin, USA) according to the manufacturer’s protocol and 
the transformed bacteria were cultured on 2 plates containing 100µg /ml penicillin. 
The plates were incubated at 37ºC for 24 hours and two colonies were inoculated in 2 
flasks containing 100 ml of LB broth and 100µg/ml penicillin. The flasks were 
incubated for 16 hours at 37ºC and 150 rpm. The vector DNA was extracted using 
QIAgen plasmid Maxi kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
suggestion. Eight µl of the purified vectors were run on 0.8% ethidium 
bromide/agarose gel to test the size and the quality of the DNA. The quantity of the 
vector DNA was measured using NanodropTM ND-1000 system (Nanodrop 
Technologies Inc, Delaware, USA). 
 
2.6.2. Transfection 
 
Transfection efficiency varies in different cell lines depending on the transfection 
method. To find the best combination of cell lines and transfection method 2 cell 
lines, including HeLa and 293T cells were used with TransFast™ Transfection 
Reagent (Promega, Madison,  Wisconsin, USA) and FuGENE® 6 to optimize 
transfection.  
 
Before transfection, 50,000 cells of each 293T and HeLa cell lines were separately 
seeded into 24 well cell culture plates (Corning, New York, USA). When the cells had 
50-80% confluency, usually after 24 hours, they were transfected with pSV-β-
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Galactosidase Control Vector. For transfection using TransFast™ Transfection 
Reagent, Hela and 293T cells were transfected with different DNA concentrations 
ranging from 250ng to 1µg according to the Promega protocol for transfection. For 
transfection using FuGENE® 6, Hela and 293T cells were transfected with different 
FuGENE® 6 Reagent:DNA ratios of 3:1, 3:2, and 6:1 (μl, for FuGENE® 6 Reagent, 
and μg for DNA, respectively) according to the protocol. Since it has been reported 
that antibiotics may have inhibitory effects on the efficiency of transfection with 
FuGENE® 6 (Jacobsen et al., 2004), the experiments were performed in the presence 
or absence of antibiotics  normally used in cell culture.  
 
2.6.3. Testing transfection efficiency 
 
Twenty four hours after transfection, the cells were fixed by replacing the medium 
with an equal volume of warm 4% paraformaldehhyde/0.2M sucrose/1×PBS and 
incubating the cells for 10 minutes at room temperature. The fixative was then 
replaced with an equal volume of 1×PBS/0.1% Triton X-100 and incubated for 10 
minutes at room temperature. The solution was then replaced with an equal volume of 
1× PBS. 
 
The fixed cells were stained using β-Gal Staining Set (Roche, Berlin, Germany). 
Briefly, the PBS in each well was replaced with 0.5 ml staining solution and 
incubated for 1 hour at 37ºC in NUAIRETM US Autoflow CO2 Water-Jacketed 
Incubator (Nuaire, Minnesota, USA). The cells were checked for color development 
using the Eclipse E200 Microscope (Nikon, Melville, USA). The settings and the cell 
line that had the most efficient transfection were selected as our transfection setting 
for the future experiments. 
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2.7. Subcellular localization of Vpr 
 
2.7.1. Cell labeling and Microscopic analysis 
 
The cell line showing the most efficient transfection, 293T cells, was used to study the 
cellular localization of Vpr. To transfect 293T cells, 5 ×105 cells were seeded into 8-
Well Lab-Tek II Chamber Slides (Fisher Scientific, Pennsylvania, USA). When the 
cells had 50-80% confluency, usually 24 hour after seeding, the cells were transfected 
with all HaloTag-Vpr expression vectors. 293T cells were individually transfected 
with HaloTag-Vpr expression vectors and HaloTag-only vector using FuGENE® 6 
Reagent: DNA ratios of 6:1 according to the protocol. The cells in one well remained 
non-transfected as the negative control.  
 
Twenty four hours after transfection, the 293T cells were labeled with HaloTag® 
TMR Ligand (Promega, Madison, Wisconsin, USA). Briefly, a 1:200 dilution of 
HaloTag® TMR Ligand was prepared in warm culture medium just prior to addition 
to cells. This was a 5X working stock solution. The cells were labeled by replacing 
one-fifth of the existing volume of medium with the 5X HaloTag® TMR ligand 
working solution, and mixed gently. The cells were incubated for 15 minutes at 37 °C 
in NUAIRETM US Autoflow CO2 Water-Jacketed Incubator (Nuaire, Minnesota, 
USA). The ligand-containing medium was replaced with an equal (or greater) volume 
of fresh DMEM complete medium. The wash was repeated twice, for a total of three 
complete rinses. The cells were incubated at 37 °C for 30 minutes to wash out 
unbound ligand. The medium was replaced with an equal volume of PBS.  
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The cells were then fixed to prevent any disturbance in Vpr localization due to the 
labeling treatments. Time is also another factor that can affect localization of Vpr due 
to the overexpression of Vpr and also apoptosis induction by Vpr if the sample 
preparing takes long. Cell fixation solves all of these problems and provides the free 
access of fluorescent dyes to cellular compartments (Kozubek et al., 2000). Briefly, 
the 293T cells were fixed by replacing the PBS with an equal volume of warm 
4%paraformaldehhyde/0.2M sucrose/1×PBS and incubating the cells for 10 minutes 
at room temperature. The fixative was then replaced with an equal volume of 
1×PBS/0.1% Triton X-100 and incubated for 10 minutes at room temperature. The 
solution was then replaced with an equal volume of 1× PBS. 
 
Since Vpr primarily trends to localize in the nucleus, the nuclei were also labelled 
using DAPI (4'-6-Diamidino-2-phenylindole) (Sigma, Saint-Louis, USA) to confirm 
the nuclear localization or cytoplasmic mislocalization of Vpr proteins. DAPI is a 
fluorescent dye that is excited with UV. When bound to double-stranded DNA, its 
absorption maximum is at 358 nm and its emission maximum is at 461 nm (Du et al., 
1998). To label the nuclei, a 900nM DAPI solution was prepared in 1X PBS as the 
working solution. The PBS in each well was replaced with 300 µl of the DAPI 
working solution and the cells were incubated for 3 minutes at room temperature. The 
cells were washed with PBS two times. The cells were observed and photographed 
under the Olympus IX 81 motorized inverted microscope (Olympus, Pennsylvania, 
USA) that was equipped with MT20 Illumination System and CellR software. 
 
In the cases that mislocalization of Vpr was observed, to ensure the mislocalization is 
not due to the overexpression of the protein, the experiments was repeated as 
described but the transfected cells were labelled after 10, 20 and 30 hours. 
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2.8. Induction of apoptosis by Vpr 
 
 
2.8.1. Reagents and optimization of flow cytometry 
 
To apply a reliable method for the assay of Vpr-induced apoptosis, the flow cytometry 
had to be optimized for the fluorescent dyes. In this study, p-HaloTag-Cons-C was 
used as control to optimize the method. p-HaloTag-Cons-C is a HaloTag-Vpr 
expression vector that expresses the consensus sequence of HIV-1 Vpr subtype C. 
Using this vector, Vpr could be detected in transfected cells using the HaloTag® TMR 
Ligand (Promega, Madison, Wisconsin, USA) that labels HaloTag-Vpr. Using this 
vector we were able to assay apoptosis in all cells (transfected and non-transfected 
cells) and in transfected cells separately. 
 
Camptothecin (Sigma, Saint-Louis, USA) was used to induce apoptosis for 
optimization of flow cytometry. Camptothecin is a strong apoptosis inducer that is 
widely used to induce and study apoptosis (Hsiang et al., 1985; Wall et al., 1966). 
Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, California, USA) was 
used in this study to assay apoptosis. Annexin V is a 35-36 kDa Ca2+ dependent 
phospholipid-binding protein that has a high affinity for phospholipid 
phosphatidylserine (PS), and binds to cells with exposed PS. Loss of plasma 
membrane is one of the earliest features. In apoptotic cells, the membrane PS is 
translocated from the inner to the outer leaflet of the plasma membrane, thereby 
exposing PS to the external cellular environment.  
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To optimize the method and flow cytometry for apoptosis assays, 5×104 293T cells 
were seeded into 8 wells of a 24 well cell culture plate (Corning, New York, USA). 
After 24 hours, the 293T cells were transfected in 3 wells with p-HaloTag-Cons-C 
using FuGENE® 6 Reagent:DNA ratios of 6:1 according to the protocol. The 293T 
cells in 3 wells were treated with camptothecin (5μl final concentration) for 24 hours. 
Twenty four hours after transfection, the cells were harvested by washing the cells 
with PBS and treating with 2 mM EDTA/PBS for 1 minute. To assay apoptosis using 
membrane factors, such as phosphatidyl serine, adherent cells cannot be trypsinated, 
instead, they should be gently treated using chelating chemicals such as EDTA. The 
cells were labeled with HaloTag® TMR ligand (according to protocol), Annexin V 
FITC (according to protocol), neither or both as shown in Table 2.3. The cell 
suspensions were analyzed using BD FACSCaliburTM (Becton Dickinson, California, 
USA). The flow cytometry was set for apoptosis assay by adjusting the plots, 
compensation, voltage, and signal intensity. 
 
Table 2.3: Treatments of 293T cells 
 
 
Wells Treatment Labeling with 
Annexin-V FITC 
Labeling with 
HaloTag® TMR 
Well 1 Transfection with  
p-HaloTag-Cons-C 
Yes No 
Well 2 Transfection with  
p-HaloTag-Cons-C 
No Yes 
Well 3 Transfection with  
p-HaloTag-Cons-C 
Yes Yes 
Well 4 5 µM Camptothecin 
for 24 hrs 
Yes No 
Well 5 5 µM Camptothecin 
for 24 hrs 
No Yes 
Well 6 5 µM Camptothecin 
for 24 hrs 
Yes Yes 
Well 7 No treatment Yes Yes 
Well 8 No treatment No No 
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2.8.2. Apoptosis assay 
 
5×105 293T cells were seeded into a 24 well cell culture plate (Corning, New York, 
USA). When the cells had 50-80% confluency, they were transfected with all the 
HaloTag-Vpr expression vectors using FuGENE® 6 Transfection Reagent (Roche, 
Berlin, Germany) according to the protocol (the vectors were described in section 
2.4.12). Twenty four hours after transfection, the cells were labeled using HaloTag® 
TMR ligand (Promega, Madison, Wisconsin, USA) and harvested by treating with 
2mM EDTA/PBS for 1 minute. The apoptotic cells were labeled with Annexin V-
FITC Apoptosis Detection Kit I (BD Biosciences, California, USA) according to 
protocol and analysed using BD FACSCaliburTM (Becton Dickinson, California, 
USA). A total of 30,000 events were collected for each sample. The main population 
was gated and applied to the other plots. The transfected cells (HaloTag TMR-labeled 
cells) were also gated and the apoptotic cells were calculated in the transfected cells. 
The cells transfected with HaloTag-only vector were used as control for apoptosis. 
 
 
2.9. Induction of cell cycle G2 arrest by Vpr 
 
2.9.1. Optimization of cell cycle analysis 
To apply a reliable method for the assay of Vpr-induced cell cycle G2 arrest, our 
method had to be optimized. In this study, p-HaloTag-Cons-C (for the expression of 
HaloTag-Cons C Vpr) was used to optimize the method. To detect HaloTag-Vpr in 
the transfected cells, the HaloTag® Oregon Green® Ligand (Promega, Madison, 
Wisconsin, USA) was used in all the experiments. This ligand differs from HaloTag® 
 97
TMR Ligand in its emission wavelength so that it could be applied in combination 
with other fluorescent dyes used in cell cycle analysis.   
 
Two fluorescent dyes were primarily used for the analysis, including propidium 
iodide (Sigma-Aldrich Co, St Louis, MO) and 7-amino actinomycin D (Sigma-
Aldrich Co, St Louis, MO). The advantage of 7-AAD over PI is the ability to be used 
in conjunction with phycoerythrin (PE)- and fluorescein isothiocyanate (FITC)- 
monoclonal antibodies in 2-color analysis, with minimal spectral overlap between 7-
AAD, PE and FITC fluorescence emissions. The 7-AAD fluorescence is detected in 
the far red range of the spectrum (650 nm long-pass filters).  
 
 
To optimize our method, 5×105 293T cells were seeded into different wells of two 24 
well cell culture plates. When the cells reached 50% confluency, they were 
transfected with p-HaloTag-Cons-C vector using our optimized transfection method. 
Twenty four hours after transfection, one plate was removed from the incubator for 
cell cycle analysis as described in the next paragraph. To find the best time for the 
assay, 24 hours after transfection, fresh complete DMEM medium was added to the 
second plate and incubated further for 24 hours (total incubation of 48 hours after 
transfection).  
 
The transfected cells were labeled with 5 µM HaloTag® Oregon Green® Ligand. The 
cells were harvested using Trypsin-Versene Mixture (Lonza, Basel, Switzerland). The 
harvested cells were resuspended in 500 µl of PBS and fixed by adding 2 ml of -20ºC 
absolute ethanol and incubating on ice for 30 minutes. Cell fixation facilitates 
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labelling the DNA content by permeabilizing the cell membranes. The fixed cells 
were centrifuged and resuspended in PBS.  
 
The DNA content was labelled with 1.2 µg/ml of 7-AAD or 1.2 µg/ml of PI and 
incubated for 10 minutes at room temperature in dark. The cell cycle was analyzed 
using flow cytometry within 6 hours. Briefly, multi-colour flow cytometry was 
performed to determine the induction of the cell cycle G2 arrest in the transfected 
293T cells. Mock-transfected cells (293T cells transfected with HaloTag-only vector) 
were used as control. Flow cytometry analysis was performed on a BD FACSCalibour 
(Becton Dickinson, California, USA) equipped with a 15 mW argon-ion and 20 mW 
red diode lasers. A total of 50,000 events were collected for cell cycle analysis. The 
transfected cells were gated based on HaloTag Oregon Green. The data were analyzed 
using BD CellQuest Pro software version 4.0 (Becton Dickinson, California, USA). 
 
2.9.2. Cell cycle assay 
5×105 293T cells were seeded into 24 well cell culture plates. When the cells reached 
50% confluency, they were transfected with all the HaloTag-Vpr expression vectors 
using FuGENE® 6 Transfection Reagent (Roche, Berlin, Germany) according to 
protocol. Based on our optimized method, 24 hours after transfection, the medium 
was replaced with fresh complete DMEM medium and 48 hours after transfection, the 
cells were labelled with 5µM HaloTag® Oregon Green® ligand (Promega, Madison, 
WI). The cells were harvested and resuspended in 500 µl of PBS and fixed by adding 
2 ml of -20ºC absolute ethanol and incubating on ice for 30 minutes. Cell fixation 
facilitates labelling the DNA content by permeabilizing the cell membranes. The fixed 
cells were centrifuged and resuspended in PBS. The DNA content was labelled with 
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1.2 µg/ml 7-AAD and incubated for 10 minutes at room temperature in dark. The cell 
cycle was analyzed using flow cytometry within 6 hours as described.  
 
 
2.10. Modulation of gene expression by Vpr 
 
2.10.1. Quantitative real-time PCR 
To study the modulation of gene expression by Vpr proteins, human 293T cells were 
plated at 400,000 cells/6 cm plate. When the cells reached 80% confluency, they were 
transfected using FuGENE® 6 Transfection Reagent (Roche, Indianapolis, IN) 
according to our optimized transfection method. 
 
The fluorescence-based quantitative real-time PCR (qPCR) was performed using 
TaqMan Human Apoptosis Arrays (Applied Biosystems, Foster City, Canada).  These 
are predesigned microfluidic cards with a 384-well format to assay the expression of 
93 human genes along with 3 endogenous controls (18S, ACTB, GAPDH) for each 
sample, 4 samples/per card. Briefly, using the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) the total RNA was extracted from the 293T cells 24 hours after transfection 
with Vpr-expression vectors. The total RNA was measured using NanodropTM ND-
1000 system (Nanodrop Technologies Inc., Delaware, USA). One μg of the total RNA 
was reverse transcribed into cDNA using ImProm-II™ Reverse Transcription System 
(Promega, Madison, WI) according to the manufacturer’s suggestions. Twenty μl of 
each cDNA sample was added to 100 μl of TaqMan Universal PCR Master Mix 
(Applied Biosystems, Foster City, Canada) and the total volume was brought to 200 
μl with nuclease free water. After gentle mixing, the solution was transferred into 2 
loading ports on a microfluidic card (100 μl per loading port). The microfluidic cards 
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were transferred to the 7900HT Fast Real-Time PCR System (Applied Biosystems, 
Foster City, Canada) and the real-time PCR conditions were set as follows: 2 min at 
50°C, 10 min at 94.5°C and 30 s at 97°C, and 1 min at 59.7°C for 40 cycles. Data 
acquisition was done according to the manufacturer’s suggestions using ABI Prism 
7900HT Sequence Detection System version 2.4 (Applied Biosystems, Foster City, 
Canada). The housekeeping genes, 18S, ACTB and GDPH were used for validation of 
results. Gene expression values were then calculated based on the ΔΔCt method, with 
data normalized to the mock sample (293T cells transfected with barnase-removed 
pF4A vector). Relative quantities (RQ) were determined using the equation: RQ=2-
ΔΔCt. Only genes with reproducible amplification curves of quadruplicate 
determinations were analyzed and presented. 
 
 
2.11. Statistical analysis 
 
Analysis of variance (ANOVA) with Bonferroni’s multiple comparison test was used 
to examine statistical significance in the ability of Vpr proteins in the induction of 
apoptosis and cell cycle G2 arrest. Statistical analysis was performed using GraphPad 
Prism 5.0 software (GraphPad software Inc., LaJolla, Ca). 
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Chapter 3 
 
 
3. Results 
 
3.1. Patient samples 
 
The patient demographics are listed in Table 3.1. The patients consist of 31 African 
females, 22 African males, 2 Caucasian males, as well as two males and one female of 
mixed race descent. Except for one patient (TV1638) who was from Kenya and was 
infected in Kenya, all of the other patients were South Africans infected in South 
Africa. The transmission pathways were, homosexual, heterosexual and unknown. 
 
 
Table 3.1: Patient demographics of the PCR amplified samples. 
Isolate Date of birth Race/Gender Transmission  
TV1325C* 1972 Mixed Race Male Unknown 
TV1345B# 1954 Caucasian Male Homosexual 
TV1421 1963 African Male Heterosexual 
TV1428B 1962 African Male Heterosexual 
TV1453 1954 African Male Heterosexual 
TV1454 1975 African Male Heterosexual 
TV1455 1979 African Female Heterosexual 
TV1459 1973 African Male Heterosexual 
TV1460 1922 African Male Heterosexual 
TV1462 1975 African Female Heterosexual 
TV1463 19-58 African Female Heterosexual 
TV1464 1977 African Female Heterosexual 
TV1466 1975 African Female Heterosexual 
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TV1467 1976 African Female Heterosexual 
TV1468 1968 African Male Heterosexual 
TV1470 1964 Mixed Race Male Heterosexual 
TV1472 1978 African Female Heterosexual 
TV1526B 1967 Caucasian Male Homosexual 
TV1565 1969 African Female Heterosexual 
TV1566 1962 African Male Heterosexual 
TV1568 1968 Mixed Race Female Heterosexual 
TV1570 1957 African Male Heterosexual 
TV1571 1976 African Female Heterosexual 
TV1573 1978 African Female Heterosexual 
TV1576 1974 African Female Heterosexual 
TV1577 1970 African Female Heterosexual 
TV1578 1983 African Female Heterosexual 
TV1579 1970 African Male Heterosexual 
TV1581 1975 African Male Heterosexual 
TV1583B 1981 African Female Heterosexual 
TV1596 1955 African Male Heterosexual 
TV1597 1971 African Female Heterosexual 
TV1598 1973 African Female Heterosexual 
TV1599 1958 African Male Heterosexual 
TV1614 1963 African Male Heterosexual 
TV1616 1972 African Female Heterosexual 
TV1623 1970 African Female Heterosexual 
TV1625 1973 African Female Heterosexual 
TV1626 1952 African Female Heterosexual 
TV1627 1975 African Female Heterosexual 
TV1628 1971 African Male Heterosexual 
TV1630 1977 African Male Heterosexual 
TV1632 1971 African Female Heterosexual 
TV1633 1961 African Male Heterosexual 
TV1638 1973 African Female Heterosexual 
TV1639 1976 African Female Heterosexual 
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TV1641 1981 African Female Heterosexual 
TV1642 1970 African Female Heterosexual 
TV1643 1958 African Female Heterosexual 
TV1644 1976 African Male Heterosexual 
TV1653 1984 African Female Heterosexual 
TV1654 1972 African Female Heterosexual 
TV1661 1980 African Male Homosexual 
TV1667 1963 African Female Heterosexual 
TV1681 1973 African Male Heterosexual 
TV1705 1974 African Female Heterosexual 
TV1707 1946 African Male Heterosexual 
TV1708 1975 African male Heterosexual 
 
* B indicates the second sample of the patient 
# C indicates the third sample of the patient. 
 
 
 
 
 
3.2. Amplification of the HIV-1 vpr gene 
 
The Access RT-PCR System has been designed for the reverse transcription and PCR 
amplification of a specific target RNA from either total RNA or mRNA (Miller & 
Storts, 1995). This one-tube, two-enzyme system provides sensitive analysis of 
RNAs. The system uses AMV reverse transcriptase (AMV RT) from avian 
myeloblastosis virus for first strand DNA synthesis and the thermostable Tfl DNA 
polymerase from Thermus flavus for second strand cDNA synthesis and DNA 
amplification. The Access RT-PCR System includes an optimized single-buffer 
system that permits detection of RNA transcripts without a requirement for buffer 
additions between the reverse transcription and PCR amplification steps. 
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A total of 100 South African HIV-1 samples were recruited in this study but only 58 
samples could be amplified. PCR amplification of a 714 bp fragment yielded sharp 
bands in parallel with 750bp band of the DNA ladder as observed on agarose gel 
(Figure 3.1). 
 
 
 
 
Figure 3.1: PCR amplification of South African HIV-1 isolates using primers HIV-vif-1F and 
HIV-vpr-R1. Fifty eight samples were amplifiable. The result of 1 run is shown in the figure. Lane M: 
1 kb DNA Marker; Lane 1: TV1568, Lane 2: TV1654, Lane 3: TV1627, Lane 4: TV1639, Lane 5: 
TV1598, Lane 6: TV1638, Lane 7: TV1628, Lane 8: TV1641, Lane 9: TV1630, Lane 10: TV1632, 
Lane 11: TV1633, Lane 12: TV1428B, Lane 13: TV1566, Lane 14: TV1565, Lane 15: TV1469, Lane 
16: TV1593, Lane 17: TV1624, Lane 18: TV1616, Lane 19: TV1456, Lane 20: TV1625, Lane 21-
negative control.  
 
 
3.3. DNA sequencing 
 
The PCR products were purified for sequencing using enzymes Exonuclease 1 (Exo1) 
and Shrimp alkaline phosphatase (SAP). These enzymes are used to degrade single-
strand DNA (such as excess primers) and diphosphates that might interfere with the 
sequencing reactions (Werle et al., 1994).  
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The BigDye Terminator Cycle Sequencing Kit, which was used in this study, provides 
the required reagent components for the sequencing reaction in a ready reaction, pre-
mixed format. The kit is based on Sanger sequencing method. This method has served 
as the cornerstone for genome sequencing, including eukaryotic, prokaryotic, viral 
sequencing, for over a decade (Goldberg et al., 2006). 
 
The sequencing of the PCR products yielded pure chromatograms of single sequences 
free of DNA contamination or non-specific amplification (Figure 3.2). By aligning the 
sequences with the reference sequences of vpr, the vpr gene was identified in the 
sequences. All vpr sequences were submitted to GenBank with accession numbers 
FJ039723-FJ039780.  
 
 
 
Figure 3.2: The sequencing chromatogram of a PCR product resulted in single peaks. The 
chromatograms do not show any traces of cross contamination of the PCR products. 
 
 
3.4. Phylogenetic analysis of South African isolates 
The vpr gene of these isolates was phylogeneticly analyzed. The phylogenetic tree 
constructed from the 291-bp fragment of the structural part of vpr gene is shown in 
Figure 3.3. The bootstrap values greater than 70% were included in the phylogenetic 
tree. Although bootstrap values greater than 95% are generally considered statistically 
significant, bootstrap values greater than 70% are generally accepted in the literature.  
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Fifty three out of 58 sequences (91%) clustered with the reference sequences of 
subtype C. The sequence of TV1573 was an outlier to subtype C. This sequence was 
analyzed using jumping profile hidden Markov model (jpHMM). The jpHMM 
predicts recombination breakpoints in a query sequence and assigns to each position 
of the sequence one of the major HIV-1 subtypes. Since incorrect subtype assignment 
or recombination prediction may lead to wrong conclusions in epidemiological or 
vaccine research, information about the reliability of the predicted parental subtypes 
and breakpoint positions is valuable (Schultz et al., 2009). The jpHMM indicated that 
the vpr gene of TV1573 belonged to HIV-1 subtype C, however, only the complete 
genome sequencing could confirm the subtype of this isolate. 
 
Four sequences (TV1526B, TV1345B, TV1626, and TV1325C) clustered with the 
reference sequences of subtype B from Thailand (B.TH.90.BK132), France 
(B.FR.83.HXB2), and the Netherlands (B.NL.00.671). Two out of four subtype B 
isolates had been transmitted homosexually, one through heterosexual contact, and 
one with an unknown route. In comparison to subtype B, only 1 (TV1661) out of 54 
subtype C isolates had been transmitted homosexually and the others had a 
heterosexual route. 
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Figure 3.3: Rooted neighbor-joining tree illustrating the evolutionary relationship among vpr 
nucleotide sequences (291 bp) from South African HIV-1 isolates and reference sequences of HIV-1 
(Los Alamos database). Fifty-eight sequences are shown with TV (Tygerberg Virology) suffixed by 
their respective clone numbers. Triangles indicate subtype C isolates and circles indicate subtype B 
isolates.  
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To investigate the Vpr protein, the vpr gene was translated and the amino acids were 
aligned with the consensus subtype C and HXB2 reference sequences. The α-helical 
domains of Vpr were shaded in gray (Figure 3.4). All of our sequences were 96 amino 
acid residues in length, except for TV1467. In this sequence an arginine residue had 
been deleted in position 90, which is located in the C-terminal domain of the protein. 
The patient was a 30-year-old African woman with symptoms of prurigo. 
 
Figure 3.4: Alignment of the deduced Vpr amino acid sequences from 58 South African isolates in 
comparison with consensus subtype C reference and the subtype B HXB2 reference. Dots represent 
identity to the consensus sequence of our isolates, at the bottom, and the only dash, in TV1467, 
represents a gap. The α-helical domains of Vpr are shaded gray. 
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The consensus Vpr amino acid sequence of our strains was identical to the consensus 
sequence of subtype C, except for position 4. Most of the sequences had a proline 
residue in this position, whereas the consensus subtype C sequence had an alanine 
residue. No mutations were observed in positions 21 and 24 of the α-helix I for which 
substitutions of proline have been shown to abrogate Vpr incorporation into virus-like 
particles (Tungaturthi et al., 2004a). A highly conserved motif in α-helix I was found 
in position 29-33 (EAVRH). Motif 42-44 of the α-helix II was highly conserved in 
our isolates of which leucine 42 and glycine are involved in Vpr incorporation (Singh 
et al., 2001; Thotala et al., 2004). Motif 55-64 in α-helix III was variable but motif 
65-83 in this domain was found highly conserved. The C-terminal domain of Vpr 
indicated the highest variability, but even in this domain, three arginine residues in 
positions 87, 88, and 95 and one glycine residue in position 92 were intact in all of 
our isolates. The motif FPRPWL, between α-helix I and II (34-39: IH1), and the motif 
TYGDTW, between α-helix II and III (49-54:IH2), were highly conserved in our 
isolates (Tungaturthi et al., 2004a). 
 
3.5. Cloning of the vpr ORF 
 
The impact of natural mutations on the established functions of Vpr and the biology 
of HIV-1 has not been studied. Many studies investigate that function of wild-type 
Vpr and the functions and significance of this protein is presented as the outcome of 
these studies while the natural mutants of Vpr are ignored. Since the natural Vpr 
mutants are frequent forms of this protein, this study addressed the functions of these 
proteins compared to that of the consensus sequence of Vpr that artificially was 
produced in this study, as well as subtype B Vpr. The sequences were selected that 
contained natural mutations distributed in different domains of Vpr. The impact of 
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these mutations on the established functions of Vpr and the biology of HIV-1 has not 
been studied. 
 
The 291 bp vpr ORF of the South African isolates (TV1453, TV1628, TV1707, 
TV1642, TV1570, and TV1466) and subtype B Vpr (pNL4-3) was amplified using 
Vpr-Sgf-F and Vpr-Pme-R as described in chapter 2. Using these primers, the 
restriction sites for Sgf-I and Pme-I endonuclease were appended to the vpr ORFs. 
The PCR products were run on ethidium bromide/agarose gel as shown in Figure 3.5 
and 3.6. The amplification was successful and resulted in 310 bp PCR products. After 
clean up of the PCR products, 60-90 ng/µl DNA was obtained from each PCR product 
that was used for cloning. 
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Figure 3.5: Amplification of the vpr ORF using the primer vpr-sgf-F and vpr-Pme-R to insert 
restriction sites at both sides of the vpr fragments. The PCR reactions resulted in 310 bp PCR 
products. (A) Amplification of TV1453. Lane 1-Negative control; Lane 2-TV1453. (B) Amplification 
of TV1628, TV1701, TV1466, TV1642, TV1570 in lane 1 to 5, respectively; Lane 6- Negative control. 
 
 
A 
B 
 112
 
Figure 3.6: PCR products of a ~300 bp fragment containing vpr ORF from pNL4-3. Lanes: Lane 
M- 1 kb DNA Marker; Lane 1 and 2-two PCR reactions for the same sample. 
 
 
The PCR products were successfully ligated to the pF4A Flexi® vector and 
transformed to JM109 cells. The transformants were cultured on LB medium with 
antibiotics and yielded 40-100 colonies for each clone. The number of the colonies 
grown on the plates was enough to verify the success of the cloning. For each clone 9 
colonies were picked and cultured in LB broth and extracted. The plasmid purification 
yielded between 50-150 ng/µl DNA for each clone. The plasmids were digested using 
the restriction enzymes (Sgf-I and Pme-I) and run on an ethidium bromide/agarose 
gel. Most of the plasmids contained the fragment of interest as shown in Figure 3.7. 
The insertion of subtype B vpr was confirmed by PCR (Figure 3.8). Four plasmids 
with confirmed integration of a ~300 bp fragment, based on gel evidence, were 
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sequenced to verify the integration of the non-mutated vpr gene. The sequencing also 
confirmed the integration of the vpr gene. One vector for each plasmid expressing 
non-mutated fragments was stored at 4ºC for the future experiments. 
 
At this stage we had 7 clones. The clones were named corresponding to their insert as 
follow: 
pF4A-subtype B, pF4A-TV1453, pF4A-TV1628, pF4A-TV1707, pF4A-TV1642, 
pF4A-TV1570, pF4A-TV1466. 
 
 
 
Figure 3.7: Nine plasmids were screened for each clone. The digested plasmids were run on agarose 
gel to screen for the integration of vpr fragments. The picture shows the clones of TV1453 in lane 1-9. 
Seven plasmids of TV1453 colons contained ~300 bp fragments corresponding to vpr gene. The 
exposure time was increased so that the small fragments could be observed. 
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Figure 3.8: PCR of 4 clones of subtype B Vpr from pNL4-3. Lanes: Lane M-1kb DNA ladder; lane 
1; positive control (pNL4-3), lane 2-5; miniprebs. 
 
 
3.6. Mutagenesis experiments 
 
Site-directed mutagenesis allows site-specific mutation in virtually any double-
stranded plasmid. The QuikChange® Lightning Site-Directed Mutagenesis Kit 
includes a derivative of PfuUltra® high-fidelity (HF) DNA polymerase for mutagenic 
primer-directed replication of both plasmid strands with the highest fidelity. The basic 
procedure utilizes a vector with an insert of interest and two synthetic primers, both 
containing the desired mutation. The primers, each complementary to opposite strands 
of the vector, are extended during temperature cycling by PfuUltra HF DNA 
polymerase, without primer displacement. Extension of the oligonucleotide primers 
generates a mutated plasmid containing staggered nicks. Following temperature 
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cycling, the product is treated with Dpn I. The Dpn I endonuclease is specific for 
methylated and hemimethylated DNA and is used to digest the parental DNA 
template.  
 
To study the role(s) of Vpr domains in different functions of the protein, Vpr was 
mutated in different domains. The plasmids that were subject to site-directed 
mutagenesis were sequenced to confirm the mutations. According to the protocol for 
site-directed mutagenesis, one can expect 80% of the clones to contain the mutation of 
interest. The outcome of site-directed mutagenesis and sequencing of the plasmid 
indicated that all the sequenced plasmids contained the mutations of interest. This 
means the efficiency of the site-directed mutagenesis was 100% in these experiments. 
 
The plasmids were named as follow: 
pF4A-P14I, pF4A-W18C, pF4A-Y47N, pF4A-Q65H, pF4A-Q88S 
 
 
3.7. Protein modelling 
 
Homology modelling is currently the most accurate computational method to generate 
reliable structural models and is routinely used in many biological applications. 
Typically, the computational effort for a modelling project is less than 2 h. However, 
this does not include the time required for visualization and interpretation of the 
model, which may vary depending on personal experience working with protein 
structures (Arnold et al., 2006; Kiefer et al., 2009; Schwede et al., 2003). 
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To define the position of mutations in mutated proteins, the 3-dimensional structure of 
proteins had to be reconstructed. These comprehensive pictures help to identify the 
position of the mutation(s) in the protein domains. Especially, if the study is intended 
for publication, these pictures help authors as a comprehensive guide to elaborate the 
experiments. Based on the sequencing of the plasmids, the proteins expressed by the 
expression plasmids were simulated using Swiss-Model and DS visualizer (Figure 3.9 
& 3.10). The backbone of the proteins was shown using ribbon representation and the 
mutations were shown using CPK representations. The pictures clearly demonstrate 
the position of the mutations in the corresponding domain. Site-directed mutagenesis 
had created mutations in the positions that did not occur in natural mutations so that 
the functional study of these domains was possible. The results from protein 
modelling indicated that the flexible N-terminal domain was intact in all of our 
natural mutants. To study the role of this domain in the functions of Vpr, this domain 
was mutated using site-directed mutagenesis. The α-helix I was intact among the most 
of the natural mutants. L22I was the only mutation observed in α-helix I of two 
natural mutants, TV1570 and TV1642. Using site-directed mutagenesis, tryptophan 
was mutated to cysteine in position 18 which is situated in α-helix I. α-helix II was 
sufficiently covered by the natural mutations P37D, S41N, Y45H, E48A, and E48 D. 
α-helix III also contained natural mutations including T55A, I60L, I61L, I63M, I63V, 
F72Y. 
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Figure 3.9: Ribbon representation of natural mutants showing the distribution of mutations in 
different domains of HIV-1 Vpr of our isolates. The mutations are represented in CPK (blue balls) 
that represent the molecular structure of the amino acids. 
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Figure 3.10: Ribbon representation of consensus sequence of HIV-1 Vpr subtype C and the 
mutants created by site-directed mutagenesis. 
 
 
3.8. Transfer of the Vpr-coding region between the vectors 
 
To verify the transfer of the Vpr-coding regions from the donor plasmids (clones of 
pF4A CMVd1 Flexi® Vector) to the acceptor plasmids (pFN22K CMVd1 Flexi® 
Vectors), vpr ORF was amplified using Vpr-Sgf-F and Vpr-Pme-R. The products of 
the PCR reactions were run on an agarose gel and short fragments (~300 bp) 
corresponding to vpr ORF were observed on the gel (Figure 3.11). The results 
indicated that vpr ORF had been successfully integrated in all the acceptor vectors. 
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The efficiency of the fragment transfer between the vectors was 100%. One vector 
was chosen from each clone. There was no need to confirm the vectors by sequencing 
at this stage because the donor vectors had not undergone PCR amplification and had 
been already sequenced and confirmed. The new vectors expressing the HaloTag-Vpr 
are listed in Table 3.2. 
 
 
Figure 3.11: Agarose gel showing the PCR bands amplified from the acceptor vectors. The 
presence of this fragment in the acceptor vectors indicates the successful transfer of the Vpr-coding 
region between the vectors. Lane 1-4: TV1628, Lnae 5-8: TV1707, Lane 9-12: TV1642, Lane 13-16: 
TV1570, Lane 17-20: TV1466, Lane 21 is a negative control.  
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Table 3.2: The donor flexi vectors and their corresponding vectors expressing 
HaloTag-Vpr 
The donor flexi vector The corresponding HaloTag-Vpr expression vector 
pF4A-sub-B p-HaloTag-sub-B 
pF4A-Cons-C p-HaloTag-Cons-C 
pF4A-TV1453 p-HaloTag-TV1453 
pF4A-TV1628 p-HaloTag-TV1628 
pF4A-TV1707 p-HaloTag-TV1707 
pF4A-TV1642 p-HaloTag-TV1642 
pF4A-TV1570 p-HaloTag-TV1570 
pF4A-TV1466 p-HaloTag-TV1466 
pF4A-P14I p-HaloTag-P14I 
pF4A-W18C p-HaloTag-W18C 
pF4A-Y47N p-HaloTag-Y47N 
pF4A-Q65H p-HaloTag-Q65H 
pF4A-Q88S p-HaloTag-Q88S 
 
 
 
3.9. Immunofluorescence assay for detection of Mycoplasma 
 
The immunofluorescence assay did not show any signs of mycobacterial 
contamination. This means the cells were not contaminated with Mycoplasma and can 
be used for transfection and other experiments.  It has been shown that mycoplasmas 
produce a variety of effects on cultured cells (e.g. changes in metabolism, 
immunologic or biochemical properties, growth, viability, etc.). Since mycoplasma 
infection in cell cultures normally is a chronic infection, which may not be obvious by 
visual inspection or light microscopy, periodic screening of cell cultures for 
mycoplasmas is important. A variety of tests to detect mycoplasmas in cell cultures 
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have been developed such as fluorochrome staining of DNA, monitoring toxic 
metabolites, culture method, etc. RIDASCREEN® Mycoplasma IFA contains a 
monoclonal antibody with specificity for a broad range of Mycoplasma species, 
including the species Acholeplasma laidlawii, Mycoplasma hyorhinis, M. arginini, M. 
orale, M. fermentans and M. salivarium, which account for more than 96% of cell 
culture infections (Blazek et al., 1990; Kamla et al., 1992).  
 
3.10. Transfection optimization 
 
Two transfection reagents, two cell lines and different transfection reagent to DNA 
ratios were compared with each other in this study to apply the most efficient method 
for transfection. TransFast™ Transfection Reagent (Promega, Madison, Wiskinson, 
USA) did not efficiently transfect either 293T or HeLa cells (Figure 3.12) even with 
different DNA concentrations of the pSV-β-Galactosidase Control Vector (Promega, 
Madison, Wiskinson, USA) as recommended by the manufacturer. Only a few cells 
appeared in blue (transfected) after staining the transfected cells with β-Gal Staining 
Set (Roche, Berlin, Germany). On the other hand, transfection using FuGENE® 6 
Transfection Reagent (Roche, Berlin, Germany) with different concentrations of the 
DNA and the transfection reagent yielded generally better results. It was suspected 
that the presence of antibiotics in the medium may also affect the efficiency of 
transfection as it has been reported that in the presence of antibiotics the efficiency of 
transfection can be dramatically reduced (Jacobsen et al., 2004). The transfection 
optimization experiments using FuGENE® 6 Transfection Reagent were performed in 
the presence or absence of penicillin/streptomycin in both 293T and HeLa cells. 
Antibiotics did not affect the transfection efficiency since similar results were 
obtained in the presence or absence of penicillin/streptomycin (Figure 3.13 and 3.14). 
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The highest transfection efficiency of FuGENE® 6 Transfection Reagent was obtained 
from the ratio of 6:1 (FuGENE® 6 Reagent:DNA ratio, respectively) in 293T cells as 
shown in Figure 3.13. Transfection of HeLa cells using FuGENE® 6 Transfection 
Reagent yielded few transfected cells (Figure 3.14). Although the transfection 
efficiency in HeLa cells was low, the ratio of 6:1 in HeLa cells still resulted in higher 
efficiency than the other ratios. 
 
Since the highest transfection efficiency was obtained from FuGENE® 6 Transfection 
Reagent, it was decided to use this reagent with the optimized ratio (6:1) for the 
transfection of 293T cells. HeLa cells and TransFast™ Transfection Reagent were 
excluded from further experiments as they did not yield high transfection efficiency.  
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Figure 3.12: Transfection optimization of HeLa cells using TransFast™ Transfection Reagent. 
HeLa cells were transfected with pSV-β-Galactosidase Control Vector and after 24 hours photographed 
at 20X magnification using the NikonTM Eclipse TS100 Microscope (Nicon Ltd. Surrey, UK). The dark 
cells indicate the transfected cells. This set up resulted in low transfection efficiency. 
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Figure 3.13: Transfection optimization of 293T cells using FuGENE® 6 Transfection Reagent. 
Human 293T cells were transfected with pSV-β-Galactosidase Control Vector and after 24 hours 
photographed at 20X magnification using the NikonTM Eclipse TS100 Microscope (Nicon Ltd. Surrey, 
UK). The dark cells indicate the transfected cells. Apparently, the presence or absence of antibiotics 
did not significantly affect the transfection efficiency. The best result was obtained from the ratio of 
6:1. 
 
 
 
 
 
 125
 
Figure 3.14: Transfection optimization of HeLa cells using FuGENE® 6 Transfection Reagent. 
HeLa cells were transfected with pSV-β-Galactosidase Control Vector and after 24 hours photographed 
at 20X magnification using the NikonTM Eclipse TS100 Microscope (Nicon Ltd. Surrey, UK). The dark 
cells indicate the transfected cells. Low transfection efficiency was observed in HeLa cells using this 
method. 
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3.11. Subcellular localization of Vpr  
 
Vpr has been shown to possess karyophilic properties and localize to the nucleus 
(Jacquot et al., 2007). To investigate the ability of naturally mutated Vpr proteins to 
localize to the nucleus and the domains of Vpr involved in the nuclear localization, 
the subcellular localization of Vpr was studied microscopically. The nuclear 
localization of Vpr is closely related to its functions and the mutations affecting the 
subcellular localization of Vpr could thus seriously affect its functions (Nitahara-
Kasahara et al., 2007). For example, as Vpr has been shown to transfer HIV-1 PIC to 
the nucleus, disturbing the karyophilic property of Vpr could result in inhibition of 
PIC transfer (Jacquot et al., 2007; Jenkins et al., 1998; Le-Rouzic et al., 2002; Suzuki 
et al., 2009).  In this study, 13 different construct expressing different forms of Vpr 
protein were used. Six constructs expressed naturally mutated Vpr proteins and five 
constructs expressed site-directed mutated Vpr proteins, one construct expressed the 
consensus HIV-1 Vpr subtype C, and one construct expressed the subtype B NL4-3 
Vpr.  
 
All the constructs contained a sequence to encode HaloTag protein tagged to the N-
terminal region of the Vpr proteins. The HaloTag® Technology is a technology 
platform for understanding protein function in biochemical and cellular environments. 
Specific applications include imaging live or fixed cells, performing gel-based 
analyses including post-translational modification of labeled fusion proteins, and 
isolating proteins or protein complexes, all using a single genetic construct. This 
technology is comprised of two essential parts: the HaloTag® protein, to which a 
protein of interest is attached at either the N- or C-terminus, and the HaloTag® 
ligands, designed to covalently bind the HaloTag® protein. 
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The HaloTag® reporter protein is an engineered, catalytically inactive derivative of a 
hydrolase that forms a covalent bond with HaloTag® ligands. Under physiological 
conditions this covalent bond forms rapidly and is highly specific and essentially 
irreversible, yielding a complex that is stable even under stringent conditions (Lang et 
al., 2006; Los, 2005; Los & Wood, 2007). The HaloTag® protein is a 33kDa 
monomeric protein not endogenous to mammalian, plant or E. coli cells, resulting in 
lower levels of background staining and therefore high labeling specificity (Los & 
Wood, 2007). 
 
Due to the tagged reporter, tracing of the expressed proteins was possible by labelling 
the transfected cells with a HaloTag ligand (HaloTag TMR). 293T cells were 
transfected according to the method optimized for FuGENE® 6 Transfection Reagent. 
The subcellular localization of the Vpr proteins was studied by 2 fluorescent dyes 
including DAPI (blue emission spectrum) and HaloTag TMR (red emission 
spectrum). DAPI binds to DNA and is commonly used to label the nuclei. The method 
for analysis used in this study was based on the overlap of the two fluorescent dyes. If 
the emission spectra of the two fluorescent dyes overlap in labelled transfected cells, 
it means Vpr localized to the nucleus and if the red dye (HaloTag TMR) does not 
overlap the blue dye (DAPI), it means Vpr localized outside of the nucleus. Although 
it has been shown that HaloTag protein does not indicate any specific trend for 
subcellular localization, the non-specific localization of HaloTag protein, using 
HaloTag only expression, was studied to ensure the localization of Vpr is not affected 
by HaloTag protein.  
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The results indicated that all naturally mutated Vpr proteins localized to the nucleus in 
a similar manner to the consensus sequence of HIV-1 Vpr subtype C (Figure 3.15). 
This observation suggest that the mutations L22I (in α-helix I), P37T, S41N, Y45H, 
E48A, E48D (in α-helix II), T55A, I60L, I61L, I63M, I63V (in α-helix III), R85P, and 
F72Y in C-terminal region did not affect the nuclear localization of Vpr. The naturally 
mutated Vpr proteins were selected such that mutations in all domains were studied. 
However, one cannot rule out the role of other domains lodging the mutations in the 
nuclear localization of Vpr. There could be other amino acids in other positions of α-
helix I, II and III, as well as the C-terminal region of Vpr protein that play roles in 
nuclear localization of Vpr.  
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Figure 3.15: 293T cells transfected with Vpr-expression vectors to express naturally mutated Vpr 
proteins. A sample was also transfected with HaloTag Expression vector as control. Twenty hours 
after transfection the cells werelabelled with DAPI (blue) and HaloTag TMR. The cells were 
photographed at 100X magnification with blue filter for DAPI and Red filter for HaloTag TMR. The 
merged photographs are also provided to show the overlap of the fluorescent dyes. HaloTag protein 
was localized non-specifically (on top of the figure). All naturally mutated Vpr proteins localized to the 
nucleus. The scale bars, 20 µm. 
 
 
The site-directed mutated Vpr proteins containing the mutations P14I, Y47N, Q65H, 
and Q88S similarly localized to the nucleus (Figure 3.16) suggesting the position of 
the mutations does not play roles in the nuclear localization of Vpr. However, similar 
to the naturally mutated Vpr proteins, the role of the mutated domains in the nuclear 
localization of Vpr cannot be ruled out. It should be noted, however, that a Vpr 
protein containing the mutation W18C indicated evidence of mislocalization of Vpr to 
the nucleus. Time is also another factor that can affect localization of Vpr due to the 
overexpression of Vpr and also apoptosis induction by Vpr if the sample preparing 
takes long. Cell fixation solves all of these problems for us and provides the free 
access of fluorescent dyes to cellular compartments (Kozubek et al., 2000). To ensure 
the mislocalization of this mutant is not due to the early expression or overexpression 
of the protein it was photographed at different times (Figre 3.17). In this mutated Vpr 
protein, tryptophan residue in position 18, which is situated at the beginning of α-
helix I, had been mutated to cysteine. The mislocalization of W18C suggests that 
tryptophan 18 in the α-helix I of Vpr may play an essential role in the nuclear 
localization of Vpr and mutations in this position could affect the karyophilic property 
of Vpr. 
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Figure 3.16: 293T cells transfected with Vpr-expression vectors to express site-directed mutated 
Vpr proteins. A sample was also transfected with HaloTag Expression vector as control. Twenty hours 
after transfection the cells were labelled with DAPI (blue) and HaloTag TMR. The cells were 
photographed at 100X magnification with blue filter for DAPI and Red filter for HaloTag TMR. The 
merged photographs are also provided to show the overlap of the fluorescent dyes. HaloTag protein 
was localized non-specifically (on top of the figure). The site-directed mutated Vpr proteins that 
localized to the nucleus are shown here. The scale bars, 20 µm. 
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Figure 3.17: Mislocalization of W18C mutant. 293T cells were transfected with the vector to 
express the site-directed mutated Vpr protein W18C. To ensure the mislocalization of this mutant is 
not the result of early expression or overexpression of the protein, 10, 20 and 30 hours after 
transfection the cells were labelled with DAPI (blue) and HaloTag TMR. The cells were photographed 
at 100X magnification with blue filter for DAPI and Red filter for HaloTag TMR. The merged 
photographs are also provided to show the overlap of the fluorescent dyes. The W18C mutant localized 
non-specifically to all the samples. The scale bars, 20 µm. 
 
 
An interesting phenomenon observed in some of the photographs is that Vpr mostly 
localizes to the nuclear envelope. The interaction between Vpr and nuclear pore 
complex (NPC) has been reported (de-Noronha et al., 2001; Le-Rouzic et al., 2002). 
The interaction of Vpr with the nuclear envelope that was observed in this study can 
be attributed to the interaction of Vpr with NPC. These interactions appeared as a 
circle or halo around the nucleus (Figure 3.16, P14I and Q88S). The nuclear 
localization of Vpr is a time-dependent phenomenon that can also be affected by the 
amount of the expressed protein. The expression level of Vpr (or any other vector 
expressed protein) varies in different cells within the same culture leading to slightly 
different localization results. The high expression levels of Vpr could result in 
 133
mislocalization of Vpr in some cells especially when this event is associated with 
apoptosis and/or damage to the nuclear envelope. Due to this phenomenon, the 
microscopic photographs of the localization of Vpr may appear slightly different. This 
means that even if the interaction of Vpr was clearly observed in some cells while it 
was not observed in others, it cannot be interpreted as mutations inhibiting the 
interaction of Vpr with the nuclear envelope. The results are interpretable only if Vpr 
does not localize to the nucleus or localizes in the both the nucleus and cytoplasm of 
all cells in the same culture. According to these criteria, W18C was the only mutation 
that disturbed the nuclear localization of Vpr. The mislocalization of the Vpr mutant 
shows that the mutation of tryptophan 18 in α-helix I to cysteine interferes with the 
nuclear localization of Vpr and indicated the importance of this residue for this 
function. The helical wheel of α-helix I (Figure 3.18) shows that residue 18 lies on the 
hydrophilic side of the α-helix I, mostly dominated by Arginine (R) and glutamic acid 
(E).  The mutation of tryptophan to cysteine (W18C), imbalances the hydrophilic 
property of the chain that results in the reduction of some interactions necessary for 
the nuclear localization of Vpr. 
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Figure 3.18: Shematic helical wheel diagram illustrating the α-helix I of (a) the consensus-C and 
(b) W18C.  Hydrophobicity is color coded, meaning the most hydrophobic residue is green, and the 
amount of green is decreasing proportionally to the hydrophobicity, with zero hydrophobicity coded as 
yellow. Hydrophilic residues are coded red with pure red being the most hydrophilic residue, and the 
amount of red decreasing proportionally to the hydrophilicity. The potentially charged residues are 
light blue. The difference between the two α-helices is residue 18 that is in the hydrophilic side of the 
α-helix I. Mutation of tryptophan 18 (hydrophobic) to the less hydrophobic amino acid cysteine 
imbalances the hydrophobicity of the peptide chain. 
 
 
3.12. Assay of Vpr-induced apoptosis by flow cytometry  
 
Camptothecin is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme 
topoisomerase I (topo I). It is isolated from the bark and stem of Camptotheca 
acuminata (Camptotheca; Happy tree), a tree native in China. Camptothecin is a 
strong apoptosis inducer that is widely used to induce and study apoptosis (Hsiang et 
al., 1985; Wall et al., 1966). In this study camptothecin induced apoptosis in about 
20% of the camptothecin treated cells 24 hours after treatment. The method for 
apoptosis assays was first optimized in camptothecin-induced apoptotic cells. 
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The apoptotic cells were also labeled with 7-AAD for late apoptotic or necrotic cells. 
Due to the interference of HaloTag TMR ligand with 7-AAD, this combination was 
not continued. Since apoptosis was induced using the Vpr-expression vectors and a 
very low level of apoptosis was observed in mock-transfected cells, only annexin V 
was used to confirm the induction of apoptosis in transfected cells. 
 
Once the method for apoptosis assay was optimized, apoptosis was assayed in all the 
transfected cells and compared with the mock transfected sample, 293T cells 
transfected with barnase-deleted pFN22K vector. The transfected 293T cells were 
distinguishable from untransfected cells based on the signal of HaloTag® TMR 
ligand. The transfected cells were gated and the percentage of apoptotic transfected 
cells was determined (Figure 3. 19). ). In the absence of a suitable antibody for 
Western blot analysis, the mean fluorescence intensity of the HaloTag signal was used 
as a surrogate marker. The intensity of the HaloTag signal was similar in all the 
transfected cells (22.21±2.46), which would appear to indicate that the expression 
level was similar in individual transfected cells (Figure 3.20). This is important since 
different expression levels in individual cells could influence the level of expressed 
protein and thus the functional responses related to protein expression (in this case 
induction of apoptosis and cell cycle G2 arrest by Vpr). Based on the mean values of 
3 independent experiments (Table 3.3 & 3.4), the lowest percentage of apoptotic cells 
was found in the mock sample with 0.08% of transfected cells being apoptotic (Figure 
3.21). In all Vpr-transfected samples the percentage of apoptotic cells was close to the 
percentage of the transfected cells suggesting that the majority of the transfected cells 
are apoptotic. This was shown by gating the transfected cells and measuring of 
apoptosis in the gated cells. This result indicated that the EDTA treatment to harvest 
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the adherent cells did not result in damage to cell membranes and the consequent 
generation of spurious results. Interestingly, the lowest percentage of apoptotic cells 
among all the Vpr-transfected cells was found in the cells transfected with the 
consensus sequence of subtype C with 82.08% apoptotic cells (p<0.05). Subtype B 
Vpr induced apoptosis in 98.20% of the transfected cells. The percentage of apoptotic 
cells detected for the other Vpr variants was similar to one another and subtype B Vpr 
(p>0.05) ranging from 96.54% for TV1466 to 98.64% for TV1628. These values are 
highly dependent on expression level of the Vpr proteins, however in the absence of 
confirmatory measurement of protein expression by Western blot we have assumed 
similar levels of expression based on intensity of the HaloTag signal across 
experiments. 
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Figure 3.19: Representative dot plots showing apoptosis induction in 293T cells transfected with 
a Vpr-expression vector. (A) Total annexin on cells gated based on scatter (G1=R1). (B) Halotag 
staining of the same population, but showing the gate R2 used to define Halotag positive or transfected 
cells. (C) Annexin V staining of the transfected cells gated in R2.  
A 
B 
C 
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Figure 3.20: Representative dot plots showing the transfected 293T cells. 293T cells were 
transfected with Vpr-expression vectors. The transfected cells were labelled with HaloTag TMR 
ligand. Apoptotic cells were measured only in the transfected cells. The similar localization of the cells 
on the dot plots suggests that the intensity of HaloTag signal is similar and therefore the expression 
level of the vectors is comparable. 
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Table 3.3: Results of the flow cytometric analysis for apoptosis.  
Sample Total apoptotic 
cells (annexin V 
positive) (%) 
Total non-apoptotic 
cells (annexin V 
negative) (%) 
Total transfected 
cells (HaloTag 
positive) (%) 
Total untransfected 
(HaloTag negative) 
(%) 
Apoptotic 
transfected cells 
(%) 
Mock 0.08  99.92 34.45 65.55 0.08 
Subtype B 24.73 75.27 24.08 75.92 98.20 
Consensus C 15.66 84.34 18.04 81.96 82.08 
TV1453 16.71 83.29 16.53 83.47 95.33 
TV1466 26.87 73.13 26.93 73.07 96.54 
TV1570 22.78 77.22 22.28 77.72 97.56 
TV1628 38.10 61.90 37.10 62.90 98.64 
TV1642 20.89 79.11 19.71 80.29 91.91 
TV1707 38.68 61.32 41.01 58.99 98.58 
P14I 16.08 83.92 17.16 82.84 92.36 
W18C 19.83 80.17 19.75 80.25 93.91 
Y47N 32.29 67.71 35.67 64.33 96.25 
Q65H 16.44 83.56 18.49 81.51 90.865 
Q88S 15.55 84.45 16.56 83.44 88.485 
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Table 3.4. Results of 3 independent apoptotic assays 
Sample Average Deviation Assay 1 Assay 2 Assay 3 
Mock sample 0.08% 0.0003 0.05% 0.07% 0.12% 
Subtype B 98.20% 0.0081 98.16% 99.03% 97.40% 
Consensus-C 82.08% 0.0264 80.20% 85.11% 80.94% 
TV1453 95.33% 0.0074 95.69% 95.83% 94.47% 
TV1466 96.54% 0.0081 97.46% 96.28% 95.89% 
TV1570 97.56% 0.0020 97.52% 97.79% 97.38% 
TV1628 98.64% 0.005 99.03% 98.92% 97.98% 
TV1642 97.91% 0.0044 97.49% 98.38% 97.86% 
TV1707 98.58% 0.0013 98.63% 98.68% 98.42% 
P14I 92.36% 0.0233 90.70% 95.03% 91.35% 
W18C 93.91% 0.0027 93.97% 93.61% 94.15% 
Y47N 96.25% 0.0227 93.89% 98.43% 96.44% 
Q65H 90.86% 0.018 89.42% 92.90% 90.25% 
Q88S 88.48% 0.0317 90.55% 84.82% 90.06% 
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Figure 3.21: The bar graph showing apoptosis induction in 293T cells by Vpr. The first sample on 
the left shows the percentage of apoptotic cells in mock sample which was prepared by transfection of 
293T cells with barnase-removed pFN22K vector. The error bars indicate the standard deviations in the 
reported measurements. Data shown represent average values of three repeats for each variant. Among 
the vpr mutants, the consensus sequence of subtype C induced apoptosis in 82.08% of the transfected 
cells which is lower than the other Vpr proteins. All the variants the induced apoptosis in a higher 
percentage of the transfected cells compared to the consensus-C as it was shown by ANOVA (p<0.05). 
 
 
 
 
3.13. Assay of Vpr-induced cell cycle G2 arrest 
 
Cell cycle was analyzed using 2 fluorescent dyes at different times. The optimization 
experiments showed that because of the overlap between PI and HaloTag® Oregon 
Green® Ligand that interfered with our assay, these 2 dyes could not be used in 
together. On the other hand our experiments using 7-AAD and HaloTag® Oregon 
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Green® Ligand showed no sign of spectral overlap indicating these 2 dyes could be 
used together in our cell cycle assays. 
 
The assays performed 24 hours after transfection showed a low percentage of G2 
arrested cells (40-50%) while 48 hours after transfection we obtained high percentage 
of G2 arrested cells. The optimized time for our assays was then set as 48 hours after 
transfection. 
 
Different values of induction of cell cycle G2 arrest were observed in the 293T cells 
transfected with different Vpr-expression vectors. Observed differences could be due 
to different expression level in the individual cells. Therefore, in the absence of 
confirmatory Western blot data, these values should be cautiously interpreted. The 
typical results of cell cycle analysis by flow cytometry are presented in Figure 3.22 
for one assay. The values of cell cycle G2 arrest are presented as bar graphs in Table 
3.5 and Figure 3.23 for three independent assays. Only the transfected cells (i.e. 
HaloTag positive) were gated for analysis based on the signal of HaloTag® Oregon 
Green® ligand. The intensity of HaloTag® Oregon Green® signal was similar in the 
transfected cells (448.17±11.61), suggesting that the expression level in the 
transfected cells was similar. 
 
The cell cycle phase was inferred based on the DNA content labeled with 7-AAD. All 
the results were compared with the mock transfected sample which was 293T cells 
transfected with barnase-removed pFN22K vector. The DNA content of the mock 
sample indicated that the majority of the cell population was at G1/S phase. In the 
mock sample only 32.45% of the cells were in the G2 phase. The highest proportion 
of cells in the G2 phase (71.57%) was observed for subtype B Vpr. This result shows 
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the majority of subtype-B Vpr transfected cells shifted to G2 phase. This result, 
however, was not significantly higher than that of the majority of the Vpr proteins 
(p>0.05). The consensus sequence of subtype C Vpr induced G2 phase in 61.65% of 
the transfected cells. The lowest value of G2 phase was observed for the TV1466 with 
54.05% of the cells in G2 phase that was significantly lower than all naturally mutated 
Vpr proteins (p<0.05) except fpr TV1628. This Vpr protein had mutations in α-helix I 
and II and the flexible C terminus. TV1570 and TV1642 that each had one mutation 
in each α-helix, induced G2 phase in 66.36% and 63.84% of the transfected cells, 
respectively. TV1453, TV1628 and TV1707 induced G2 phase in 65.28%, 61.51% 
and 61.60% of the transfected cells, respectively. Except for TV1453 that had Y45H 
mutation in α-helix I, the two latter proteins had several mutations distributed in 
different domains. All variants of Vpr proteins were thus able to induce G2 arrest but 
at different levels. Although the induction of G2 arrest by subtype B Vpr was higher 
than the consensus sequence of subtype C and all the subtype C variants, however this 
was not statistically significant for TV1453, TV1570 and TV1642 (p>0.05). The 
induction of G2 arrest by consensus C was found in the same range of Vpr mutants 
but lower than Subtype B (p<0.05). None of the induced mutations significantly 
affected the G2 arrest activity of Vpr. All these values should be interpreted based on 
the assumption of similar expression levels of the proteins. Although some values 
were found significantly different, it should be noted that the uneven expression level 
of the proteins could increase/decrease the induction of cell cycle G2 arrest. 
Dissimilar expression levels of the protein could have a major impact on a functional 
read-out and may play a role in the less efficient induction of cell cycle G2 arrest by 
some of the subtype C Vpr proteins. 
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Except for W18C, the site-directed mutations showed similar ability to induce G2 
arrest. W18C mutant induced G2 arrest in 56.65 % of the transfected cells. Although 
it was not found significantly lower than that of other site-directed mutations, it was 
significantly lower than that of subtype B Vpr. 
 
Figure 3.22: Flowcytometric analysis of cell cycle in 293T cells transfected with Vpr-expression 
vectors. Forty eight hours after transfection, cell cycle was analyzed in the transfected cells. The 
HaloTag-Vpr proteins were labaled using HaloTag® Oregon Green® Ligand and the DNA content was 
labelled using 7-AAD. The transfected cells were gated based on the HaloTag signal and cell cycle was 
analyzed only in the transfected cells. The first peak in each graph indicates the cells at G1/S phase and 
the second peak indicates the cells at G2 phase. Mock sample is a cell culture of 293T cells transfected 
with the HaloTag expression vector as control. 
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Table 3.5: Results of three independent assays for Vpr-induced G2 arrest  
Sample 
Average G2 
arrested cells (%) deviation
G2 arrest 
Assay 1 (%) 
G2 arrest 
Assay 2 (%) 
G2 arrest 
Assay 3 (%) 
Mock sample 32.45 0.007 32.68 31.65 33.01 
Subtype B 71.57 0.015 71.24 70.20 73.28 
Consensus-C 61.65 0.011 60.46 62.68 61.81 
TV1453 65.28 0.022 63.05 65.31 67.49 
TV1466 54.05 0.063 52.58 48.59 60.97 
TV1570 66.36 0.026 64.59 65.07 69.41 
TV1628 61.51 0.034 58.09 61.40 65.03 
TV1642 63.84 0.021 61.42 64.87 65.24 
TV1707 61.60 0.022 60.00 60.65 64.15 
P14I 65.76 0.071 60.09 63.43 73.76 
W18C 56.65 0.007 56.59 55.91 57.46 
Y47N 66.67 0.068 66.44 59.93 73.64 
Q65H 61.26 0.022 58.84 61.62 63.33 
Q88S 62.26 0.056 57.62 60.53 68.62 
 
 
 
Figure 3.23: Bar graphs showing the induction of G2 arrest in 293T cells transfected with Vpr-
expression vectors. The highest percentage of G2 phase was observed in the cells transfected with 
subtype B Vpr. The lowest percentage of G2 phase was observed in mock samples. Mock samples 
were cell cultures of 293T cells transfected with the HaloTag expression vector as control. The 
asterisks (*) indicate the variants that induced G2 arrest in a lower percentage of the transfected cells 
compared to subtype B Vpr as it was shown by ANOVA (p<0.05). 
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3.14. Modulation of gene expression by Vpr  
 
The real-time PCR assay of several genes, with a focus on the genes involved in 
apoptosis, was performed for 293T cells transfected with Vpr-expression vectors. 
Since the values are highly dependent on the efficiency of transfection, which could 
vary, they cannot be directly compared. However, it is useful to indicate the 
overexpression of several genes triggered by Vpr proteins. The results presented in 
Table 3.1 show that the consensus sequence of subtype C and all the subtype C Vpr 
variants, similarly to subtype B, are able to modulate the examined genes.  
 
In this study, the modulation of apoptosis-regulating genes was specifically addressed. 
As discussed in more detail in Chapter 1, apoptosis, in general, is triggered through 
one of two known cell death-signaling pathways: the extrinsic (or death receptor) 
pathway and the intrinsic (or mitochondrial) pathway (Fulda & Debatin, 2006; 
Ghobrial et al., 2005). As reviewed by Romani and Engelbrecht, Vpr induces 
apoptosis through the intrinsic pathway (Romani & Engelbrecht, 2009). In this study, 
the mRNA profile of 293T cells for intrinsic and extrinsic pathway as well as anti-
apoptotic genes was examined. Data is presented in Table 3.6 and Figures 3.24 and 
3.25. The overexpression of caspase-3 and -6 was observed in the transfected cells.  
Both caspases are involved in both extrinsic and intrinsic pathways (Klaiman et al., 
2009; Legewie et al., 2006; Zimmermann et al., 2001). No significant overexpression 
of caspase-7, -8, and -10 by any of Vpr variants was observed. Caspase-7 has been 
shown in both apoptosis pathways (Bhat et al., 2006; Du et al., 2006) and Caspase-8 
and -10 have been shown in the extrinsic pathway (Bhat et al., 2006; Kischkel et al., 
2001). The expression level of caspase-9, which is involved in the intrinsic pathway 
(Du et al., 2006), remained unchanged in all the transfected cells. Although the 
 147
induction of apoptosis by Vpr through the intrinsic pathway was not strongly 
supported by the expression level of caspases, the significant overexpression of BID 
(Bcl-2 interacting domain) was shown in all variants. BID is a pro-apoptotic Bcl-2 
family member that triggers the intrinsic pathway of apoptosis by promoting 
cytochrome c release from mitochondria (Slee et al., 2000; Yi et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6. mRNA profile of 293T cells 24 hours after transfection with Vpr-expression vectors. 
The average fold change is presented for each gene and each sample.  
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Figure 3.24: Overexpression of caspases induced by Vpr Proteins in 293T cells. (a) The expression 
of Vpr proteins in the transfected cells increased the expression of caspase-3. (b) The expression of Vpr 
proteins in the transfected cells increased the expression of caspase-6. 
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Figure 3.25: Overexpression of BID and BCL-10 induced by Vpr proteins in 293T cells. (a) 
Subtype B and subtype C Vpr proteins induced the overexpression of BID. (b) Subtype B and subtype 
C Vpr proteins induced the overexpression of BCL-10. 
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Chapter 4 
 
4. Discussion and conclusion 
 
4.1. Sequences of South African HIV-1 strains 
Heterosexual contact is the major route of HIV-1 transmission in sub-Saharan Africa. 
In South Africa, unlike the rest of sub-Saharan Africa, HIV-1 was initially transferred 
by homosexual contact (Van-Harmelen et al., 1997). The first two South African 
cases of AIDS, recorded in 1982, were male homosexuals (Ras et al., 1983), and until 
1987 HIV-1 was diagnosed almost exclusively in men (Van-Harmelen et al., 1997). 
In 1988, an increasing number of HIV-infected women were reported, indicating the 
start of a second epidemic. Migration is one of many factors that have contributed to 
the AIDS epidemic in this region. Several studies have shown that people who are 
more mobile or who have recently changed residence tend to be at higher risk for HIV 
and other sexually transmitted diseases (STDs) than people in more stable living 
arrangements (Lurie et al., 2003). In South Africa, people who had recently changed 
their residence were 3 times more likely to be infected with HIV than those who had 
not (Abdool-Karim et al., 1992). It has been argued that it is not so much the 
movement itself but rather the “conditions and structure of the migration process” that 
put people at risk for HIV and other STDs (Lurie et al., 2003). 
 
Phylogenetic analyses of nucleotide sequences from the env gene have resulted in the 
classification of group M strains into at least 9 different envelope genetic subtypes, 
designated by letters from A to K. However, studies of the HIV-1 full-length genome 
sequences have demonstrated complex patterns of HIV-1 intersubtype recombination, 
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suggesting that the present classification requires more precision with regard to the 
definition of HIV-1 subtypes and intersubtype recombinants (Osmanov et al., 2002). 
In South Africa, subtype C was the first HIV genotype that was identified in the 
heterosexual population and was subsequently shown to be the major virus subtype 
within this country (Williamson et al., 1995). HIV-1 Subtype B strains, commonly 
found in Europe and America, are not often detected in Africa. Study of genetic 
heterogeneity is important in the development and application of vaccines whose 
efficacy could be influenced by virus variation (Mascola et al., 1994).  
 
Scriba et al. have studied the sequences of South African HIV-1 accessory genes, vif, 
vpr and vpu. They showed that the amino acid alignments of the Vif, Vpr, and Vpu 
from South African strains were well-conserved. The Vpr sequences of South African 
strains in this study were all shown to belong to HIV-1 subtype C (Scriba et al., 
2001).  The finding that HIV-1 subtype C Vpr sequences were highly conserved, was 
confirmed in a subsequent study be Bell et al. (Bell et al., 2007).  
 
In the current study, phylogenetic analysis of Vpr characterized 54/58 strains (93%) 
as HIV-1 subtype C and 4/58 strains (7%) as HIV-1 subtype B. Except for one 
subtype C, Vpr was confirmed to be conserved in length in all other subtype C 
isolates (53 in total) and all 4 subtype B isolates. Fifty three subtype C isolates (98%) 
showed the heterosexual pattern which is the predominant form of subtype C 
transmission. Two out of 4 subtype B strains (50%) showed the homosexual pattern of 
transmission. This is in agreement with the homosexual pattern of transmission 
previously observed for subtype B in this region.  
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4.2 Physiological relevance of the model system used in this study 
HIV-1 infects T cells and monocytes in both a latent and productive manner 
(Makonkawkeyoon et al., 1993). Therefore in vitro experiments that address HIV-1 
should attempt to be physiologically relevant to the in vivo infections. In vitro studies 
of T cell and monocyte derived cell lines may be more relevant to actual infection 
than 293T cells. Jurkat T cells and U937 cells, a T cell line and monocytic cell line, 
respectively, and also peripheral blood mononuclear cells are commonly used in in 
vitro studies of HIV-1. (Borgatti et al., 2005; Ciuffi et al., 2005; Furtado et al., 1999; 
Wang et al., 1999). However, the results of experiments using these lines or cells may 
not be representative of actual in vivo conditions since the complex interactions 
between different cells, serum proteins, cytokines, metabolites and other factors 
cannot be accurately reproduced.  
 
Human 293T cell line is commonly used in functional studies of HIV-1 proteins. A 
major reason for this is the ability to easily transfect these cells, the same reason why 
they were selected for use in the current study (Gavrilescu & Van-Etten, 2007). Vpr 
targets fundamental cellular pathways common to many eukaryotic cells. It has been 
shown that Vpr could exert its functions even in yeast cells and these cells have been 
frequently used to study the functions of Vpr (Benko et al., 2007; Elder et al., 2001; 
Huard et al., 2008). Functional studies of Vpr in 293T cells are very common (Belzile 
et al., 2007; Felzien et al., 1998; Kino et al., 2005b). However, since 293T cells are 
not the natural hosts of HIV-1, the results of such studies should ideally be compared 
with results obtained using natural HIV host immune cells most accurately mimicking 
in vivo conditions. The outcomes of this study need to be reproducible and relevant to 
the actual infection. Although the impact of the expressed Vpr proteins on 293T cells 
cannot be directly linked to in vivo infections, the impact of mutations on in vitro 
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functionality of subtype C Vpr proteins provides an indication of cellular activity and 
provides a base for future experiments. Infecting T cell and monocyte derived cells 
with pseudotyped viruses that carry or do not carry Vpr would be one important 
approach for further studies.  
 
In this study the differences observed between the Vpr proteins may not be indicative 
of in vivo infection but they do suggest that not all Vpr proteins have the same 
functional potential. Therefore, these results emphasize that natural Vpr mutants need 
to be compared in vivo or in natural host cells. On the other hand since in this study, 
Vpr proteins have been expressed using expression vectors, the results may to some 
extent exaggerate the impact of the virus-expressed proteins. To obtain a reliable 
comparison between the Vpr proteins, Vpr proteins could be compared in 
pseudotyped viruses that carry or do not carry the Vpr proteins. 
 
4.3. Subtype C Vpr variants 
Vpr is a dynamic mobile protein that shuttles between the nucleus and cytoplasmic 
compartments (Jenkins et al., 2001; Sherman et al., 2003a; Sherman et al., 2001). The 
karyophilic property of subtype B Vpr and its localization to the nuclear pore complex 
(NPC), has been well established and it is believed to be a prerequisite for the nuclear 
import of PIC (Fassati et al., 2003). However, the karyophilic property of Vpr needs 
to be addressed in other subtypes and mutants as well. Up to now, this property of Vpr 
has not been shown for other HIV-1 subtypes or mutants. In this study, it was shown 
that subtype C variants or mutants show similar affinity for the nucleus.  
 
Induction of G2 arrest by Vpr has been documented in many studies. The detailed 
mechanism of this phenomenon has also been studied but remains not fully 
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characterized, with novel details still being revealed (Belzile et al., 2007; Dehart et 
al., 2007; Kino et al., 2005a; Zhou & Ratner, 2000). However, the previous studies 
have investigated the cell cycle G2 arrest in subtype B Vpr and there is a lack of data 
regarding the induction of cell cycle G2 arrest by other HIV-1 subtypes. The ability of 
Vpr variants to induce G2 arrest is another question that has not been addressed in 
previous studies. In this study, it was shown that subtype B Vpr induces the cell cycle 
G2 arrest more efficiently than most subtype C Vpr variants. The consensus sequence 
of subtype C Vpr indicated no significant deviation from the average G2 arrest that 
was observed for the other subtype C variants. However, as stressed in the results 
section, the results of this experiment were highly dependent on the similarity of the 
expression level of the Vpr proteins in the individual cells. Different expression levels 
may affect the arresting of the cell cycle in a particular cell. Western Blot is a 
common method to check the expression level of proteins, but in this study the 
expression level of the proteins were compared based on HaloTag Oregon Green 
signal. Therefore the results should be evaluated within the context of similar 
expression levels based on the surrogate marker of expression, intensity of HaloTag 
signal. The intensity of the HaloTag Oregon Green signal was similar in the 
transfected cells, suggesting the obsereved differences were most likely not due to the 
different expression level. In contrast to apoptosis, mutations in Vpr did not 
significantly increase the ability of Vpr variants to induce G2 arrest. 
 
Mutational analysis has shown that the C-terminal portion of Vpr, known to harbour 
its cell cycle-arresting activity, binds directly to 14-3-3 protein. 14-3-3 proteins 
regulate the G2/M transition by activating Cdc25C. The interaction of the C-terminus 
of Vpr promotes the association of 14-3-3 and Cdc25C, leading to the triple complex 
of Vpr/14-3-3/Cdc25C that is not able to propel the cell cycle (Bolton et al., 2008; 
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Kino et al., 2005b). In the current study, TV1466 and TV1628 that had R85P 
mutations in their C-terminus did not show lower potential to induce G2 arrest 
compaered to the majority of the naturall mutants of subtype C Vpr.  
 
The C-terminal region of Vpr is probably not the only region of this protein that 
affects G2 arrest. Several studies have documented that the association of HIV-1 Vpr 
with DCAF-1 (DDB1- and CUL4-associated factor 1), also known as VprBP (Vpr-
binding protein), leads to G2 arrest (Gieffers et al., 2000; Hrecka et al., 2007; Wen et 
al., 2007). It has been shown that the Vpr (Q65R) mutant, which is defective in 
DCAF1 binding, undergoes proteasome-mediated degradation at a higher rate than 
wild-type Vpr. Therefore mutations outside of the C-terminal region, such as Q65R 
could affect the G2 arrest activity of Vpr (Le-Rouzic et al., 2008). In this study, 
mutations outside of C-terminus region occurred in the variants but their impact could 
not be individually investigated since multiple mutations occurred in the Vpr proteins.    
 
The modulation of gene expression by Vpr has been well established (Romani & 
Engelbrecht, 2009; Zhu et al., 2003). In this study, it was shown that subtype C Vpr 
variants modulate the apoptotic genes in a similar manner to the subtype B Vpr. 
Furthermore, it was shown that both subtype B and C induce apoptosis through the 
intrinsic pathway. Although the overexpression of caspases specifically involved in 
the intrinsic pathway of apoptosis, such as caspase-9, was not detected, the induction 
of apoptosis might not always be dependent on overexpression of certain gene 
products, but available gene products. The overexpression of BID that was observed 
does, however, support the induction of apoptosis through the intrinsic pathway. No 
evidence for the induction of apoptosis through the extrinsic pathway was found for 
any of Vpr variants. 
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The pro-apoptotic activity of subtype C Vpr variants from India has been shown to be 
similar to that of subtype B Vpr (Bano et al., 2009a). Jian and Zhao by comparing 
three HIV-1 subtypes demonstrated a moderate level of pro-apoptotic activity for a 
subtype B Vpr and an A/G subtype recombinant Vpr, whereas a subtype D Vpr had 
no detectable activity. It has been suggested that Vpr proteins from different HIV-1 
subtypes as well as Vpr variants that emerge during HIV-1 infection may have 
different proapoptotic potentials and contribute to the diversity of AIDS pathogenesis 
(Jian & Zhao, 2003b). Bano et al. have also shown that several B, C and D 
recombinant Vpr proteins were capable of inducing apoptosis to varying extents 
(Bano et al., 2009a). 
 
In this current study, it was shown that South African subtype C Vpr variants were 
able to induce apoptosis at a similar rate to subtype B Vpr. Interestingly; it was found 
that the consensus sequence of subtype C Vpr induced apoptosis at a lower rate, 
compared to mutant Vpr proteins and subtype B Vpr. TV1453 that differs from the 
consensus sequence in one amino acid residue, Y45H mutation in α-helix II, indicated 
a higher pro-apoptotic activity (P<0.05). The other natural mutations at other 
positions also were shown in this study to potentiate the proapoptotic activity of Vpr. 
It has been documented that the C-terminal peptides containing the conserved 
sequence at amino acid 71-82 can even induce apoptosis (Arunagiri et al., 1997). 
Many of the mutations that were shown in this study to enhance to pro-apoptotic 
activity of Vpr do not lie at position 71-82. Other studies have also shown that 
mutations outside of this motif could affect the pro-apoptotic activity of Vpr (Bolton 
& Lenardo, 2007; Stewart et al., 1997; Tungaturthi et al., 2004a). Many factors 
including ion channel activity of Vpr, DNA fragmentation factor activation, 
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interaction of Vpr with other proteins, and localization of Vpr could affect the 
proapoptotic activity of Vpr (Lum et al., 2003; Piller et al., 1999; Shostak et al., 
1999). Each of these functions is conducted by individual regions that could be 
outside of the motif 71-82.  
 
It has been shown that substitutions of a single amino acid residue, Leu64 with Pro, 
Ala, or Arg, dramatically enhance the proapoptotic activity of Vpr (Jian & Zhao, 
2003b). The possible consequences of particular mutations should also be examined 
separately for different subtypes since the same mutation has been shown to impact 
variably in different subtypes. The results of the current study also confirm the 
previous studies and suggest that the variations in subtype C Vpr cannot be regarded 
as defective mutations disturbing the functionality of the protein. 
 
The mutations occurring in Vpr might have been selected under biological pressures 
and the evolutionary importance of these mutations cannot be ruled out. The study 
raises the concern as to what exactly is a wild-type HIV-1 protein? A number of 
studies have suggested that the consensus sequence approach could overcome the high 
genetic diversity of HIV-1C and facilitate an AIDS vaccine design while others have 
challenged this idea (Ellenberger et al., 2002; Gaschen et al., 2002). If the consensus 
sequence of subtype C Vpr does not function, at least for apoptosis induction, as 
effectively as some mutated Vpr proteins, could it be the case with other HIV-1 
proteins as well? In addition, are the common reference sequences of HIV-1, such as 
the NL4-3 clone that was used in this study, the best representatives of the wild-type 
HIV-1? If we select the non-mutated or less mutated sequences as the wild-type 
sequence, are they the most functional sequences?  
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4.4. Artificially mutant Vpr proteins 
It has been shown that substitution mutations in the N-terminus and α-helix I of Vpr 
disturb the nuclear localization of Vpr in human cell lines (Jacquot et al., 2007; Yao 
et al., 1995). Here we demonstrated that α-helix I contains the determinants required 
for the nuclear localization of Vpr. The W18C mutant that localized both to the 
nucleus and cytoplasm did not show a reduced activity in the induction of G2 arrest. 
A number of studies have found a link between the nuclear localization of Vpr and 
induction of G2 arrest (Jacquot et al., 2007). On the other hand, it has been shown that 
G2 arrest activity of Vpr is induced by the residues lying at the C-terminus of Vpr but 
deletion of 14 amino acid from the N-terminus of Vpr reduces the extent of G2 arrest 
(Chen et al., 1999). A possible explanation is that although C-terminal residues of Vpr 
are responsible for its G2 arrest activity, it is important for Vpr to localize to the 
nucleus to efficiently get access to the nuclear proteins regulating cell cycle. 
Therefore, the mutations in the N-terminus could potentially reduce G2 arrest activity 
without affecting the nuclear localization of Vpr. But mutations in the C-terminus and 
α-helix I that disturb the nuclear localization of Vpr could reduce the G2 arrest 
activity of Vpr. However it should be noted that the same issue as described for the 
expression level of natural mutants of Vpr applies to the artificial mutants. Uneven 
expression level could significantly affect the results therefore the values need to be 
cautiously compared. 
 
The substitution mutations did not reduce the G2 arrest activity of Vpr. However, the 
G2 arrest activity of all the mutants, as well as consensus-C, was lower than that of 
subtype B Vpr. The differences in G2 arrest activity were not due to the different 
expression level since the expression level in individual cells (intensity of the 
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HaloTag Oregon Green signal) was similar in the transfected cells. In contrast to G2 
arrest, the apoptotic activity of all the mutants was significantly affected by the 
mutations. All the substitution mutations at 5 different domains of Vpr increased the 
apoptotic activity of Vpr compared to the consensus-C. The results of gene expression 
assays show that Vpr-mutants similarly to consensus-C and subtype B Vpr induce the 
overexpression of certain pro-apoptotic genes. The overexpression of these genes 
showed that all the Vpr proteins induced apoptosis through the intrinsic pathway and 
the mutant proteins did not show a diminished ability to induce expression of 
apoptotic genes. It has been shown that the substitution of leucine residue at position 
64 increases the apoptotic activity of Vpr (Jian & Zhao, 2003b) but these apoptotic-
enhancing mutations have not been described further. It could be due to the use of 
problematic wild-type subtype B. The subtype B reference sequences already contain 
natural mutations that discriminate them from the consensus sequence of the 
corresponding subtype. These mutations could enhance the apoptotic activity of Vpr 
and therefore other apoptotic-enhancing mutations are not able to enhance the 
apoptotic activity of Vpr any further. In this study we found five apoptotic-enhancing 
mutations that enhance the apoptotic activity of the consensus sequence of subtype C 
Vpr. These mutations may not enhance the apoptotic activity of the reference 
sequences of wild-type subtype C Vpr or other subtypes that already contains 
mutations.  
 
A conserved motif in the C-terminal region of Vpr has been implicated in its apoptotic 
activity. The C-terminal peptides containing the conserved sequence at amino acid 71-
82 can even induce apoptosis. Extracellular addition of C-terminal peptides to human 
CD4+ cells causes membrane permeabilization, DNA fragmentation and formation of 
apoptotic bodies, which are all signs of apoptosis. Similar effects can also be observed 
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by adding the polypeptides to yeast, indicating that Vpr targets fundamental cellular 
pathways that are common among eukaryotic cells (Arunagiri et al., 1997). Several 
studies have reported a link between Vpr-induced apoptosis and G2 arrest (Andersen 
et al., 2008; Jacquot et al., 2007) while other studies have reported that these 
functions are independent (Chen et al., 1999; Romani & Engelbrecht, 2009). Based on 
the results of our study, we cannot confirm or rule out the existence of a functional 
link between apoptosis and G2 arrest. However, our results suggest that although 
apoptosis is independently induced by a short motif of Vpr, other regions of Vpr can 
contribute to the efficiency of apoptosis. The increase in the induction of apoptosis 
that was found in our mutants could be due to other factors, such as the secondary 
structure of the protein, domain charges and subcellular localization.   
 
Mutations in Vpr have been shown to be subtype-dependent. It is has been 
hypothesized that Vpr proteins from different HIV-1 subtypes as well as Vpr variants 
that emerge during HIV-1 infection may have different apoptotic potentials that 
contribute to the diversity of AIDS pathogenesis (Jian & Zhao, 2003b). Enhancing 
apoptotic potential of Vpr in different subtypes and strains may be achieved through 
different mutations. The results of our study suggest that instead of having a highly 
conserved sequence that could be easily disturbed by mutations, HIV-1 Vpr has 
certain exchangeable residues that make substitution mutations at these residues are 
tolerable for the protein and could even potentially increase certain activities of the 
protein.  
 
4.5. Future perspectives 
Although HIV-1 subtype B has been intensively studied from different aspects, the 
functionality of other HIV-1 subtypes is less known. In this study several functions of 
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subtype C Vpr were studied and compared with subtype B Vpr. It was shown that the 
same functions attributed to subtype B Vpr can also be exerted by subtype C Vpr. 
Other proteins of HIV-1 subtype C could also be studied to identify their 
functionality.  
 
The prevalence of subtype C in sub-Saharan countries may suggest the adaptation of 
this subtype to the genetic population of sub-Saharan countries. If there is such 
adaptive function or mutation in subtype C proteins, it could only be identified by 
functional studies of subtype C proteins of sub-Saharan strains.  
 
Vpr interacts with many cellular proteins of which the expression level may be 
different in different tissues. Therefore the functions of Vpr could be studied in 
different cell lines. Since human 293T cells are not representative of a natural host 
cell of HIV-1, experiments could be designed that simulate in vivo infection. The use 
of T cell and monocyte derivatived cells could improve the physiologic relevance of 
the study since they are the natural hosts of HIV-1. However, any cell line is at best 
an approximation of a natural cell, since all cell lines are unnatural in the context of 
their immortality.  The use of pseudotyped virus on the other hand could significantly 
improve the relevance of experiments as related to actual infection. Using 
pseudotyped viruses that contain or do not contain Vpr, it will be possible to study the 
role of virion-incorporated Vpr. 
 
Determining the expression level of Vpr should be considered in future studies. Since 
different vectors may have different expression levels, it is important to compare the 
expression level of the relevant proteins as well as the size of the expressed proteins 
using Western-Blot. Monoclonal as well as polyclonal antibodies for detection of 
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South African subtype C Vpr could be produced to aid in monitoring protein 
expression levels in future studies.. 
 
4.6. Conclusion 
In summary, the findings of this study indicate that both HIV-1 subtype B and C Vpr 
display a similar ability for nuclear localization and apoptosis induction. The 
induction of cell cycle G2 arrest by HIV-1 subtype B Vpr is, however, more robust 
than many subtype C Vpr proteins. The natural mutations studied in the isolates did 
not disturb the functions of subtype C Vpr and in some cases even potentiated the 
protein to induce apoptosis. This study demonstrates that naturally occurring 
mutations in HIV-1 Vpr cannot be regarded as defective mutations, since enhanced 
functionality would be more indicative of an adaptive role. The increased potency of 
the mutated Vpr proteins suggests that Vpr may increase the pathogenicity of HIV-1 
by adapting apoptotic enhancing mutations.  This is supported by the lack of pro-
apoptotic activity of Vpr in non-pathogenic SIV species. The pro-apoptotic activity 
HIV-1 Vpr has been suggested to play a pivotal role in pathogenicity of Vpr. This 
study highlights the importance of studying the functionality of HIV-1 proteins from 
different subtypes to exclude or confirm the functional capacity of those proteins in 
different subtypes. The distribution of particular subtypes in some areas might be 
related to the adaptive mutations occurring in HIV-1 to adapt the virus to the genetic 
diversity of the population. 
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Appendix B: 
pF4A CMV Flexi® Vector 
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Appendix C:  
pFN22K (HaloTag® 7) CMVd1 Flexi® Vector 
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Appendix D 
Statistical analysis of the results of apoptosis assays using Bonferroni’s multiple 
comparison test 
Bonferroni’s multiple comparison test Mean diff. t Significant (P<0.05) 
Mock sample vs Subtype B -98.120 117.0 Yes 
Mock sample vs Consensus-C -82.000   97.77 Yes 
Mock sample vs TV1453 -95.250   113.6 Yes 
Mock sample vs TV1466 -96.460   115.0 Yes 
Mock sample vs  TV1570 -97.480   116.2 Yes 
Mock sample vs TV 1628 -98.560   117.5 Yes 
Mock sample vs TV1642 -97.830   116.6 Yes 
Mock sample vs TV1707 -98.500   117.4 Yes 
Mock sample vs P14I -92.280   109.2 Yes 
Mock sample vs W18C                -93.830   110.0 Yes 
Mock sample vs Y47N                -96.170   114.8 Yes 
Mock sample vs Q65H                -90.780   107.1 Yes 
Mock sample vs Q88S                -88.400   103.8 Yes 
Subtype B vs Consensus-C           16.120   19.21 Yes 
Subtype B vs TV1453                2.870   3.41 No 
Subtype B vs TV1466               1.660   1.97 No 
Subtype B vs TV1570                0.6400 0.75 No 
Subtype B vs TV1628               -0.4400   0.53 No 
Subtype B vs TV1642                0.2900   0.34 No 
Subtype B vs TV1707                -0.3800   0.45 No 
Subtype B vs P14I                  5.840   6.51 Yes 
Subtype B vs W18C                 4.290   5.10 Yes 
Subtype B vs Y47N                  1.950   2.05 No 
Subtype B vs Q65H                 7.340   8.12 Yes 
Subtype B vs Q88S                  9.720   10.57 Yes 
Consensus-C vs TV1453               -13.250   15.79 Yes 
Consensus-C vs TV1466                -14.460   17.24 Yes 
Consensus-C vs TV1570               -15.480   18.46 Yes 
Consensus-C vs TV1628               -16.560   19.74 Yes 
Consensus-C vs TV1642               -15.830   18.87 Yes 
Consensus-C vs TV1707              -16.500   19.66 Yes 
Consensus-C vs P14I                 -10.280   12.30 Yes 
Consensus-C vs W18C                  -11.830   13.78 Yes 
Consensus-C vs Y47N                 -14.170   17.00 Yes 
Consensus-C vs Q65H                 -8.780   9.42 Yes 
Consensus-C vs Q88S                -6.400   7.23 Yes 
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TV1453 vs TV1466               -1.210   1.44 No 
TV1453 vs TV1570               -2.230   2.663 No 
TV1453 vs TV1628                -3.310   3.950 Yes 
TV1453 vs TV1642                -2.580   3.07 No 
TV1453 vs TV1707                -3.250   3.87 Yes 
TV1453 vs P14I                2.970   3.59 No 
TV1453 vs W18C                  1.420   1.84 No 
TV1453 vs Y47N                 -0.920  1.17 No 
TV1453 vs Q65H                  4.470   5.18 Yes 
TV1453 vs Q88S                  6.850   7.52 Yes 
TV1466 vs TV1570              -1.020   1.21 No 
TV1466 vs TV1628               -2.100   2.50 No 
TV1466 vs TV1642               -1.370   1.63 No 
TV1466 vs TV1707               -2.040   2.42 No 
TV1466 vs P14I                4.180   5.06 Yes 
TV1466 vs W18C                 2.630   3.31 No 
TV1466 vs Y47N                0.290  0.34 No 
TV1466 vs Q65H                 5.680   6.33 Yes 
TV1466 vs Q88S                 8.060   9.20 Yes 
TV1570 vs TV1628                -1.080   1.29 No 
TV1570 vs TV1642                -0.350 0.41 No 
TV1570 vs TV1707                -1.020   1.21 No 
TV1570 vs P14I                 5.200   6.13 Yes 
TV1570 vs W18C                  3.650   3.95 Yes 
TV1570 vs Y47N                1.310   1.54 No 
TV1570 vs Q65H                  6.700   7.44 Yes 
TV1570 vs Q88S                  9.080   10.02 Yes 
TV1628 vs TV1642               0.730 0.87 No 
TV1628 vs TV1707             0.060 0.08 No 
TV1628 vs P14I                 6.280   7.14 Yes 
TV1628 vs W18C                  4.730   5.61 Yes 
TV1628 vs Y47N                 2.390   2.97 No 
TV1628 vs Q65H                 7.780   8.85 Yes 
TV1628 vs Q88S                10.160   12.07 Yes 
TV1642 vs TV1707                -0.670 0.79 No 
TV1642 vs P14I                 5.550   6.21 Yes 
TV1642 vs W18C                  4.00 4.92 Yes 
TV1642 vs Y47N                 1.660   1.91 No 
TV1642 vs Q65H                  7.050   7.96 Yes 
TV1642 vs Q88S                  9.430   10.33 Yes 
TV1707 vs P14I                 6.220   7.09 Yes 
TV1707 vs W18C                  4.670   5.95 Yes 
TV1707 vs Y47N                 2.330   3.11 No 
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TV1707 vs Q65H                 7.720   8.72 Yes 
TV1707 vs Q88S                10.100   12.26 Yes 
P14I vs W18C                  -1.550   1.90 No 
P14I vs Y47N                -3.890   4.21 Yes 
P14I vs Q65H                  1.500   1.87 No 
P14I vs Q88S                  3.880   4.27 Yes 
W18C vs Y47N                -2.340   3.29 No 
W18C vs Q65H                 3.050   3.64 No 
W18C vs Q88S                 5.430   6.44 Yes 
Y47N vs Q65H                  5.390   6.35 Yes 
Y47N vs Q88S                  7.770   8.65 Yes 
Q65H vs Q88S                 2.380   3.17 No 
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Appendix E 
 Statistical analysis of Cell cycle G2 arrest using Bonferroni’s multiple comparison 
test 
 
Bonferroni’s multiple comparison test Mean diff. t Significant (P<0.05) 
Mock sample vs Subtype B -38.94 16.13 Yes 
Mock sample vs Consensus-C -28.94 11.99 Yes 
Mock sample vs TV1453 -32.41 13.55 Yes 
Mock sample vs TV1466 -21.63 8.96 Yes 
Mock sample vs  TV1570 -33.94 14.06 Yes 
Mock sample vs TV 1628 -28.92 11.98 Yes 
Mock sample vs TV1642 -31.15 12.90 Yes 
Mock sample vs TV1707 -29.05 12.03 Yes 
Mock sample vs P14I -33.310   14.48 Yes 
Mock sample vs W18C                -24.200   10.14 Yes 
Mock sample vs Y47N                -34.220   15.76 Yes 
Mock sample vs Q65H                -28.810   11.64 Yes 
Mock sample vs Q88S                -29.810   12.02 Yes 
Subtype B vs Consensus-C           9.997 4.14 Yes 
Subtype B vs TV1453                6.227 2.57 No 
Subtype B vs TV1466               17.31 7.16 Yes 
Subtype B vs TV1570                5.000 2.07 No 
Subtype B vs TV1628               10.02 4.14 Yes 
Subtype B vs TV1642                7.790 3.22 No 
Subtype B vs TV1707                9.893 4.09 Yes 
Subtype B vs P14I                  5.810   2.12 No 
Subtype B vs W18C                 14.920   5.95 Yes 
Subtype B vs Y47N                  4.900   2.00 No 
Subtype B vs Q65H                 10.310   4.14 Yes 
Subtype B vs Q88S                  9.310   3.79 No 
Consensus-C vs TV1453               -3.770 1.56 No 
Consensus-C vs TV1466                7.310 3.02 No 
Consensus-C vs TV1570               -4.997 2.07 No 
Consensus-C vs TV1628               0.020 0.00 No 
Consensus-C vs TV1642               -2.207 0.91 No 
Consensus-C vs TV1707              -0.103 0.04 No 
Consensus-C vs P14I                 -4.110   1.56 No 
Consensus-C vs W18C                  5.000   2.08 No 
Consensus-C vs Y47N                 -5.020   2.08 No 
Consensus-C vs Q65H                 0.3900   0.10 No 
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Consensus-C vs Q88S                11.230   4.59 Yes 
TV1453 vs TV1466               11.08 4.58 Yes 
TV1453 vs TV1570               -1.227 0.50 No 
TV1453 vs TV1628                3.790 1.57 No 
TV1453 vs TV1642                1.563 0.64 No 
TV1453 vs TV1707                3.667 1.51 No 
TV1453 vs P14I                -0.4800   0.28 No 
TV1453 vs W18C                  8.630   3.41 No 
TV1453 vs Y47N                 -1.390   0.57 Yes 
TV1453 vs Q65H                  4.020   1.55 Yes 
TV1453 vs Q88S                  3.020   1.57 Yes 
TV1466 vs TV1570              -12.31 5.09 Yes 
TV1466 vs TV1628               -7.290 3.02 No 
TV1466 vs TV1642               -9.517 3.94 Yes 
TV1466 vs TV1707               -7.413 3.07 No 
TV1466 vs P14I                -11.710   4.58 Yes 
TV1466 vs W18C                 -2.600   0.99 No 
TV1466 vs Y47N                -12.620   5.12 Yes 
TV1466 vs Q65H                 -7.210   3.23 No 
TV1466 vs Q88S                 -8.210   3.44 No 
TV1570 vs TV1628                5.017 2.07 No 
TV1570 vs TV1642                2.790 1.15 No 
TV1570 vs TV1707                4.893 2.02 No 
TV1570 vs P14I                 0.6000   0.45 No 
TV1570 vs W18C                  9.710   4.00 Yes 
TV1570 vs Y47N                -0.3100    0.12 No 
TV1570 vs Q65H                  5.100   2.06 No 
TV1570 vs Q88S                  4.100   1.47 No 
TV1628 vs TV1642               -2.227 0.92 No 
TV1628 vs TV1707             -0.123 0.05 No 
TV1628 vs P14I                 -4.250 1.62 No 
TV1628 vs W18C                  4.860   1.87 No 
TV1628 vs Y47N                 -5.160   2.11 No 
TV1628 vs Q65H                 0.250 0.12 No 
TV1628 vs Q88S                -0.750  0.41 No 
TV1642 vs TV1707                2.103 0.87 No 
TV1642 vs P14I                 -1.920   0.79 No 
TV1642 vs W18C                  7.190   3.01 No 
TV1642 vs Y47N                 -2.830   1.30 No 
TV1642 vs Q65H                  2.580   1.21 No 
TV1642 vs Q88S                  1.580   0.62 No 
TV1707 vs P14I                 -4.160   1.58 No 
TV1707 vs W18C                  4.950   1.89 No 
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TV1707 vs Y47N                 -5.070   2.08 No 
TV1707 vs Q65H                 0.340 0.13 No 
TV1707 vs Q88S                -0.660 0.40 No 
P14I vs W18C                  9.110   3.81 No 
P14I vs Y47N                -0.910 0.50 No 
P14I vs Q65H                  4.500   1.67 No 
P14I vs Q88S                  3.500 1.48 No 
W18C vs Y47N                -10.020   4.13 Yes 
W18C vs Q65H                 -4.610   1.61 No 
W18C vs Q88S                 -5.610   2.08 No 
Y47N vs Q65H                  5.410   2.05 No 
Y47N vs Q88S                  4.410   1.59 No 
Q65H vs Q88S                 -1.000   0.49 No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 212
Appendix F 
 
Molecular and Phylogenetic Analysis of HIV Type 1 
vpr Sequences of South African Strains 
 
AIDS Research and Human Retroviruses 
(2009) 25: 357-362 
 
 213
 
 214
 
 215
 
 216
 217
 218
 
 
 219
Appendix G 
 
Human immunodeficiency virus type 1 Vpr: 
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